CA2993918A1 - 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same - Google Patents

1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same Download PDF

Info

Publication number
CA2993918A1
CA2993918A1 CA2993918A CA2993918A CA2993918A1 CA 2993918 A1 CA2993918 A1 CA 2993918A1 CA 2993918 A CA2993918 A CA 2993918A CA 2993918 A CA2993918 A CA 2993918A CA 2993918 A1 CA2993918 A1 CA 2993918A1
Authority
CA
Canada
Prior art keywords
alkyl
mmol
added
synthesis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2993918A
Other languages
French (fr)
Other versions
CA2993918C (en
Inventor
Jaekwang Lee
Moo Sung Ko
Younghue HAN
Yuntae Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chong Kun Dang Corp
Original Assignee
Chong Kun Dang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chong Kun Dang Corp filed Critical Chong Kun Dang Corp
Publication of CA2993918A1 publication Critical patent/CA2993918A1/en
Application granted granted Critical
Publication of CA2993918C publication Critical patent/CA2993918C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed is a novel 1,3,4-oxadiazole amide derivative compound represented by the general formula I:
(see formula I)>
having histone deacetylase 6 (HDAC6) inhibitory activity, an optical isomer or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a treatment method using the composition, and a preparation method therefor. The novel compound, optical isomer thereof or pharmaceutically acceptable salts thereof have histone deacetylase 6 (HDAC6) inhibitory activity and are effective for the prevention or treatment of HDAC6-associated diseases, including infectious diseases;
neoplasm; endocrine, nutritional and metabolic diseases;
psychological and behavioral disorders; neurological diseases; eye and adnexa diseases; circulatory system diseases; respiratory system diseases; digestive system diseases; skin and subcutaneous tissue diseases; musculoskeletal system and connective tissue diseases; or congenital malformations, deformations and chromosomal abnormalities.

Description

[DESCRIPTION]
[Invention Title]
1,3,4-Oxadiazole Amide Derivative Compound as Histone Deacetylase 6 Inhibitor, and Pharmaceutical Composition Containing Same [Technical Field]
The present invention relates to 1,3,4-oxadiazole amide derivative compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof; uses thereof for the preparation of therapeutic medicaments; methods of treating diseases using the same; pharmaceutical compositions comprising the same; and methods for preparing the same.
[Background Art]
Post-translational modifications such as acetylation are very crucial regulatory modules at the heart of biological processes in the cells and are tightly regulated by a multitude of enzymes. Histones are the chief protein components of chromatin and act as spools around which DNA strands to assist in DNA condensation. Also, the balance of histone acetylation and deacetylation is a critical role in the regulation of gene expression.
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysine residues on histone proteins of chromatin, and are known to be associated with gene silencing and induce cell cycle arrest, angiogenic inhibition, immune regulation, cell death, etc. (Hassig et al., Curr. Opin. Chem.
Biol. 1997, 1, 300-308). In addition, it was reported that the inhibition of enzymatic function of HDACs induces the apoptosis of cancer cells in vivo by reducing the activity of cancer cell survival-associated factors and activating cancer cell apoptosis-associated factors (Warrell et al, J. Natl. Cancer Inst. 1998, 90, 1621-1625).
In humans, 18 HDACs have been identified and are W subdivided into four classes based on their homology to yeast HDACs. Among them, 11 HDACs use zinc as a cofactor and can be divided into three groups: Class I (HDAC1, 2, 3 and 8), Class II (ha: HDAC4, 5, 7 and 9; IIb: HDAC6 and 10), Class IV (HDAC
11). Additionally, 7 HDACs of Class III (SIRT 1-7) require NAD+
instead of zinc as a cofactor (Bolden et al., Nat. Rev. Drug Discov. 2006, 5(9), 769-784).
Various HDAC inhibitors are in preclinical or clinical development, but to date, only non-selective HDAC inhibitors have been identified as anticancer agents, and only vorinostat (SAHA) and romidepsin (FK228) have been approved for the treatment of cutaneous T-cell lymphoma and panobinostat(LBH-589) have been approved for the treatment of multiple meyeloma.
However, non-selective HDAC inhibitors are known to cause side effects such as fatigue and nausea, generally at high doses (Piekarz et al., Pharmaceuticals 2010, 3, 2751-2767). Such side
2 effects have been reported to be due to the inhibition of class I HDACs. Due to such side effects, the use of non-selective HDAC inhibitors in the development of drugs other than anticancer drugs has been limited (Witt et al., Cancer Letters, 2009, 277, 8-21).
Meanwhile, it was reported that the selective inhibition of class II HDACs would not show toxicity shown in the inhibition of class I HDACs. Also, when selective HDAC
inhibitors are developed, side effects such as toxicity, which are caused by the non-selective HDAC inhibition, can be overcome. Thus, selective HDAC inhibitors have potential to be developed as therapeutic agents effective for the treatment of various diseases (Matthias et al., Mol. Cell. Biol. 2008, 28, 1688-1701).
It is known that HDAC6, a member of Class IIb HDACs, is present mainly in the cytoplasm and is involved in the deacetylation of a number of non-histone substrates (HSP90, cortactin, etc.), including tubulin (Yao et al., Mol. Cell 2005, 18, 601-607). HDAC6 has two catalytic domains, and the zinc finger domain of C-teLminal can bind to ubiquitinated proteins. It is known that HDAC6 has a number of non-histone proteins as substrates, and thus plays an important role in various diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders (Santo et al., Blood 2012 119:
3 2579-258; Vishwakarma et al., International Immunopharmacology 2013, 16, 72-78; Hu et al., J. Neurol. Sci. 2011, 304, 1-8).
The common structural characteristic of various HDAC
inhibitors is a structure consisting of a cap group, a linker and a zinc-binding group (ZBG), as shown in the following Vorinostat structure. Many researchers have conducted studies on enzyme inhibitory activity and selectivity by structurally modifying the cap group and the linker. Among these groups, the zinc-binding group is known to play a more important role in enzyme inhibitory activity and selectivity (Wiest et al., J.
Org. Chem. 2013 78: 5051-5065; Methot et al., Bioorg. Med.
Chem. Lett. 2008, 18, 973-978).
Cap Zinc Binding Unlw Group Group (ZBD) I¨L-1 NOH

The zinc-binding group is generally a hydroxamic acid or benzamide derivative. Herein, the hydroxamic acid derivative exhibits a potent HDAC inhibitory effect, but has problems of low bioavailability and severe off-target activity. In addition, the benzamide derivative has a problem in that it can produce toxic metabolites in vivo, because it contains aniline (Woster et al., Med. Chem. Commun. 2015, online publication).
Accordingly, there is a need for the development of
4 selective HDAC 6 inhibitors for treatment of diseases such as cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders, which have a zinc-binding group with improved bioavailability and, at the same time, cause no side effects, unlike non-selective inhibitors that cause side effects.
[Disclosure]
[Technical Problem]
It is an object of the present invention to provide 1,3,4-oxadiazole amide derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.
Another object of the present invention is to provide pharmaceutical compositions containing 1,3,4-oxadiazole amide derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.
Still another object of the present invention is to provide methods for preparing the novel compounds.
Still another object of the present invention is to provide pharmaceutical compositions for prevention or treatment of HDAC6 activity-associated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular
5 diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above-described compounds.
Still another object of the present invention is to provide the use of the compounds for the preparation of therapeutic medicaments against HDAC6 activity-associated diseases.
Yet another object of the present invention is to provide methods for treating HDAC6 activity-associated diseases, which comprise administering a therapeutically effective amount of the pharmaceutical compositions containing the compounds.
[Technical Solution]
The present inventors have discovered 1,3,4-oxadiazole amide derivative compounds, which have histone deacetylase 6 (HDAC6) inhibitory activity, and have found that these compounds can be used for the inhibition or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases, thereby completing the present invention.
1,3,4-oxadiazole amide derivative compounds To achieve the above objects, the present invention provides an 1,3,4-oxadiazole amide derivative compound represented by the following formula I, a stereoisomer thereof,
6 or a pharmaceutically acceptable salt thereof:
[Formula I]
R3 ¨L3 Z2=Zi Li .\\ N
N
112 _____ </. Z3-24 wherein Li, L2 and L3 are each independently -(Co-C2 alkyl)-;
Zi to Z4 are each independently N or CRz, wherein three or more of ZI to Z4 may not be simultaneously N, and Rzis -H or -X;
R1 is -CX2H or -CX3;
R2 is - (C1-C4 alkyl) , - (01-04 alkyl) -0 (Ci-C4 alkyl) , - (CI-C.4 alkyl) -C(=0)-0(Ci-C4 alkyl), -(C3-C6 cycloalkyl), -aryl, -heteroaryl, Hr R4 \ ____________ R7 ¨
/Y

, or , wherein at least one H of the -(03-C6 cycloalkyl), -aryl or -heteroaryl may be substituted with -X, -OH, -(Ci-C4 alkyl), -0(Ci-C4 alkyl), -C(=0)-(01-04 alkyl), -C(=0)-0(01-04 alkyl) or -CF3, Y is -N-, -0- or -s(=0)2-, when Y is -N-, R4 and R3 are each independently -H, -(01-04 alkyl), -C(=0)-(01-04 alkyl), -C(=0)-(C3-C6 cycloalkyl), -C(=0)-0 (01-04 alkyl) , -C (=0) -CF3, -S (=0) 2- (CI-C.4 alkyl) , -(02-06
7 heterocycloalkyl), benzyl or amine protecting group, wherein the -(02-06 heterocycloalkyl) may contain an N, 0 or S atom in the ring, and when Y is -0- or -S(=0)2-, R4and R8 are null, R5 to R8 are each independently -H, -(Cl-C4 alkyl), -OH, -CH2OH or -C(=0)-NH2, and a to c are each independently an integer of 1, 2 or 3;
R3 is -H, -(01-04 alkyl), -(C1-04 alkyl)-0(01-04 alkyl), -(01-04 alkyl)-C(=0)-0(Ci-C4 alkyl), -(03-06 cycloalkyl), -\>(\\

\ >Mb 4.6 heteroaryl, or Z2=Zi 5 ELI c.3¨Zi N , wherein at least one H of the -(C3-C6 cycloalkyl), -aryl or -heteroaryl may be independently substituted with -X, -OH, -(01-04 alkyl), -0(01-04 alkyl), -C(=0) -(01-C4 alkyl), -C(=0)-0(01-04 alkyl) or -CF3, and R4, R5, R6, Y, a, b, Ri, LI, Zi, Z2, Z3 and Z4 are as defined above; and X is F, Cl, Br or I.
According to preferable embodiment of the present invention,
8 Li and L3 are each independently -(Coalkyl)-;
L2 is -(01-02 alkyl)-;
ZI to Z4 are each independently N or CRz, wherein two or more of ZI to Z4 may not be simultaneously N, and Rzis -H or -X;
Ri is -CX2H or -OX3;
R2 is -(01-04 alkyl), -(C3-06 cycloalkyl), -aryl, -heteroaryl, \/\a /\
R4¨Y\ __________________ R7 tj N4b)R6 R
, or 8 , wherein at least one H of the -(C3-06 cycloalkyl), -aryl or -heteroaryl may be substituted with -X, -OH, -(01-04 alkyl), -0(01-04 alkyl), -C(=0)-(01-04 alkyl), -c(=0)-0(C1-C4 alkyl) or -CF3i Y is -N-, -0- or -S(=0)2-, when Y is -N-, R4 and R8 are each independently -H, -(01-04 alkyl) , -C (=0) - (01-04 alkyl) , -C (=0) -0F3, -S (=0) 2- (01-04 alkyl), -(02-CE heterocycloalkyl), -C(=0)-(03-C6 cycloalkyl), benzyl or amine protecting group, wherein the -(02-06 heterocycloalkyl)may contain an 0 atom in the ring, and when Y is -0- or -S(=0)2-, R4and Rsare null, R5 to R8 are each independently -H, -(C1-C4alkyl), -OH, -CH2OH or -C(=0)-NH2, and a to c are each independently an integer of 1, 2 or 3;
R3 is -aryl or -heteroaryl, wherein at least one H of the -aryl or -heteroaryl may be independently substituted with -X, -OH, -
9 (Cl-C4 alkyl), -0(Cl-C4 alkyl), -C(=0)-(Cr-C4 alkyl), -C(=0)-0(Ci-C4 alkyl) or -CF3; and X is F, Cl, Br or I.
According to more preferable embodiment of the present invention, Li and L3 are each independently -(Coalkyl)-;
L2 is -(C1 alkyl)-;
Z1 to Z4 are each independently N or CRz, wherein two or more of Zi to Z4 may not be simultaneously N, and Rz is -H or -X;
Ri is -CF2H or -CF3;

;\

.b R2 is -(Ci-C4 alkyl), -pyridinyl or , wherein at least one H of the pyridinyl may be substituted with -X, -OH, -(Cl-C4 alkyl), -0(Ci-C4 alkyl), -C(=0)-(Ci-C4 alkyl), -C(=0)-0(Ci-C4alkyl) or -CF3, Y is -N-, R4 is -(C1-C4 alkyl), -C(=0)-(Ci-C4 alkyl) or -S(=0)2-(Ci-C4 alkyl), R5 and R6 are each independently -H or -(Ci-C4alkyl), and a and b are each independently an integer of 1 or 2;
R3 is -aryl, wherein at least one H of the aryl may be substituted with -X; and X is F, Cl, Br or I.

According to particularly preferable embodiment of the present invention, Li and L3 are each independently -(Coalkyl)-;
L2 is -(Clalkyl)-;
ZI to Z4 are each independently N or CRz, wherein two or more of ZI to Z4 may not be simultaneously N, and Rzis -H or -X;
Rlis -CF214 or -CF3;
\\>\7\11 R4 --Y\ >
R2 is -pyridinyl or , wherein at least one H
of the pyridinyl may be substituted with -X, -OH, -(Ci-C4 alkyl), -0(C1-C4 alkyl), -C(=0)-(Ci-C4 alkyl), -C(=0)-o(Ci-C4 alkyl) or -CF3, Y is -N-, R4 is -(C1-C4 alkyl), -C(=0)-(C1-C4 alkyl) or -s(-0)2-(Ci-C4 alkyl), R5 or R6 are each independently -H, and a and b are each independently an integer of 1 or 2;
R3 is -aryl, wherein at least one H of the aryl may be substituted with -X; and X is F, Cl, Br or I.
The specific compounds represented by formula I are shown in Table 1 below:
[Table 1]

Ex. Camp. Structure Ex. Camp. Structure 1 11022 It 41 Ilia:k N - pi II 'ii *11S0 ti 0 0.----L-0 1 :,>---cFs ti ¨11 I -II
SI III F

0-r----0 .
r----------0 0 1 , :,)__cFiii 1 I. F

(---õ.õ--0 0 8 11134 40 NI .1)--CF2H
NN
13 oc II -H
*N 41 11 0 U

ark ,,,,3 H tifa ,N H -H
Boo H CI

o 12 11138 r OP
r-----------o III 0 HN N-N
lij----o Of H

1------k0 j i)¨CF3 r"-------"-Lo 0 N¨ I e----CF3 c N -N H
=---.."-- ti 11 * 0 N

15 11141 5 rakb16 11142 IT-Lici 5 o =
M
rII
---1( 0 14 'ii 0 1 o o ),N
----11 4 * H
19 11158 A 20 11159 o fy"-o /=,--"40 4 t õ).--CF 3 _,.. H -if 0 ..,11 H -H

11 .
21 11160 j = 22 11161 N 4 0 _11ra"L
b.--CF3 ----b *11 0 0 *

23 11162 24 11163 rs'''''' tr" :/>--CF 3 I C F

õ..1,, -- 44 0 N
--- -,-r--- N -N
--,--',, 0 *

ti 0 0 25 11164 r---"----'Lo o ,)¨cF3 26 11165 0 y 11 3)i/D ,,-- H --H 0 riso 0 i i aL0 1 >--CF3 28 11187 . 11 0 o ti -N)>--CF 3 0 i1 t1 -H

. F
F H0 F *N F
0,1 . =

$ o 0 t =i)--cF3 til N ,-- N - N
F
F
= ti *
IS H .

$ r----',---0 ti -o t>¨CF, 11 ,.,....õ--ti -N
H -H
,,, I
. F 5 F

33 11202 * ch 34 11203 0 -A0 -.11 0ifi I H -N
* N F 5 F
II
35 11204 rak'o Ili 0 36 11205 nA0 5 o I ,>-C F3 NN
,---j --=õ,, ....--F N F
0 ri 0 o -D---Lo,.,9 ,Nia--.4 N -.N

CF 3 0"O

II . * N F
1 i).-CF2FI
39 11208 40 11209 0 =
r------,-L0 0 1 >--cF2H ,NaL0 N -N
, U .,- H -N
I
N F
= H F
41 11210cF2H 1 ,, 0 42 11211 0 o =,>----CF 2H

43 11212 r--------- 0 0 0 c F2H 44 11213 0 * 1 , >¨CF2H
1 =/).--0)N N -N 0 ..,10 H =-if , -,,-1`---45 11214F2 H 0 1 o 46 11215 0 N =
(------A-0 I. *
>,-,IC ,)--CF2H
_ , N ,N 113- H-11 ).-- ----0 pi F5 F

N
riA:, * = 48 11233 11 0 fi $

N -N' ti -14' , 49 11234 1-----0 = o 50 11235 1 /j----16 51 11236 r----"Lo 1 >--cF3 52 11237 z 0% li0 H-ti II -tiµ
0 ' \

0 s 0 y j>--CF2H ..ra"6-0 1 ;>--CF 2H
II H-H
* N F 0111 F

TNy ,rk' IS o a 56 11241 N
ry---0 = 0 I 2).--C F2 H
-.
NN

I. F

iN
ia---o IS o 58 11243 N
ra''''Cl 116 0 N -N N
N -N

1 .
. 60 11245 411 11 =

59 11244 F3 C liN1., 0 t ;)--CF2H
0 I .1--CF2 H
H
0 0 -. \
0 i? F 5 F
61 11246 62 11247 = H

y ---CF 3 N ,-N H-H

0¨'4o SI . 64 11326 0---o II i%)__CF2H

../
F F SI N F F le N

t66 11328 C F2H
r,----0 . 0 t ;,-CF2F1 N - N -N Ni N --N

F F
F i H * F IS 11 1110 >¨cF2H
11- H -11' H 11-it ----c ---1 F * N F 01 F N F
69 11331 ri---o 0 0 70 11332 ri----0 . 0 b-C F2H
N N - N
I N -N

FSN F
F . N F

i-0 1.1 = o 334 0 I >¨CF2H
0 L .õ)--CF2H
N - N ,os,Ny N -N
-S' 0 - \ 0 ' ) c 0 F F
73 11339 ' rl =
-----o o 74 11340 F H
---La 0 0 1 õ>--C F2 H
NN I -H

F = H =
75 11341 r,...A6 1 ) H ..,fp-- H -n I -n , * F
F . H F
0 77 11357 ' A 0 = 78 11358 a I õ)-CF2H ----.60 1 o..-CF2H
----- N-N I -H
, F 80 11360 ' . 11 L 411N
..i...
¨cF3 .
...

1 ;)¨cF2u I
u ,-- H -n Ni ....s-,-.--1 N-N

F lie,,-,,,oll H
81 11376 cryL 82 11414 ,-- o , --- a 1 ;)¨cF2H o 1 i'',-CF2H
F = N -.----"---(NN.
83 11418 iõ....,...___k, I 84 11419 N r F F
F

CI . H ditii N
85 11534 õ,-k, go 0 86 11535 CI
I
o 1 1 a:,>--CF2H
y ,:?¨iCF2H
N N-N
0 Co) F
F
*
CI
[Oil . ci F
¨cF,Ei F
*
87 11536 o o, 88 11537 rt.o 1 ,e- 0 N N-N e.--CF2H
q. N
0-....-'0H N -N
OH
F
F
CI . N

r--o $ o 90 11584 o 1 s/.--CF2H
H2N)LcN) F F

CI = N F

o 0 o 92 11603 1 =/ .¨c Fa 1 o,>--CF2H

F CI 4, F F Ali 1 F
CI
trLO 110 93 11610 1o:" .-CF2F1 94 11611 N N al 14-0isf-CF2H
N -N
C ) ( ) N
S, F F al CI I. N F
CI F

if,,0 110 tof)._CF2H 710 = 0 N -.N
(N N ) ( ) N
I
F Iiitl F
rlo 0 IP

C r'a----0 161 0 ) Nr 1 --N
0' --/

. N F

0----L.0 0--) Preferably, the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11110, 11189, 11233, 11237, 11238, 11239, 11240, 11241, 11242, 11243, 11245, 11327, 11332, 11333, 11334, 11339, 11341, 11359, 11360, 11376, 11414, 11418 and 11419. More preferably, the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11189, 11233, 11239, 11241, 11242, 11243, 11333, 11334, 11341, 11359, 11360, 11376, 11414, 11418 and 11419.
As used herein, the term "pharmaceutically acceptable salt" means any salt that is generally used in the pharmaceutical field. Examples of the pharmaceutically acceptable salt include, but are not limited to, salts with inorganic ions such as calcium, potassium, sodium or magnesium ions, salts with inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid or sulfuric acid, salts with organic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid or the like, salts with sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid or naphthalenesulfonic acid, salts with amino acids such as glycine, arginine or lysine, and salts with amines such as trimethylamine, triethylamine, ammonia, pyridine or picoline.
In the present invention, preferred salts include hydrochloride, phosphate, sulfate, trifluoroacetate, citrate, bromate, maleate or tartrate, and preferred examples of such compounds include 11022, 11136 and 11137 as disclosed herein.
The compounds represented by formula I may contain one or more asymmetrical carbon atoms, and thus may exist in the fo/m of racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. The compounds of formula I can be separated into such isomers by methods known in the art, for example, column chromatography or HPLC. Alternatively, stereoisomers of the compounds of fo/mula I may be synthesized by stereospecific synthesis using optically pure starting materials and/or reagents of known configuration.
Methods for preparation of 1,3,4-oxadiazole amide derivative compounds The present invention provides methods for the preparation of the 1,3,4-oxadiazole amide derivative compounds presented by fo/mula I, stereoisomers thereof, or pharmaceutically acceptable salts thereof.
Preferred methods for the preparation of the 1,3,4-oxadiazole amide derivative compounds presented by formula I, stereoisomers thereof, or phaimaceutically acceptable salts thereof are as shown in reaction schemes 1 to 5 below, and also include modifications obvious to those skilled in the art.
[Reaction Scheme 1]

0 xf X.4 0 H \L'4 H X2 X3 0-alkyl XfX4 0 1-1 R2-L2-NH2 R2 ,1.3- )--.444 ____________________________________ ) Xi-X4 0 L2NH X2 X3 0-alkyl r___(/

X X2 X3 0-alkyl 1 Ri-ACI

XfX4 h0 R2 1-3-(1 "--1-11-4C, /XI& p L2N, X2 X3 HN-NH2 R2 ,L3.- 7--Lec 0 ...---} L2'N X2 X3 0-alkyl Ri 1-6 Ri 1-5 1 .***4`......,..A
iXi-X4p.....,R3 xfx4 9 0 , , R2 L3-< `,>----L4-- II R2 ,L3"-<' ")---14-4( )'\--R3 L2fil X2 X3 N'N +..... L2111 X2 X3 HN-NH

Ri 1-7 RI 1-6 Reaction scheme 1 above shows a method for synthesis of compounds having an amide structure. As shown in reaction scheme 1, a compound of foimula 1-1 is subjected to reductive amination with an amine compound, or a compound of formula 1-2 is subjected to a substitution reaction with an amine compound, thereby preparing a compound of folmula 1-3. The compound of foLmula 1-3 is reacted with an acyl chloride of formula 1-4 to synthesize a compound of formula 1-5, which is then reacted with hydrazine, thereby preparing a compound of formula 1-6.
The compound of formula 1-6 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to produce a compound of formula 1-7. When a compound of formula 1-8 in which an oxadiazole ring is not formed is obtained, it is reacted with 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent) to obtain a compound of folmula 1-8.
Compounds that are synthesized according to reaction scheme 1 are compounds 11022, 11105, 11106, 11107, 11108, 11109, 11110, 11188, 11189, 11246, 11247, 11339, 11340, 11341, 11356, 11357, 11358, 11359, 11360, 11376 and 11584.
[Reaction Scheme 2]

r--\--0 LtNH X1-X4 0 R2-1.2-NR2 0 / __ \ i/
+ X X2X3 0-alkyl , PG y lb PG 1.2 Xi& St i(fX4 p R2 ,i-3.-- `1----L4 -1K /12 ,L3-(' µ--.L.4 -I( L2.141 X2 X3 0¨alkyl L2'N X2 X3 UN¨NH2 pdY lb ,Y 4\y 1 / \
XI; 0-...r, R3 A1x4 o 0 R2 ,L.3-(/ 2-1.4-4 Li R2 el-3-< )-*1-44 >µ--113 IA X2X3 N-" L214 X2X3 UN¨NH
1 iµkr.0 4*--- l µIIP0 Y I b ;Y 1 b Pd 2-5 PG 24 2(114 0,-y'R3 Xl.X4 .õ/R3 La:
' oX2x3 "
t., 14 I-2-N X2 Y.3 N-O
.......Ø 1 16...
lb '41 I 47 lb , Reaction scheme 2 above shows a method for synthesis of compounds having a heterocycloalkyl amide structure. As shown in reaction scheme 2, a compound of folmula 2-1 is reacted with an amine compound to synthesize a compound of formula 2-2, which is then subjected to a substitution reaction, thereby synthesizing a compound of formula 2-3. The compound of formula 2-3 is reacted with hydrazine to produce a compound of formula 2-4. The compound of formula 2-4 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to produce a compound of foLmula 2-5. When a compound of formula 2-6 in which an oxadiazole ring is not formed is obtained, it is reacted with 1-methoxy-N-triethylaRmoniosulfonyl-methanimidate (Burgess reagent) or methanesulfonyl chloride to obtain a compound of formula 2-5, which is then deprotected, thereby producing a compound of foLmula 2-7. The compound of folmula 2-7 is reacted with aldehyde, acyl chloride, sulfonyl chloride, acetic anhydride, oxetan-3-one or the like, thereby synthesizing a compound of formula 2-8.
Compounds that are synthesized according to reaction scheme 2 above are compounds 11134, 11135, 11136, 11137, 11138, 11139, 11140, 11141, 11142, 11143, 11157, 11158, 11159, 11160, 11161, 11162, 11163, 11164, 11165, 11166, 11187, 11200, 11201, 11202, 11203, 11204, 11205, 11206, 11207, 11208, 11209, 11210, 11211, 11212, 11213, 11214, 11215, 11232, 11233, 11234, 11235, 11236, 11237, 11238, 11239, 11240, 11241, 11242, 11243, 11244, 11245, 11325, 11326, 11327, 11328, 11329, 11330, 11331, 11332, 11333, 11334, 11621 and 11622.

[Reaction Scheme 3]
X1.X4 0 X1X4 0 R2 ,L3- -Y/P- R2 ,L3-)-1-4 L2.N X2 X3 0-alkyl L2'N X2 X3 0-alkyl Y lb 2-3 3-4 PG
XfX4 AP
x1x4 0 R2 ,L3-R2 ,L3- )-1-4 _____0, L2'N X2 X3 HN-NH2 L2.N X2X3 0-alkyl 0 I \I-aPi y lb 3-6 /µ1 3-5 R4 Xi-X4 0 R3 L2'N X2 X3 N""

lb 3-7 Reaction scheme 3 above shows a method for synthesis of compounds having a heterocycloalkyl amide structure. As shown in reaction scheme 3, a compound of formula 2-3 is deprotected to produce a compound of formula 3-4, which is then subjected to reductive amination, thereby preparing a compound of foLmula 3-5. The compound of formula 3-5 is reacted with hydrazine to W produce a compound of formula 3-6. The compound of formula 3-6 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to synthesize a compound of formula 3-8.
Compounds that are synthesized according to reaction scheme 3 above are compounds 11414, 11418 and 11419.
[Reaction Scheme 4]

(,0 R2-12^N H2 t 0 /444 + ...4:1 r--- \ ).-44 --0.
on OPG X 14; 0-alkyl X14 pIxtxt p L-R2 ,3-'' '--1-4--4c R2 , Ls- \'i 2-1-4-\
L2 N X2 X3 0-alkyl L2N X2 X3 HN-NH, to OPG OPG

Xi =X4 10 0\ , XfX4 ,0 0, R2 ,L3-(/ :?-"L4-< > R3 R2 La -'' `21-4-1< )---Rs L2'N X2 X3 RN-NH L2 N X2 X3 RN -N H
to 41.11111100.* (*to OPG OH

...ili R2 L2 N X2 X3 N ¨> L2 N, X2 X3 to to OMs N---, 4-8 J I n = 0, 1 i Ri4/
IXI-X1 p, ., R3 Xi X4 0-...,,,R3 R2 itc,¨/ R2 ii---/\/: µ 11 L2 141, X2 Xs N - N
...........4. L2 N X2 xa N-N
Co O
_.11 4-9 ___) 4-10 Z Z.

Reaction scheme 4 above shows a method for synthesis of compounds having a heterocycloalkyl amide structure. As shown in reaction scheme 4, a compound of formula 4-1 is reacted with an amine compound to obtain a compound of formula 4-2, which is then subjected to a substitution reaction, thereby synthesizing a compound of formula 4-3. The compound of formula 4-3 is reacted with hydrazine to produce a compound of formula 4-4.
The compound of formula 4-4 is reacted with difluoroacetic anhydride to synthesize a compound of formula 4-5. The compound of formula 4-5 is deprotected to obtain a compound of formula 4-6, which is then reacted with methanesulfonyl chloride, thereby preparing a compound of formula 4-7. The compound of formula 4-7 is reacted with substituted cycloamine to produce a compound of formula 4-8. In addition, the compound of formula 4-7 is reacted with morpholine, thiomorpholine or piperazine derivative to synthesize a compound of formula 4-9. When the product is unsubstituted piperizine, it is reacted with sulfonyl chloride, acetic anhydride or oxetan-3-one to produce a compound of formula 4-10.
Compounds that are synthesized according to reaction scheme 4 above are compounds 11534, 11535, 11536, 11537, 11538, 11610, 11611, 11612, 11613 and 11614.
[Reaction Scheme 5]

0 R2-L2-NH2 ___s0 Xi.X4 0 _______________________ v. + /
X X2 X3 0-alkyl Xi' X4 0 Xi' X4 h0 R2 /I-3- ,--1_44 ___)õ.._ R 2 , L 3 - "-L4-`c L2'N X2 X3 0-alkyl L2-N X2 X3 HN-NH2 3=0 02S_3 (0 Xi' X4 0 R\ x1-;0--y/R3 R2 /1_3 )---L44 7-123 R2 /1_3- 2-1_4--µ II
L2.N X2X3 HN-NH L2'N X2 X3 N'N
__30 __AN..
12c 02S 02S( Reaction scheme 5 above shows a method for synthesis of compounds having a heterocycloalkyl amide structure. As shown in reaction scheme 5, a compound of formula 5-1 is reacted with an amine compound to obtain a compound of formula 5-2, which is then subjected to a substitution reaction to obtain a compound of formula 5-3. The compound of formula 5-3 is reacted with hydrazine to produce a compound of formula 5-4. The compound of formula 5-4 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to synthesize a compound of foLmula 5-5, which is then reacted with methanesulfonyl chloride, thereby synthesizing a compound of formula 5-6.
Compounds that are synthesized according to reaction scheme 5 above are compounds 11602 and 11603.
Compositions comprising 1,3,4-oxadiazole amide derivative compounds, the use thereof and the method of treating diseases using the same The present invention provides a pharmaceutical composition for preventing or treating histone deacetylase 6 (HDAC6) activity-associated diseases, which contains, as an active ingredient, a compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
[Formula I]
R3-L3 Z2=Z1 Li C) wherein formula I is as defined above.
The phaLmaceutical composition according to the present invention exhibits a remarkable effect on the prevention or treatment of histone deacetylase 6 activity-associated diseases by selectively inhibiting histone deacetylase 6.
The histone deacetylase 6 activity-associated diseases include infectious diseases such as prion disease; neoplasms such as benign tumor (e.g. myelodysplastic syndrome) or malignant tumor (e.g. multiple myeloma, lymphoma, leukemia, lung cancer, rectal cancer, colon cancer, prostate cancer, urothelial carcinoma, breast cancer, melanoma, skin cancer, liver cancer, brain cancer, gastric cancer, ovarian cancer, pancreatic cancer, head and neck cancer, oral cancer, or glioma); endocrine, nutritional and metabolic diseases such as Wilson's disease, amyloidosis or diabetes; mental and behavioral disorders such as depression or Rett's syndrome, and the like; neurological diseases such as atrophy of central nervous system (e.g. Huntington's disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)), neurodegenerative disease (e.g. Alzheimer's disease), movement disorder (e.g.
0 Parkinson's disease), neuropathy (e.g. hereditary neuropathy (Charcot-Marie-Tooth disease)), sporadic neuropathy, inflammatory neuropathy, drug-induced neuropathy), motor neuron diseases (amyotrophic lateral sclerosis (ALS)), or demyelinating diseases of the central nervous system (e.g.
multiple sclerosis (MS)), and the like; diseases of the eye and adnexa, such as uveitis; cardiovascular diseases such as atrial fibrillation or stroke and the like; respiratory diseases such as asthma; digestive diseases such as alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease, and the like; diseases of the skin and subcutaneous tissue, such as psoriasis; diseases of the musculoskeletal system and connective tissue, such as rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus (SLE), and the like; or congenital malformations, deformations and chromosomal abnormalities, such as autosomal dominant polycystic kidney disease, as well as disorders or diseases associated with the abnormal function of histone deacetylase.
The phaimaceutically acceptable salt is as described above with respect to a pharmaceutically acceptable salt of the compound represented by formula I according to the present invention.
For administration, the phalmaceutical composition according to the present invention may further contain at least one pharmaceutically acceptable carrier in addition to the compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable carrier that is used in the present invention may be at least one of physiological saline, sterile water, Ringer solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of two or more thereof. If necessary, the composition may contain other conventional additives such as an antioxidant, a buffer or a bacteriostatic agent. In addition, the composition may be formulated into injectable formulations such as solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant. Thus, the composition of the present invention may be in the form of patches, liquids, pills, capsules, granules, tablets, suppositories, etc. These formulations may be prepared either by conventional methods that are used for formulation in the art or by the method disclosed in Remington's Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton PA, and may be prepared depending on diseases or components.
The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended use. The dose of the pharmaceutical composition 0 varies depending on the patient's weight, age, sex, health conditions and diet, the time of administration, the mode of administration, excretion rate, the severity of the disease, and the like. The daily dose of the compound of formula I
according to the present invention may be about 1 to 1000 mg/kg, preferably 5 to 100 mg/kg, and may be administered once to several times a day.
The pharmaceutical composition of the present invention may further contain, in addition to the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, one or more active ingredients that exhibit medicinal efficacy identical or similar thereto.
The present invention also provides a method for preventing or treating a histone deacetylase 6 activity-associated disease, which comprises administering a therapeutically effective amount of the compound represented by folmula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
As used herein, the term "therapeutically effective amount" refers to the amount of the compound represented by foLmula I, which is effective for the prevention or treatment of histone deacetylase 6 activity-associated diseases.
The present invention also provides a method of selectively inhibiting HDAC6, which comprises administering the compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof to mammals including humans.
The method of preventing or treating histone deacetylase 6 activity-associated diseases according to the present invention includes inhibiting or averting the disease as well as addressing the disease itself, prior to the onset of symptoms by administering the compound represented by folmula I. In the management of diseases, the magnitude of a prophylactic or therapeutic dose of a particular active ingredient will vary with the nature and severity of the disease or condition, and may also vary according to the route by which the active ingredient is administered. The dose and the dose frequency will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens may be readily selected by those skilled in the art with due consideration of such factors. In addition, the method of preventing or treating histone deacetylase 6 activity-associated diseases according to the present invention may further comprise administering a therapeutically effective amount of an additional active agent helpful for the treatment W of the disease together with the compound represented by formula I, in which the additional active agent may exhibit a synergistic effect with the compound of formula I or an assistant effect.
The present invention is also intended to provide the use of the compound represented by formula I, a stereoisomer thereof or a phaLmaceutically acceptable salt thereof, for the preparation of a medicament for treating histone deacetylase 6 activity-associated diseases. For the preparation of the medicament, the compound represented by formula I may be mixed with a pharmaceutically acceptable adjuvant, diluent, carrier or the like, and combined with other active agents such that the active ingredients can have synergistic effects.
The particulars mentioned in the use, composition and treatment method of the present invention may be appropriately combined unless contradictory to one another.

[Advantageous Effects]
The compounds represented by formula I according to the present invention, stereoisomers thereof or pharmaceutically acceptable salts thereof can selectively inhibit HDAC6, and thus exhibit excellent effects on the prevention or treatment of histone deacetylase 6 activity-associated diseases.
[Mode for Invention]
Hereinafter, the present invention will be described in further detail with reference to examples and experimental examples. However, these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Preparation of 1,3,4-oxadiazole amide derivative compounds Specific methods for preparing the compounds of formula I
are as follows.
Example 1: Synthesis of compound 11022, N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)isonicotinamide [Step 1] Synthesis of methyl 4-((phenylamino)methyl)benzoate NH2 H OMe Aniline (1.961 mL, 21.475 mmol), methyl 4-formylbenzoate (4.230 g, 25.770 mmol) and acetic acid (0.614 mL, 10.738 mmol) were dissolved in methylene chloride (50 mL), and the solution was stirred at 0 C for 10 minutes. Then, sodium triacetoxyborohydride (6.828 g, 32.213 mmol) was added to the stirred solution, followed by additional stirring at room temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0 % to 80 %) and concentrated to give the title compound (4.730 g, 91.3 %) as colorless oil.
[Step 2] Synthesis of methyl 4-((N-phenylisonicotinamido)methyl)benzoate N opi OMe _____________________________________ rAo 4111 OMe 4-((phenylamino)methyl)benzoate (0.150 g, 0.622 mmol) synthesized in step 1, isonicotinoyl chloride hydrochloride (0.221 g, 1.243 mmol) and N,N-diisopropylethylamine (0.194 mL, 1.243 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and the solution was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0 % to 50 %) and concentrated to give the title compound (0.179 g, 83.1 %) as a white solid.
[Step 3] Synthesis of N-(4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide 'N 'N
N 4110 N ollt OMe N,NH2 Methyl 4-((N-phenylisonicotinamido)methyl)benzoate (0.179 g, 0.517 mmol) synthesized in step 2, and hydrazine hydrate (0.488 mL, 10.335 mmol) were mixed in ethanol (10 mL), and the mixture was heated by microwave irradiation at 120 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/methylene chloride = from 0% to 15%) and concentrated to give the title compound (0.134 g, 74.9%) as a white solid.
[Step 4] Synthesis of compound 11022 N N
14.
Si 0 /111:2)''' ..2 N-(4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide (0.105 g, 0.303 mmol) synthesized in step 3, trifluoroacetic anhydride (0.051 mL, 0.364 mmol) and triethylamine (0.084 mL, 0.606 mmol) were dissolved in methylene chloride (20 mL) at room temperature, and the solution was stirred at the same temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was W washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge;
methanol/methylene chloride = from 0% to 30%) and concentrated to give the title compound (0.035 g, 26.1%) as a white foam solid.
NMR (400 MHz, CDC13) 6 8.48 (d, 2H, J = 5.8 Hz), 8.06 (d, 2H, J = 8.3 Hz), 7.49 (d, 2H, J - 8.2 Hz), 7.28 - 7.14 (m, 5H), 6.98 - 6.82 (m, 2H), 5.17 (d, 2H, J = 19.0 Hz); LRMS (ES) m/z 425.2 (M++1).
[Step 5] Synthesis of compound 11022 hydrochloride ________________________________________ NCI ( ,001 I

(-11.LI 0 1.1 0 N-N Nõ N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadizol-2-yl)benzyl)isonicotinamide (0.100 g, 0.236 mmol) synthesized in step 4 was dissolved in dichloromethane (10 mL) at room temperature, and hydrochloric acid (1.00 M solution in ethyl acetate, 0.259 mL, 0.259 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent, and ethyl acetate (2 mL) was added to the concentrate, followed by stirring. The precipitated solid was filtered, washed with ethyl acetate solution, and dried to give the title compound (0.108 g, 99.5%) as a white solid.
Example 2: Synthesis of compound 11105, N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)acetamide [Step 1] Synthesis of methyl 4-((N-phenylacetamido)methyl)benzoate N 1111 __'N
OMe 1110 OMe Methyl 4-((phenylamino)methyl)benzoate (0.200 g, 0.829 mmol) and diisopropylethylamine (0.290 mL, 1.658 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and acetyl chloride (0.088 mL, 1.243 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
W from 0 % to 80 %) and concentrated to give the title compound (0.220 g, 93.7%) as a white solid.
[Step 2] Synthesis of N-(4-(hydrazinecarbonyl)benzy1)-N-phenylacetamide ______w " OMe N.NH2 15 Methyl 4-((N-phenylacetamido)methyl)benzoate (0.220 g, 0.776 mmol) synthesized in step 1 and hydrazine hydrate (0.733 mL, 15.530 mmol) were mixed in ethanol (10 mL), and the mixture was heated by microwave irradiation at 120 C for 2 hours, and then cooled down to room temperature to teminate 20 the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/methylene chloride = from 0% to 15%) and concentrated to give the title compound (0.145 g, 65.9 %) as a white foam solid.
[Step 3] Synthesis of N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)acetamide N,NH2 /L0 110 j(F3 N-(4-(hydrazinecarbonyl)benzy1)-N-phenylacetamide (0.145 g, 0.512 mmol) synthesized in step 2 and triethylamine (0.142 mL, 1.024 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and trifluoroacetic anhydride (0.087 mL, 0.614 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.180 g, 92.7%, yellow foam solid).
[Step 4] Synthesis of compound 11105 111 * H 0 N
N, N 0 CF3 0 )--CF3 N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)acetamide (0.180 g, 0.475 mmol) synthesized in step 3 and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.170 g, 0.712 mmol) were mixed in tetrahydrofuran (10 ml,), and the mixture was heated by microwave irradiation at 150 C for 30 minutes and cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 50%) and concentrated to give the title compound (0.088 g, 51.3%) as light yellow oil.
NMR (400 MHz, CDC13) 5 8.03 (d, 2H, J = 8.3 Hz), 7.47 -7.13 (m, 5H), 7.02 (dd, 2H, J = 7.8, 1.5 Hz), 4.98 (s, 2H), 1.93 (s, 3H); LRMS (ES) m/z 362.3 (M++1).
Example 3: Synthesis of compound 11106, N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)cyclohexanecarboxamide [Step 1] Synthesis of 4-((N-phenylcyclohexanecarboxamido)methyl)benzoate H N crL
OMe OMe Methyl 4-((phenylamino)methyl)benzoate (0.200 g, 0.829 mmol) and N,N-diisopropylethylamine (0.290 ml, 1.658 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and cyclohexanecarbonyl chloride (0.166 mL, 1.243 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.285 g, 97.8%) as a white solid.
[Step 2] Synthesis of N-(4-(hydrazinecarbonyl)benzy1)-N-phenylcyclohexanecarboxamide N N
0,,L0 o m e 0A) 101N H 2 4-((N-phenylcyclohexanecarboxamido)methyl)benzoate (0.285 g, 0.811 mmol) synthesized in step 1 and hydrazine hydrate (0.766 mL, 16.219 mmol) were mixed in ethanol (10 mL), and the mixture was heated by microwave irradiation at 120 C
for 2 hours, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge;
methanol/methylene chloride = from 0% to 15%) and concentrated to give the title compound (0.239 g, 83.9%) as a white foam solid.
[Step 3] Synthesis of N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)cyclohexanecarboxamide N N vi 0 0 'N AC F3 NNH

N-(4-(hydrazinecarbonyl)benzy1)-N-phenylcyclohexanecarboxamide (0.239 g, 0.680 mmol) synthesized in step 2 and triethylamine (0.189 mL, 1.360 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and trifluoroacetic anhydride (0.115 mL, 0.816 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with W magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.300 g, 98.6%, white foam solid).
[Step 4] Synthesis of compound 11106 N w 0 = N

CrLO = isi'NACF3 C:r0 N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)cyclohexanecarboxamide (0.300 g, 0.670 mmol) synthesized in step 3 and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.240 g, 1.006 mmol) were mixed 20 in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 30 minutes and cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate.

The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; methanol/dichloromethane = from 0% to 50%) and concentrated to give the title compound (0.096 g, 33.3%) as a white solid.
NMR (400 MHz, CDC13) 5 8.02 (d, 2H, J = 8.3 Hz), 7.44 -7.31 (m, 5H), 7.07 (ddd, 2H, J = 60.8, 5.1, 4.6 Hz), 4.94 (s, 2H), 2.18 (ddd, 1H, J - 11.4, 7.3, 3.1 Hz), 1.74 - 1.48 (m, 7H), 1.32 - 1.08 (m, 1H), 1.08 - 0.40 (m, 2H) ; LRMS (ES) m/z 430.3 (PP+1).
Example 4: Synthesis of compound 11107, N-phenyl-N--(4-(5-[Step 1] Synthesis of methyl 4-((N-phenylbenzamido)methyl)benzoate OMe N 110 0 OMe Methyl 4-((phenylamino)methyl)benzoate (0.200 g, 0.829 mmol) and N,N-diisopropylethylamine (0.290 mL, 1.658 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and benzoyl chloride (0.175 g, 1.243 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 50%) and concentrated to give the title compound (0.264 g, 92.2%) as a white solid.
[Step 2] Synthesis of N-(4-(hydrazinecarbonyl)benzy1)-N-phenylbenzamide N
N
OMe N,NH2 Methyl 4-((N-phenylbenzamido)methyl)benzoate (0.264 g, 0.764 mmol) synthesized in step 1 and hydrazine hydrate (0.722 mL, 15.287 mmol) were mixed in ethanol (10 mL), and the mixture was heated by microwave irradiation at 120 C for 2 hours, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 12 g cartridge; methanol/methylene chloride = from 0% to 15%) and concentrated to give the title compound (0.222 g, 84.1%) as a white foam solid.
[Step 3] Synthesis of N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)benzamide N
N'NH2 N H 0 N-(4-(hydrazinecarbonyl)benzy1)-N-phenylbenzamide (0.364 g, 1.054 mmol) synthesized in step 2 and triethylamine (0.292 mL, 2.108 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and trifluoroacetic anhydride (0.178 mL, 1.265 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.450 g, 96.7%, white foam solid).
[Step 4] Synthesis of compound 11107 = ) N'(CF3 , 0/?--CF3 N-phenyl-N-(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)benzamide (0.450 g, 1.019 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.364 g, 1.529 mmol), were mixed in tetrahydrofuran (10 ml,), and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane - from 0% to 50%) and concentrated to give the title compound (0.250 g, 57.9%) as light yellow solid.
NMR (400 MHz, CDC13) 6 8.04 (d, 2H, J = 8.3 Hz), 7.54 (t, 2H, J = 9.9 Hz), 7.38 - 7.31 (m, 2H), 7.26 - 7.06 (m, 6H), 6.95 (dd, 2H, J = 10.5, 9.1 Hz), 5.23 (s, 2H); LRMS (ES) m/z 430.3 (M++1) Example 5: Synthesis of compound 11108, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylisonicotinamide CrIO 1111 --CF2H N,NH2 N-(4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide (0.200 g, 0.577 mmol) synthesized in step 3 of Example 1, 2,2-difluoroacetic anhydride (0.075 mL, 0.693 mmol) and triethylamine (0.160 mL, 1.155 mmol) were dissolved in N,N-dimethylformamide (10 mL) at room temperature, and the solution was stirred at 80 C for 1 hour and cooled to room temperature to teLminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane - from 0% to 80%) and concentrated to give the title compound (0.158 g, 67.3%) as a white solid.
NMR (400 MHz, CDC13) 6 8.47 (d, 2H, J = 4.5 Hz), 8.06 (d, 2H, J = 8.2 Hz), 7.47 (d, 2H, J = 8.1 Hz), 7.19 (d, 5H, J =
5.1 Hz), 7.02 (d, 1H, J = 15.5 Hz), 6.90 (d, 3H, J = 5.8 Hz), 5.19 (s, 2H); LRMS (ES) m/z 407.3 (WA-1) .
Example 6: Synthesis of compound 11109, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylisonicotinamide [Step 1] Synthesis of methyl 3-fluoro-4-((N-phenylisonicotinamido)methyl)benzoate " 110OMe OMe Methyl 3-fluoro-4-((phenylamino)methyl)benzoate (0.640 g, 2.468 mmol) and N,N-diisopropylethylamine (0.638 g, 4.937 mmol) were dissolved in methylene chloride (10 mL) at room temperature, and isonicotinoyl chloride hydrochloride (0.879 g, 4.937 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane - from 0% to 80%) and concentrated to give the title compound (0.840 g, 93.4%) as a yellow foam solid.
[Step 2] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide OMeNs NH2 Nrj 0 0 3-fluoro-4-((N-phenylisonicotinamido)methyl)benzoate (0.840 g, 2.305 mmol) synthesized in step 1 and hydrazine hydrate (2.177 mi, 46.106 itunol) were mixed in ethanol (10 ml), and the mixture was heated by microwave irradiation at 120 C
for 2 hours, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/methylene chloride = from 0% to 15%) and concentrated to give the title compound (0.814 g, 96.9%) as a white solid.
[Step 33 Synthesis of compound 11109 N 'NH2 CO, , N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide (0.100 g, 0.274 mmol) synthesized in step 2 and triethylamine (0.076 mL, 0.549 mmol) were dissolved in N,N-dimethylformamide (10 mL) at room temperature, and trifluoroacetic anhydride (0.046 mL, 0.329 mmol) was added to the solution. The mixture was stirred at 80 C for 1 hour, and then cooled to room temperature to teLminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/methylene chloride = 0% to 15%) and concentrated to give the title compound (0.060 g, 49.4%) as a white solid.
NMR (400 MHz, CDC13) 6 8.49 (s, 2H), 7.89 (dd, 1H, J =
8.0, 1.4 Hz), 7.79 - 7.64 (m, 2H), 7.25 (d, 1H, J = 9.0 Hz), 7.29 - 7.03 (m, 5H), 7.03 - 6.89 (m, 2H), 5.27 (s, 2H); LRMS
(ES) m/z 443.2 (M++1).
Example 7: Synthesis of compound 11110, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenylisonicotinamide [Step 1] Synthesis of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-N-phenylisonicotinamide r I NH2 t* rL1 H 0 N, N,NACF2H =VLI 0 .1 0 N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylisonicotinamide (0.100 g, 0.274 mmol), synthesized in step 2 of Example 6, and triethylamine (0.076 mL, 0.549 mmol), were dissolved in methylene chloride (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.057 g, 0.329 mmol) was added to the solution, followed by stirring at the sane temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.120 g, 98.8%, colorless oil).
[Step 2] Synthesis of compound 11110 'N F

N, = H N CF2H
NJ' = o>--CF2H

N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-phenylisonicotinamide (0.120 g, 0.271 mmol), synthesized in step 1, and 1-methoxy-N-triethylanutoniosulfonyl-methanimidate (Burgess reagent, 0.097 g, 0.407 mmol), were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.027 g, 23.5 %) as a light yellow solid.
NMR (400 MHz, CDC13) 6 8.49 (d, 2H, J = 5.5 Hz), 7.91 (dd, 1H, J= 8.0, 1.5 Hz), 7.90 - 7.57 (m, 2H), 7.29 - 7.07 (m, 5H), 6.95 (ddd, 3H, J = 64.6, 48.3, 41.3 Hz), 5.27 (d, 2H, J =

14.0 Hz); LRMS (ES) m/z 425.3 (M++1) .
Example 8: Synthesis of compound 11134, tert-butyl 3-(pheny1(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)carbamoyl)azetidine-l-carboxylate [Step 1] Synthesis of tert-butyl 3-(phenylcarbamoyl)azetidine-1-carboxylate ' BocNIDL
Aniline (1.961 mL, 21.475 mmol), 1-(tert-butoxycarbonyl)azetidine-3-carboxylic acid (4.321 g, 21.475 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (6.175 g, 32.213 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (HOBt) (4.353 g, 32.213 mmol) and N,N-diisopropylethylamine (5.703 mL, 32.213 mmol) were dissolved in methylene chloride (150 mL) at M room temperature, and the solution was stirred at the same temperature for 12 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 120 g cartridge; ethyl acetate/hexane = from 5% to 50%) and concentrated to give the title compound (4.880 g, 82.2%) as a white solid.
[Step 2] Synthesis of tert-butyl 3-((4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate NH
Boc' 0 (Si 0 Boe Tert-butyl 3-(phenylcarbamoyl)azetidine-l-carboxylate (1.000 g, 3.619 mmol) synthesized in step 1 was dissolved in tetrahydrofuran (70 mL), and sodium hydride (60.00 %, 0.289 g, 7.237 mmol) was added slowly to the solution while the W temperature was maintained at 0 C. The mixture was stirred for 20 minutes, and methyl 4-(bromomethyl)benzoate (0.829 g, 3.619 mmol) was added thereto, followed by additional stirring at 45 C for 12 hours. The reaction mixture was cooled to room temperature, and then water (10 mL) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with ethyl acetate. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 120 g cartridge; ethyl acetate/hexane =
from 5% to 50%) and concentrated to give the title compound (1.200 g, 78.1%) as colorless oil.
[Step 3] Synthesis of tert-butyl 3-((4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate N
Boc 0 B0, , 0 N'NH 2 ,oc"-N

Tert-buty13-((4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (1.500 g, 3.534 mmol), synthesized in step 2, and W hydrazine monohydrate (3.435 mL, 70.671 mmol), were mixed in ethanol (15 mL) at room temperature, and the mixture was heated by microwave irradiation at 120 C for 1 hour, and then cooled to room temperature to terminate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent, and water was added to concentrate, followed by extraction with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.400 g, 93.3%, white solid).
[Step 4] Synthesis of tert-butyl 3-(pheny1(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamoyl)azetidine-1-carboxylate N ,N H2 N.N)CF3 Boc,NIA 0 Boc-Ni A 0 Tert-buty13-((4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (1.800 g, 4.240 mmol), synthesized in step 3, and triethylamine (0.710 mL, 5.088 mmol), were dissolved in N,N-dimethylformamide (30 mL) at room temperature, and trifluoroacetic anhydride (0.649 mL, 4.664 mmol) was added to the solution. The mixture was stirred at 90 C for 12 hours, and then cooled to room temperature to teLminate the reaction.
Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 40 g cartridge; ethyl acetate/hexane = from 5% to 60%) and concentrated to give the title compound (1.500 g, 68.0%) as a white solid.
[Step 5] Synthesis of compound 11134 H
N ,N F3 0 0 I.
Boc'Nr Boc'1,11 F3 Tert-buty13-(pheny1(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamoyl)azetidine-1-carboxylate (1.500 g, 2.882 mmol), synthesized in step 4, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 1.030 g, 4.323 mmol) were mixed in tetrahydrofuran (15 m1) at room temperature, and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to terminate the reaction. Water was added to the W reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g 0 cartridge; ethyl acetate/hexane - from 5% to 30%) and concentrated to give the title compound (1.200 g, 82.9%) as a white solid.
NMR (700 MHz, CDC13) 5 8.02 (d, 2H, J = 8.2 Hz), 7.44 - 7.31 (m, 5H), 6.97 - 6.86 (m, 2H), 4.97 (s, 2H), 4.11 (dd, 2H, 20 J = 9.9, 4.1 Hz), 3.65 (dd, 2H, J = 11.2, 5.8 Hz), 3.34 - 3.14 (m, 1H), 1.40 (s, 9H); LRMS (ES) m/z 403.4 (M+-100).
Example 9: Synthesis of compound 11135, tert-butyl 4-(pheny1(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-25 yl)benzyl)carbamoyl)piperidine-l-carboxylate [Step 1] Synthesis of tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate Olt NH

Boc'N
Aniline (1.961 mL, 21.475 mmol), 1-(tert-butoxycarbonyl)piperidine-4-carboxylic acid (4.924 g, 21.475 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (6.175 g, 32.213 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (HOBt) (4.353 g, 32.213 mmol) and N,N-diisopropylethylamine (5.703 mL, 32.213 mmol) were dissolved in methylene chloride (150 mL) at M room temperature, and the solution was stirred at the same temperature for 12 hours.
Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 120 g cartridge; ethyl acetate/hexane = from 5% to 50%) and concentrated to give the title compound (5.040 g, 77.1%) as a white solid.
[Step 2] Synthesis of tert-butyl (methoxycarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate 'NH

Boe N
Boe N 0 Tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate (1.000 g, 3.285 mmol) synthesized in step 1 was dissolved in tetrahydrofuran (70 mL), and sodium hydride (60.00 %, 0.263 g, 6.571 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The mixture was stirred for 20 minutes, and methyl 4-(bromomethyl)benzoate (0.753 g, 3.285 mmol) was added thereto, followed by additional stirring at 45 C for 12 hours. The reaction mixture was cooled to room temperature, and then water (10 mL) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with ethyl acetate. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 120 g cartridge; ethyl acetate/hexane =
from 5% to 50%) and concentrated to give the title compound (1.300 g, 87.4 %) as colorless oil.
[Step 3] Synthesis of tert-butyl 4-((4-(hydazinecarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate 411 N 41" N
N.N H2 Boc'N 0 Tert-butyl 4-((4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (1.500 g, 3.315 mmol), synthesized in step 2, and hydrazine monohydrate (3.319 g, 66.291 mmol), were mixed in ethanol (15 mL) at room temperature, and the mixture was heated at 120 C for 1 hour, and then cooled to room temperature to te/minate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent, and water was W added to the concentrate, followed by extraction with methylene chloride. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.400 g, 93.3 %, white solid).
[Step 4] Synthesis of tert-butyl 4-(pheny1(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamoyl)piperidine-1-carboxylate A
N, NH r0 NN
2 )L
0 ' CF3 Tert-butyl (hydazinecarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (1.800 g, 3.977 mmol), synthesized in step 3, and triethylamine (0.666 mL, 4.773 mmol), were dissolved in N,N-dimethylformamide (30 ml) at room temperature, and trifluoroacetic anhydride (0.609 mL, 4.375 mmol) was added to the solution. The mixture was stirred at 9000 for 12 hours, and then cooled to room temperature to terminate the reaction.
Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane = from 5% to 60%) and concentrated to give the title compound (1.600 g, 73.3 %) as a white solid.
[Step 5] Synthesis of compound 11135 , NCF3 o>-C F3 Boc,N 0 Boc,N N-N
Tert-butyl 4-(pheny1(4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)carbamoyl)piperidine-l-carboxylate (1.600 g, 2.917 mmol), synthesized in step 4, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 1.043 g, 4.375 mmol) were mixed in tetrahydrofuran (15 mL), and the mixture was heated by microwave irradiation at 15000 for 30 minutes, and cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 5% to 30%) and concentrated to give the title compound (1.400 g, 90.5 %) as a white solid.
NMR (700 MHz, CDC13) 5 8.03 (d, 2H, J = 8.0 Hz), 7.43 -7.32 (m, 5H), 7.00 (d, 2H, J = 7.1 Hz), 4.96 (d, 2H, J = 20.2 Hz), 4.15 - 3.93 (m, 2H), 2.45 (s, 2H), 2.34 (t, 1H, J = 11.3 Hz), 1.77 (qd, 2H, J = 12.8, 4.0 Hz), 1.60 (d, 2H, J = 12.7 Hz), 1.44 (s, 9H); LRMS (ES) m/z 531.4 (M++1).
Example 10: Synthesis of compound 11136, N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride *N N
Boc (10 11 0 H C

)--' N HN
N-N N-N
Tert-butyl 3-(pheny1(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)carbamoyl)azetidine-l-carboxylate (1.100 g, 2.189 mmol) synthesized in Example 8 was dissolved in dichloromethane (50 mL), and hydrochloric acid (4.00 M solution in dioxane, 2.736 mL, 10.945 mmol) was added to the solution at 0 C, followed by stirring at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was suspended in diethyl ether (50 mL) and filtered. The obtained solid was washed with diethyl ether and dried to give the title compound (0.920 g, 95.8%) as a white solid.
NMR (700 MHz, CDC13 + Me0D) 6 7.96 (dd, 2H, J = 45.0, 36.1 Hz), 7.35 (ddd, 5H, J = 40.2, 37.9, 10.0 Hz), 6.99 (d, 2H, J = 77.6 Hz), 5.12 - 4.80 (m, 1H), 4.33 (s, 2H), 3.78 (d, 2H, J
= 25.5 Hz), 3.30 (d, 1H, J = 120.8 Hz), 2.37 (s, 2H); LRMS (ES) m/z 403.0 (M++1) .
Example 11: Synthesis of compound 11137, N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride , N-N N-N
HCI
Tert-butyl 4-(pheny1(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)carbamoyl)piperidine-l-carboxylate (1.300 g, 2.450 mmol) synthesized in Example 9 was dissolved in dichloromethane (50 mL), and hydrochloric acid (4.00 M solution in dioxane, 3.063 mL, 12.251 mmol) was added to the solution at 000, followed by stirring at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was suspended in diethyl ether (50 mL) and filtered. The obtained solid was washed with diethyl ether and dried to give the title compound (1.080 g, 94.4%) as a white solid.
NMR (700 MHz, CDC13 + Me0D) 6 7.91 (dd, 2H, J = 103.5, 50.3 Hz), 7.72 - 7.19 (m, 5H), 6.95 (s, 2H), 5.24 - 4.68 (m, 2H), 4.03 - 3.27 (m, 2H), 3.04 - 2.64 (m, 2H), 2.49 (s, 2H), 2.09 (s, 2H), 1.78 (d, 2H, J = 93.2 Hz); LRMS (ES) m/z 431.4 (M++1).
Example 12: Synthesis of compound 11138, 1-methyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide 0.0 40 HCIN

"----CF3 N-N N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.100 g, 0.228 mmol), synthesized in Example 10, and formaldehyde (37.00 %
solution in water, 0.025 mL, 0.342 mmol), were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.072 g, 0.342 mmol) was added to the solution. The mixture was stirred at the sane temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0 % to 15 %) and concentrated to give the title compound (0.038 g, 40.0 %) as a white solid.
NMR (400 MHz, CDC13) 5 8.02 (d, 2H, J = 8.2 Hz), 7.52 -7.30 (m, 6H), 6.90 (dd, 2H, J = 6.5, 2.8 Hz), 4.92 (d, 2H, J =
19.3 Hz), 3.51 - 3.14 (m, 5H), 2.35 (s, 3H); LRMS (ES) m/z 417.3 (M+1).
Example 13: Synthesis of compound 11139, 1-ethyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide [Step 1] Synthesis of compound 11139 Hc,3(11 j,.N
, , HN N-N
N-N
i N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.100 g, 0.228 mmol), synthesized in Example 10, and acetaldehyde (0.019 mL, 0.342 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.072 g, 0.342 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was M purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.042 g, 42.8%) as a white solid.
NMR (400 MHz, CDC13) 6 8.07 - 7.97 (nri, 2H), 7.34 (dt, 5H, J = 22.3, 14.0 Hz), 6.95 - 6.83 (m, 2H), 4.92 (d, 2H, J =
0 19.5 Hz), 3.55 - 3.08 (m, 5H), 2.58 (q, 2H, J = 7.2 Hz), 0.96 (t, 3H, J = 7.2 Hz) ; LRMS (ES) m/z 431.3 (M++1).
Example 14: Synthesis of compound 11140, 1-methyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-20 yl)benzyl)puperidine-4-carboxamide Olt Olt HCIN

N-N
N- N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.100 g, 0.214 mmol), synthesized in Example 11, and formaldehyde (37.00 % solution in water, 0.024 mL, 0.321 nutol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.068 g, 0.321 'mini) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to give the title compound (0.072 g, 75.6%) as a white solid.
IH NMR (400 MHz, CDC13) 6 8.02 (d, 2H, J - 8.3 Hz), 7.43 -7.30 (m, 5H), 6.97 (dd, 2H, J - 6.4, 3.2 Hz), 4.94 (s, 2H), 2.78 (d, 2H, J = 113.6 Hz), 2.16 (dd, 4H, J = 68.5, 23.5 Hz), 1.96 (dt, 3H, J = 20.3, 13.8 Hz), 1.73 (s, 2H) ; LRMS (ES) m/z 431.3 (M++1).
Example 15: Synthesis of compound 11141, 1-ethyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide HCILN

0 o---CF3 N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.100 g, 0.214 mmol), synthesized in Example 11, and acetaldehyde (0.018 mL, 0.321 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.068 g, 0.321 mmol) was added to the solution, followed by stirring at the sane temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.065 g, 66.2%) as colorless oil.
NMR (400 MHz, CDC13) 6 8.02 (d, 2H, J = 8.3 Hz), 7.43 -7.31 (m, 5H), 6.97 (dd, 2H, J = 6.6, 2.9 Hz), 4.94 (s, 2H), 3.04 (s, 2H), 2.40 (d, 3H, J = 75.4 Hz), 2.02 - 1.66 (m, 6H), 1.15 (dd, 3H, J= 32.3, 25.8 Hz) ; LRMS (ES) m/z 459.34 (M++1) Example 16: Synthesis of compound 11142, 1-isopropyl-N-phenyl-N- (4- (5- (trifluoromethyl) -1,3,4-oxadiazol-2-yl ) benzyl) azetidine-3-carboxamide IN

HN N-N
N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.100 g, 0.228 mmol), synthesized in Example 10, and acetone (0.025 mL, 0.342 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.072 g, 0.342 mmol) was added to the solution, followed by stirring at the sane temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.056 g, 55.3%) as a white solid.
NMR (400 MHz, CDC13) 6 8.02 (d, 2H, J = 8.2 Hz), 7.42 -7.28 (m, 5H), 6.91 (dd, 2H, J - 6.4, 3.1 Hz), 4.94 (s, 2H), 3.31 (d, 5H, J - 21.1 Hz), 2.50 (s, 1H), 0.94 (d, 6H, J = 6.1 Hz); LRMS (ES) m/z 445.3 (M++1).
Example 17: Synthesis of compound 11143, 1-isopropyl-N-phenyl-N- (4- (5- (trifluoromethyl) -1,3,4-oxadiazol-2-y1) benzyl) piperidine-4-carboxamide , N-N N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.100 g, 0.214 mmol), synthesized in Example 11, and acetone (0.024 mL, 0.321 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.068 g, 0.321 mmbl) was added to the solution, followed by stirring at the same temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.021 g, 20.8%) as a white solid.
NMR (400 MHz, CDC13) 6 8.03 (d, 2H, J = 8.3 Hz), 7.36 (dd, 5H, J = 7.4, 4.2 Hz), 6.95 (dd, 2H, J = 6.5, 3.1 Hz), 4.92 (s, 2H), 3.37 (d, 3H, J = 63.0 Hz), 2.75 (d, 3H, J = 67.4 Hz), 2.22 (s, 1H), 1.96 (s, 2H, J = 30.4 Hz), 1.25 (s, 6H, J = 169.3 Hz); LRMS (ES) m/z 473.3 (M++1).

Example 18: Synthesis of compound 11157, N-pheny1-1-propionyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide HCN I 1.1LN 40 0 N-N
H
') N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.080 g, 0.182 mmol), synthesized in Example 10, and N,N-diisopropylethylamine (0.063 mL, 0.365 matol) were dissolved in dichloromethane (10 W mL) at room temperature, and propionyl chloride (0.018 mL, 0.201 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; ethyl acetate/hexane - from 0% to 80%) and concentrated to give the title compound (0.008 g, 9.6%) as colorless oil.
'H NJ, R (400 MHz, CDC13) 5 8.03 (d, 2H, J = 8.2 Hz), 7.45 -7.29 (m, 6H), 6.92 (dd, 2H, J = 6.5, 2.8 Hz), 4.98 (s, 2H), 4.37 - 4.08 (m, 2H), 3.79 (d, 2H, J = 6.7 Hz), 3.30 (ddd, 1H, J
= 15.1, 8.8, 6.4 Hz), 2.15 - 1.94 (m, 3H), 1.25 (s, 1H, J =
20.0 Hz), 1.09 (t, 3H, J = 7.5 Hz); LRMS (ES) m/z 459.3 (M++1).
Example 19: Synthesis of compound 11158, 1-isobutyryl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide lit Olt 40 0, N
Os 0 0 NiD.L /7--CF3 N-N
HN N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.080 g, 0.182 mmol), synthesized in Example 10, and N,N-diisopropylethylamine (0.063 mL, 0.365 mmol) were dissolved in dichloromethane (10 mi) at room temperature, and isobutyryl chloride (0.021 mI, 0.201 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (5i02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.025 g, 29.0%) as colorless oil.
IH NMR (400 MHz, CDC13) 6 8.03 (d, 2H, J = 8.3 Hz), 7.45 -7.28 (m, 5H), 6.92 (dd, 2H, J = 6.3, 3.2 Hz), 5.04 - 4.87 (m, 2H), 4.53 - 4.16 (m, 1H), 3.95 - 3.59 (m, 2H), 3.36 - 3.20 (m, 1H), 2.39 (td, 2H, J = 13.6, 6.8 Hz), 1.07 (dd, 6H, J - 16.3, 6.8 Hz); LRMS (ES) m/z 473.3 (M++1).
Example 20: Synthesis of compound 11159, N-phenyl-1-(2,2,2-trifluoroacety1)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide HC1? r, N
0 /.
0 % 0 --CF3 )--CF3 ON YO N-N
HN
N-N

N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.080 g, 0.182 mmol), synthesized in Example 10, and N,N-diisopropylethylandne (0.063 mL, 0.365 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2,2-trifluoroacetic anhydride (0.028 mL, 0.201 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.013 g, 14.3%) as colorless oil.
'H NMR (400 MHz, CDC13) 5 8.04 (d, 2H, J= 8.2 Hz), 7.44 -7.31 (m, 5H), 6.96 - 6.83 (m, 2H), 4.97 (t, 2H, J - 8.2 Hz), 4.72 - 4.62 (m, 1H), 4.14 (dt, 2H, J = 14.4, 8.2 Hz), 3.89 -3.76 (m, 1H), 3.50 - 3.36 (m, 1H); LRMS (ES) m/z 499.3 (M++1).
Example 21: Synthesis of compound 11160, 1- (methylsulfonyl) -N-phenyl-N- (4-(5- (trifluoromethyl) -1,3, 4-oxadiazol-2-y1) benzyl) azetidine-3-carboxamide N

N
HN N-N
N,N
0' \
4-oxadiazol-2-hydrochloride (0.080 g, 0.182 mmol), synthesized in Example 10, and N,N-diisopropylethylamine (0.064 mL, 0.365 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and methanesulfonyl chloride (0.016 ml, 0.201 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.018 g, 20.6%) as a white solid.
NMR (400 MHz, CDC13) 5 8.08 - 7.98 (m, 2H), 7.43 - 7.31 (m, 5H), 6.91 (ddd, 2H, J = 5.5, 4.6, 2.9 Hz), 4.96 (s, 2H), 4.12 (dd, 2H, J = 15.2, 7.3 Hz), 3.72 - 3.62 (m, 2H), 3.38 -3.26 (m, 1H), 2.89 (d, 3H, J = 4.0 Hz); LRMS (ES) m/z 481.2 (M++1).
Example 22: Synthesis of compound 11161, 4-oxadiazol-2-N
HCI

g el I F3 --C
HN N N-N
N--N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 mmol), synthesized in Example 11, and N,N-diisopropylethylamine (0.059 mL, 0.343 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.013 mL, 0.188 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.052 g, 64.2%) as a white solid.
NMR (400 MHz, CDC13) 6 8.02 (d, 2H, J = 8.3 Hz), 7.37 (dd, 5H, J= 5.4, 3.0 Hz), 6.99 (dd, 2H, J= 6.6, 2.9 Hz), 4.94 (s, 2H), 4.51 (s, 1H), 3.77 (s, 1H), 2.80 (s, 1H), 2.38 (ddd, 2H, J = 30.5, 20.3, 9.3 Hz), 2.04 (s, 3H, J = 9.5, 4.9 Hz), 1.88 - 1.53 (m, 4H); LRMS (ES) m/z 473.3 (W+1).
Example 23: Synthesis of compound 11162, N-pheny1-1-propionyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide HCI NOlt Ort.1 HN N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 hutol), synthesized in Example 11, and N,N-diisopropylethylamine (0.059 mL, 0.343 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and propionyl chloride (0.016 mL, 0.188 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column W chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.061 g, 73.2%) as a white solid.
NMR (400 MHz, CDC13) 5 8.02 (d, 2H, J = 8.0 Hz), 7.37 (dd, 5H, J = 5.0, 3.0 Hz), 6.99 (dd, 2H, J= 6.2, 2.6 Hz), 4.94 (s, 2H), 4.51 (s, 1H), 3.85 (s, 1H), 2.36 (ddd, 4H, J = 21.9, 14.8, 9.1 Hz), 1.90 - 1.52 (m, 5H), 1.12 (t, 3H, J = 7.5 Hz);
LRMS (ES) m/z 487.4 (M++1).
Example 24: Synthesis of compound 11163, 1-isobutyryl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide HU

HN N-N

N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 mmol), synthesized in Example 11, and N,N-diisopropylethylamine (0.059 mL, 0.343 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and isobutyryl chloride (0.020 mL, 0.188 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.064 g, 74.6%) as colorless oil.
NMR (400 MHz, CDC13) 5 8.02 (d, 2H, J = 8.3 Hz), 7.37 (dd, 5H, J= 5.3, 3.1 Hz), 6.99 (dd, 2H, J= 6.2, 3.2 Hz), 4.94 (s, 2H), 2.74 (dt, 2H, J - 13.4, 6.7 Hz), 2.48 - 2.26 (nri, 2H), 1.90 - 1.49 (m, 6H), 1.10 (t, 6H, J = 11.3 Hz); LRMS (ES) m/z 501.3 (M++1) .
Example 25: Synthesis of compound 11164, N-phenyl-1-(2,2,2-trifluoroacety1)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide 1401.1 HCIN
, õcõ 0 N
N-N
N-N

N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 mmol), synthesized in Example 11, and N,N-diisopropylethylamine (0.059 mL, 0.343 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2,2-trifluoroacetic anhydride (0.027 mL, 0.188 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by W extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.061 g, 67.6%) as colorless oil.
NMR (400 MHz, CDC13) 5 8.03 (d, 2H, J = 8.2 Hz), 7.38 (t, 5H, J = 7.1 Hz), 7.05 - 6.87 (m, 2H), 4.94 (q, 2H, J = 14.5 Hz), 4.42 (d, 1H, J = 13.2 Hz), 3.97 (d, 1H, J = 14.3 Hz), 2.93 (t, 1H, J = 13.1 Hz), 2.62 (t, 1H, J = 12.0 Hz), 2.50 (dd, 1H, J = 12.5, 8.5 Hz), 1.89 (dd, 2H, J = 24.8, 13.1 Hz), 1.72 (d, 2H, J = 14.0 Hz); LRMS (ES) m/z 527.3 (M++1) .

Example 26: Synthesis of compound 11165, 1-(methylsulfony1)-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide MCI* N

OA Si o Ox o 1111 HN N-N N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 mmol), synthesized in Example 11, and N,N-diisopropylethylamine (0.060 mL, 0.343 mmol) were dissolved in dichloromethane (10 nE) at room temperature, and methanesulfonyl chloride (0.015 mL, 0.188 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.070 g, 80.3%) as a white solid.
NI R (400 MHz, CDC13) 6 8.02 (d, 2H, J = 8.1 Hz), 7.37 (dd, 5H, J= 5.3, 2.8 Hz), 6.98 (dd, 2H, J= 6.3, 2.7 Hz), 4.94 (s, 2H), 3.80 - 3.62 (m, 2H), 2.72 (s, 3H), 2.51 (dd, 2H, J =
16.4, 7.1 Hz), 2.38 - 2.22 (m, 1H), 2.02 - 1.84 (m, 2H), 1.78 -1.66 (m, 2H); LRMS (ES) m/z 509.2 (M++1) .
Example 27: Synthesis of compound 11166, 1-benzyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide [Step 1] Synthesis of compound 11166 ilt HCI , N N-N

N-N

N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperidine-4-carboxamide hydrochloride (0.080 g, 0.171 mmol), synthesized in Example 11, and N,N-diisopropylethylamine (0.059 mL, 0.343 mmol) were dissolved in dichloromethane (10 mL) at roam temperature, and (bromomethyl)benzene (0.024 mL, 0.206 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.060 g, 67.3%) as a white solid.
NMR (400 MHz, CDC13) 5 8.01 (d, 2H, J = 8.0 Hz), 7.44 -7.24 (m, 10H), 7.02 - 6.84 (m, 2H), 4.94 (s, 2H), 3.41 (s, 2H), 2.83 (s, 2H), 2.17 (s, 1H), 1.93 (d, 2H, J = 10.8 Hz), 1.64 (d, 5H, J = 36.5 Hz); LRMS (ES) m/z 521.4 (M++1).
Example 28: Synthesis of compound 11187, Nl-acetyl-N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide 010 Oit , , HN 01õN
N-N
N-N
N-phenyl-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)azetidine-3-carboxamide hydrochloride (0.080 g, 0.182 mmol), synthesized in Example 10, and N,N-diisopropylethylamine (0.063 mL, 0.365 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.014 mL, 0.201 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02 plate, 20 x 20 x 1 mm;
100%-aqueous ethyl acetate solution/hexane = 100 %)) and concentrated to give the title compound (0.020 g, 24.7%) as colorless oil.
IH NKR (400 MHz, CDC13) 6 8.03 (d, 2H, J = 8.1 Hz), 7.44 -7.28 (m, 5H), 6.91 (dd, 2H, J = 6.5, 2.4 Hz), 4.97 (s, 2H), 4.44 (s, 1H), 3.92 (dd, 3H, J = 107.3, 55.1 Hz), 3.29 (ddd, 1H, J = 15.2, 8.8, 6.3 Hz), 1.81 (d, 3H, J = 6.8 Hz); LRMS (ES) m/z 445.3 (M++1).
Example 29: Synthesis of compound 11188, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-(3-fluorophenyl)isonicotinamide [Step 1] Synthesis of methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate 1.1 N
NI-12 F OMe 3-Fluoroaniline (0.200 g, 1.800 mmol), methyl 4-(bromomethyl)-3-fluorobenzoate (0.445 g, 1.800 mmol) and calcium carbonate (0.497 g, 3.600 mmol) were dissolved in acetonitrile (15 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane - from 0% to 50%) and concentrated to give the title compound (0.324 g, 64.9%) as colorless oil.
[Step 2] Synthesis of methyl 3-fluoro-4-((N-(3-fluorophenyl)isonicotinamido)methyl)benzoate F = N
OMe 001 OMe Methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate (0.320 g, 1.154 mmol) synthesized in step 1, isonicotinoyl hydrochloride (0.247 g, 1.385 mmol) and N,N-diisopropylethylamine (0.398 mL, 2.308 mmol) were dissolved in dichloromethane (10 n1) at room temperature, and the solution was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 100%) and concentrated to give the title compound (0.300 g, 68.0%) as a yellow foam solid.
[Step 3] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)isonicotinamide le F

F r,..7 L1 0 Sr. 0 H
OMe N,NH2 I I
IsIN 0 N,. 0 Methy13-fluoro-4-((N-(3-fluorophenyl)isonicotinamido)methyl)benzoate (0.300 g, 0.785 mmol), synthesized in step 2, and hydrazine hydrate (0.786 g, 15.692 mmol) were mixed in ethanol (20 mL), and the mixture was heated at reflux for 18 hours, and then cooled down to room temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.250 g, 83.3 %) as a yellow foam solid.
[Step 4] Synthesis of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-(3-fluorophenyl)isonicotinamide F

N (100 N F r.A1 = H 0 2r, NH2 1 0 N CF3 N 0 Iµ1,. 0 H

N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)isonicotinamide (0.125 g, 0.327 mmol), synthesized in step 3, and triethylamine (0.091 mL, 0.654 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and trifluoroacetic anhydride (0.055 mL, 0.392 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.145 g, 92.7%) as yellow foam solid.
[Step 5] Synthesis of compound 11188 1 , 0 = NsNACF 0 0 N¨N
N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-(3-fluorophenyl)isonicotinamide (0.160 g, 0.334 mmol), synthesized in step 4, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.120 g, 0.502 mmol) were mixed in tetrahydrofuran (10 n1), and the mixture was heated by microwave irradiation at 150 C for 30 minutes and cooled down to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 12 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.058 g, 37.7%) as a white solid.
IH NKR (400 MHz, CDC13) 6 8.53 (s, 2H), 7.91 (dd, 1H, J =
8.0, 1.5 Hz), 7.83 - 7.57 (m, 2H), 7.37 - 7.27 (m, 2H), 7.17 (dd, 1H, J= 8.1, 6.3 Hz), 6.94 (td, 1H, J= 8.1, 2.3 Hz), 6.78 - 6.62 (m, 2H), 5.23 (d, 2H, J = 20.2 Hz); LRMS (ES) m/z 461.3 (M++1).
Example 30: Synthesis of compound 11189, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluorophenyl)isonicotinamide [Step 1] Synthesis of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)-N-(3-fluorophenyl)isonicotinamide H
N'N H 11 /Z,/'Lo 110 N,H

N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)isonicotinamide (0.125 g, 0.327 mmol), synthesized in step 3 of Example 29, and triethylamine (0.091 mL, 0.654 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.043 mL, 0.392 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.135 g, 89.7%) as a yellow foam solid.
[Step 2] Synthesis of compound 11189 Si 0, 0 N)LCF2H 0 N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)isonicotinamide (0.160 g, 0.348 mmol), synthesized in step 1, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.124 g, 0.521 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 30 minutes and cooled down to room temperature to teLminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.089 g, 57.9%) as a white solid.
NMR (400 MHz, CDC13) 6 8.54 (d, 2H, J = 4.8 Hz), 7.91 (d, 1H, J = 7.8 Hz), 7.77 (d, 1H, J = 9.9 Hz), 7.68 (t, 1H, J =
7.6 Hz), 7.32 (d, 2H, J = 2.9 Hz), 7.17 (dd, 1H, J = 14.7, 7.3 Hz), 7.05 - 6.83 (m, 2H), 6.83 - 6.61 (m, 2H), 5.33 - 5.12 (m, 2H); LRMS (ES) m/z 442.9 (M++1) .
Example 31: Synthesis of compound 11200, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-methyl-N-phenylpiperidine-4-carboxamide [Step 1] Synthesis of tert-butyl 4-((2-fluoro-4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate 011 Olt NH
0 aL0 Boc'N 0 Boc'4::(L
Tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate (2.000 g, 6.571 mmol) synthesized in step 1 of Example 9 was dissolved in tetrahydrofuran (80 ml,), and sodium hydride (60.00 %, 0.526 g, 13.141 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The mixture was stirred for 20 minutes, and methyl 4-(bromomethyl)-3-fluorobenzoate (1.948 g, 7.885 mmol) was added thereto, followed by additional stirring at 50 C for 12 hours. The reaction mixture was cooled down to room temperature, and then water (20 ifl) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane =
from 5% to 50%) and concentrated to give the title compound (2.600 g, 84.1%) as colorless oil.
[Step 2] Synthesis of tert-butyl piperidine-l-.F F
411) N
0 N'NH2 0:*:LI
Boc,N 0 0 Boc Tert-butyl 4-((2-fluoro-4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (2.500 g, 5.313 mmol), synthesized in step 1, and hydrazine monohydrate (5.154 mL, 106.261 mmol) were mixed in ethanol (100 mL) at room temperature, and the mixture was heated at reflux for 12 hours and cooled down to room temperature. Then, the reaction mixture was concentrated under reduced pressure to remove the solvent. Water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (2.400 g, 96.0 %) as white solid.
[Step 3] Synthesis of tert-butyl 4-((2-fluoro-4-(2-N
N
1.4 0 40 110 0.NH2 N.N)(CF3 ,141, 0 Boe Boc Tert-butyl piperidine-l-(1.200 g, 2.550 mmol), synthesized in step 2, and triethylamine (0.427 mL, 3.060 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and trifluoroacetic anhydride (0.390 mL, 2.805 mmol) was added to the solution, followed by stirring at the same temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.400 g, 96.9%)as colorless oil.
[Step 4] Synthesis of tert-butyl 4-((2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate 'N H 0 N'N'C F3 faL

BoeN 0 Boc'N NN
Tert-butyl 4-((2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)(phenyl)carbamoyl)piperidine-l-carboxylate (1.400 g, 2.471 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.883 g, 3.707 mmol) were mixed in tetrahydrofuran (100 ml,) at room temperature, and the mixture was heated under reflux for 12 hours, and then cooled down to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane = 10%
to 30%) and concentrated to give the title compound (0.740 g, 54.6%) as a white solid.
[Step 5] Synthesis of N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylpiperidine-4-carboxamide hydrochloride 0 so , N-N N-N
Tert-butyl 4-((2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (0.740 g, 1.349 mmol) synthesized in step 4 was dissolved in dichloromethane (50 mL) at room temperature, and hydrochloric acid (4.00 M solution in dioxane, 1.686 mL, 6.745 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was suspended in diethyl ether (50 mL) and filtered. The obtained solid was washed with diethyl ether and dried to give the title compound (0.610 g, 93.3%) as a white solid.
[Step 6] Synthesis of compound 11200 HC Olt N so 0 =

N-N N N -N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol) synthesized in step 5, formaldehyde (37.00% solution in water, 0.012 mL, 0.155 mmol) and sodium triacetoxyborohydride (0.033 g, 0.155 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.020 g, 41.9%) as a white solid.
111 NMR (700 MHz, CDC13) 6 7.86 (d, 1H, J = 7.8 Hz), 7.72 (d, 1H, J= 9.4 Hz), 7.56 (t, 1H, J = 7.0 Hz), 7.36 (d, 3H, J=
12.4 Hz), 7.03 (t, 2H, J = 13.6 Hz), 5.01 (d, 2H, J= 22.8 Hz), 3.32 - 3.03 (m, 2H), 2.53 - 2.38 (m, 4H), 2.03 (dd, 4H, J =
43.3, 40.1 Hz), 1.86 (d, 2H, J = 48.6 Hz); LRMS (ES) m/z 463.3 (M++1).
Example 32: Synthesis of compound 11201, 1-ethyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylpiperidine-4-carboxamide HClaL 0 0 r7L0 0 >--CF3 HN
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride 20 (0.050 g, 0.103 mmol) synthesized in step 5 of Example 31, acetaldehyde (0.009 mL, 0.155 mmol) and sodium triacetoxyborohydride (0.033 g, 0.155 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.025 g, 50.9%) as a white solid.
NMR (700 MHz, CDC13) 5 7.85 (d, 1H, J = 6.8 Hz), 7.71 (d, 1H, J = 8.8 Hz), 7.53 (s, 1H), 7.36 (s, 3H), 7.01 (d, 2H, J
= 26.5 Hz), 5.11 - 4.94 (m, 2H), 3.26 (s, 3H), 2.77 (s, 2H), 2.48 (s, 3H), 2.05 - 2.00 (ra, 3H, J = 57.5 Hz), 1.22 (d, 3H, J
= 5.3 Hz); LRMS (ES) m/z 477.3 (M4+1).
Example 33: Synthesis of compound 11202, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-isopropyl-N-phenylpiperidine-4-carboxamide HCIN ro 0 N-N
HN,7 N-N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol) synthesized in step 5 of Example 31, acetone (0.011 mL, 0.155 mmol) and sodium triacetoxyborohydride (0.033 g, 0.155 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.020 g, 39.5%) as a white solid.
NMR (700 MHz, CDC13) 5 7.86 (d, 1H, J = 7.9 Hz), 7.73 (d, 1H, J = 9.5 Hz), 7.55 - 7.48 (m, 1H), 7.40 - 7.33 (m, 3H), 7.05 - 6.98 (m, 2H), 5.02 (s, 2H), 3.40 (t, 3H, J = 58.2 Hz), 2.78 (d, 2H, J = 8.9 Hz), 2.60 (s, 1H), 2.11 (d, 2H, J = 36.1 Hz), 2.00 (d, 4H, J - 9.5 Hz), 1.30 (d, 4H, J = 5.9 Hz); LRMS
(ES) m/z 491.0 (M++1) .
Example 34: Synthesis of compound 11203, 1-acetyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylpiperidine-4-carboxamide HMort 110 (:)710 II 0 0 ¨CF3 HN N-N 01õN N-N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol), synthesized in step 5 of Example 31, and N,N-diisopropylethylamine (0.036 mL, 0.206 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and acetyl chloride (0.008 mL, 0.113 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.032 g, 63.3%) as colorless oil.
NMR (700 MHz, CDC13) 5 7.87 (d, 1H, J = 7.9 Hz), 7.72 (d, 1H, J - 9.4 Hz), 7.62 - 7.55 (m, 1H), 7.39 (s, 3H), 7.12 -7.02 (m, 2H), 5.04 (s, 2H), 4.53 (s, 1H), 3.79 (s, 1H), 2.84 (s, 1H), 2.51 - 2.42 (m, 1H), 2.34 (s, 1H), 2.06 (t, 4H, J = 4.7 Hz), 1.78 (d, 3H, J = 69.3 Hz); LRMS (ES) m/z 491.1 (M++1).
Example 35: Synthesis of compound 11204, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenyl-1-propionylpiperidine-4-carboxamide HCIN [110 (..õ0 0 o.--CF3 N-N' N-N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol), synthesized in step 5 of Example 31, and N,N-diisopropylethylamine (0.036 mL, 0.206 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and propionyl chloride (0.010 mL, 0.113 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 57.7%) as colorless oil.
NMR (700 MHz, CDC13) 6 7.87 (t, 1H, J = 6.2 Hz), 7.74 -7.70 (m, 1H), 7.58 (d, 1H, J = 6.7 Hz), 7.39 (d, 3H, J - 4.5 Hz), 7.06 (s, 2H), 5.04 (s, 3H), 4.54 (s, 1H), 3.83 (s, 1H), 2.78 (s, 1H), 2.31 (s, 4H), 1.77 (s, 2H, J - 67.0 Hz), 1.19 -1.02 (m, 4H); LRMS (ES) m/z 505.3 (M++1).
Example 36: Synthesis of compound 11205, -1-isobutyryl-Olt HCINr,L.
õ
, c, N-N
N-N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol), synthesized in step 5 of Example 31, 20 and N,N-diisopropylethylamine (0.036 mL, 0.206 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and isobutyryl chloride (0.012 mL, 0.113 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 56.1%) as colorless oil.
NMR (700 MHz, CDC13) 6 7.87 (d, 1H, J = 8.0 Hz), 7.71 (t, 1H, J - 11.3 Hz), 7.58 (t, 1H, J = 7.5 Hz), 7.42 - 7.37 (m, 3H), 7.07 (d, 2H, J = 7.7 Hz), 5.00 (d, 2H, J = 39.7 Hz), 4.56 (s, 1H), 4.04 - 3.80 (m, 1H), 2.94 - 2.66 (m, 2H), 2.53 - 2.41 (m, 1H), 2.31 (dt, 1H, J = 45.9, 23.1 Hz), 1.76 (dd, 2H, J =
36.0, 30.1 Hz), 1.10 (d, 8H, J = 6.8 Hz); LRMS (ES) m/z 519.5 (M++1).
Example 37: Synthesis of compound 11206, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenyl-1-(2,2,2-trifluoroacetyl)piperidine-4-carboxamide 0, rA0 =
0 />--0 F3 0 N
N-N
c, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.103 mmol), synthesized in step 5 of Example 31, and N,N-diisopropylethylamine (0.036 mL, 0.206 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and trifluoroacetic anhydride (0.016 mL, 0.113 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (S102, 4 g cartridge;
ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 53.4%) as colorless oil.
NMR (700 MHz, CDC13) 6 7.87 (d, 1H, J - 8.0 Hz), 7.73 (d, 1H, J = 9.6 Hz), 7.57 (t, 1H, J = 7.4 Hz), 7.41 (d, 3H, J =
5.4 Hz), 7.07 (d, 2H, J = 6.9 Hz), 5.10 - 4.98 (m, 2H), 4.43 (d, 1H, J = 13.4 Hz), 3.98 (d, 1H, J = 13.8 Hz), 2.96 (t, 1H, J =
12.8 Hz), 2.74 - 2.58 (m, 1H), 2.54 (t, 1H, J = 10.5 Hz), 1.96 - 1.81 (m, 2H), 1.75 (d, 2H, J = 13.0 Hz); LRMS (ES) m/z 545.4 (M++1)15 Example 38: Synthesis of compound 11207, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-(methylsulfony1)-N-phenylpiperidine-4-carboxamide HCH.L
N
0 >

>-CF3 N--N
HN N-N
6'0 N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxandde hydrochloride (0.050 g, 0.103 mmol), synthesized in step 5 of Example 31, and N,N-diisopropylethylamine (0.036 mL, 0.206 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and methanesulfonyl chloride (0.009 mL, 0.113 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 55.3%) as a white solid.
NMR (700 MHz, CDC13) 5 7.87 (d, 1H, J = 7.8 Hz), 7.73 (d, 1H, J = 9.4 Hz), 7.58 (t, 1H, J = 6.4 Hz), 7.39 (s, 3H), 7.06 (d, 2H, J = 5.7 Hz), 5.04 (s, 2H), 3.74 (d, 2H, J = 10.1 Hz), 2.74 (d, 3H, J = 2.1 Hz), 2.54 (t, 2H, J = 11.7 Hz), 2.36 (dd, 1H, J = 10.1, 7.7 Hz), 1.95 (dd, 2H, J = 23.6, 11.6 Hz), 1.75 (d, 2H, J = 13.2 Hz); LRMS (ES) m/z 527.3 (M++1)15 Example 39: Synthesis of compound 11208, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-methyl-N-phenylpiperidine-4-carboxamide [Step 1] Synthesis of tert-butyl 4-((4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzyl)(phenyl)carbamoyl)piperidine-l-carboxylate N
N

r`LO Ns NH2 r'N'7L0 = LCF2H

Boc,N 0 Tert-butyl 4-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (1.200 g, 2.550 mmol), synthesized in step 2 of Example 31, and triethylamine (0.427 mL, 3.060 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and difluoroacetic anhydride (0.349 mL, 2.805 mmol) was added to the solution. The mixture was stirred at the same temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.350 g, 96.5%) as colorless oil.
[Step 2] Synthesis of tert-butyl 4-((4-(5--= rõ,,L 010 N, A 0 (0 H N CF2H 0 I ¨CF21-1 Boc'N 0 N¨N
Tert-butyl 4-((4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)(phenyl)carbamoyl)piperidine-1-20 carboxylate (1.350 g, 2.461 mmol), synthesized in step 1, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.880 g, 3.691 mmol) were mixed in tetrahydrofuran (100 mL) at room temperature, and the mixture was heated at reflux for 12 hours, and then cooled down to room temperature.
The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane =
from 10% to 30%) and concentrated to give the title compound (0.800 g, 61.3%) as a white solid.
[Step 3] Synthesis of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenylpiperidine-4-carboxamide hydrochloride Olt BoeN N-N
HCI
Tert-butyl 4-((4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)(phenyl)carbamoyl)piperidine-1-carboxylate (0.800 g, 1.508 mmol) synthesized in step 2 was dissolved in dichloromethane (50 mL) at room temperature, and hydrochloric acid (4.00 M solution in dioxane, 1.885 mL, 7.539 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure, and the concentrate was suspended in diethyl ether (50 mL) and filtered. The obtained solid was washed with diethyl ether and dried to give the title compound (0.660 g, 93.7%) as a white solid.
[Step 4] Synthesis of compound 11208 0 rc) 0 0 >-CF2H ----CF2H
HN N-WN N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol) synthesized in step 3, formaldehyde (37.00 % solution in water, 0.012 mL, 0.161 mmol) and sodium triacetoxyborohydride (0.034 g, 0.161 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to give the title compound (0.022 g, 46.2%) as a white solid.
NMR (700 MHz, CDC13) 6 7.86 (t, 1H, J = 13.4 Hz), 7.72 (d, 1H, J = 9.7 Hz), 7.55 (t, 1H, J = 7.5 Hz), 7.41 - 7.33 (m, 3H), 7.09 - 7.02 (m, 2H), 6.92 (t, 1H, J = 51.7 Hz), 5.07 -4.94 (m, 2H), 3.16 - 3.02 (m, 2H), 2.38 (s, 1H), 2.24 (s, 3H), 1.97 (d, 3H, J = 9.6 Hz), 1.81 (d, 3H, J = 9.7 Hz); LRMS (ES) m/z 445.3 (M++1).
Example 40: Synthesis of compound 11209, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-ethyl-N-phenylpiperidine-4-carboxamide N
0 ______, N
s-L 1110 0 , ro , N-N N-N
HCI
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol) synthesized in step 3 of Example 39, acetaldehyde (0.009 mL, 0.161 mmol) and sodium triacetoxyborohydride (0.034 g, 0.161 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (S102, 4 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to give the title compound (0.025 g, 50.9%) as a white solid.
NMR (700 MHz, CDC13) 6 7.86 (d, 1H, J = 6.0 Hz), 7.73 (d, 1H, J = 6.7 Hz), 7.52 (s, 1H), 7.37 (s, 3H), 7.03 (s, 2H), 6.88 (d, 1H, J = 51.6 Hz), 5.02 (s, 2H), 3.48 (d, 2H, J = 5.4 Hz), 3.25 (s, 3H), 2.77 (s, 3H), 2.50 (s, 2H), 1.25 (s, 4H);
LRMS (ES) m/z 459.2 (W+1).

Example 41: Synthesis of compound 11210, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-isopropyl-N-phenylpiperidine-4-carboxamide HCHLN= 0 ¨CFH0 N-N N N-N
5 N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol) synthesized in step 3 of Example 39, acetone (0.012 mL, 0.161 mmol) and sodium triacetoxyborohydride (0.034 g, 0.161 mmol) were dissolved in dichloromethane (4 mL)
10 at room temperature, and the solution was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and 15 concentrated to give the title compound (0.020 g, 39.5%) as a white solid.
NMR (700 MHz, CDC13) 5 7.85 (t, 1H, J = 17.4 Hz), 7.75 (d, 1H, J = 9.5 Hz), 7.46 (d, 1H, J = 25.1 Hz), 7.38 (d, 3H, J
= 2.9 Hz), 7.01 (d, 2H, J = 2.6 Hz), 6.97 - 6.81 (nt, 1H), 5.08 20 - 4.98 (m, 2H), 3.59 (s, 1H), 3.38 (d, 1H, J = 17.5 Hz), 2.87 (d, 2H, J = 199.2 Hz), 2.30 (d, 3H, J - 82.5 Hz), 1.95 (d, 3H, J = 47.9 Hz), 1.40 (s, 6H); LRMS (ES) m/z 473.1 (M++1) .

Example 42: Synthesis of compound 11211, 1-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide Olt HC) 0 0 I*1 HN N-N N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol), synthesized in step 3 of Example 39, and N,N-diisopropylethylamine (0.037 ml, 0.214 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and acetyl chloride (0.008 mL, 0.118 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 59.3%) as colorless oil.
NMR (700 MHz, CDC13) 6 7.87 (d, 1H, J = 7.8 Hz), 7.72 (d, 1H, J = 9.5 Hz), 7.56 (t, 1H, J = 7.2 Hz), 7.39 (s, 3H), 7.06 (d, 2H, J = 6.1 Hz), 6.92 (t, 1H, J - 51.6 Hz), 5.03 (t, 2H, J = 11.0 Hz), 4.54 (d, 1H, J = 11.3 Hz), 3.75 (t, 1H, J =
41.8 Hz), 2.83 (d, 1H, J = 11.1 Hz), 2.41 (ddd, 3H, J = 79.6, 32.3, 14.8 Hz), 1.85 (d, 2H, J - 10.1 Hz), 1.79 - 1.62 (m, 4H);

LRMS (ES) m/z 473.4 (M++1).
Example 43: Synthesis of compound 11212, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenyl-1-propionylpiperidine-4-carboxamide HCIN r0 ESI 0 N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol), synthesized in step 3 of Example 39, and W N,N-diisopropylethylamine (0.037 mL, 0.214 mmol) were dissolved in dichloromethane (4 mi) at room temperature, and propionyl chloride (0.010 mL, 0.118 Eno') was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to 15 remove the solvent, and the concentrate was purified by column chromatography (S102, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 57.6%) as colorless oil.
IH NMR (700 MHz, CDC13) ö 7.87 (d, 1H, J = 7.8 Hz), 7.72 20 (d, 1H, J = 9.5 Hz), 7.56 (t, 1H, J = 7.1 Hz), 7.39 (d, 3H, J =
5.5 Hz), 7.05 (t, 2H, J = 13.9 Hz), 6.92 (t, 1H, J = 51.7 Hz), 5.02 (d, 3H, J = 27.7 Hz), 4.55 (s, 1H), 3.92 - 3.68 (m, 1H), 2.96 - 2.66 (m, 2H), 2.45 (t, 2H, J = 10.5 Hz), 1.78 (d, 4H, J
= 56.0 Hz), 1.13 (t, 3H, J - 7.1 Hz); LRMS (ES) m/z 487.2 (M++1).
Example 44: Synthesis of compound 11213, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-isobutyryl-N-phenylpiperidine-4-carboxamide , N-N
N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol), synthesized in step 3 of Example 39, and N,N-diisopropylethylamine (0.037 mL, 0.214 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and isobutyryl chloride (0.012 mL, 0.118 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 56.0%) as colorless oil.
NMR (700 MHz, CDC13) 5 7.90 - 7.82 (m, 1H), 7.72 (t, 1H, J = 10.3 Hz), 7.56 (d, 1H, J = 6.6 Hz), 7.39 (d, 3H, J = 4.7 Hz), 7.06 (d, 2H, J = 3.0 Hz), 6.99 - 6.82 (m, 1H), 5.01 (d, 3H, J = 32.5 Hz), 4.56 (s, 1H), 3.91 (s, 1H), 2.76 (dd, 3H, J =
23.9, 18.5 Hz), 2.46 (d, 2H, J = 6.7 Hz), 2.31 (s, 1H), 1.82 (s, 1H), 1.29 - 1.20 (m, 2H), 1.13 - 1.09 (m, 4H); LRMS (ES) m/z 501.3 (M++1) .
Example 45: Synthesis of compound 11214, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-pheny1-1-(2,2,2-trifluoroacetyl)piperidine-4-carboxamide Olt 40 is r.
0 , N-N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.050 g, 0.107 mmol), synthesized in step 3 of Example 39, and N,N-diisopropylethylamine (0.037 mL, 0.214 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and trifluoroacetic anhydride (0.017 mL, 0.118 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 5% to 70%) and concentrated to give the title compound (0.030 g, 53.2%) as colorless oil.
NMR (700 MHz, CDC13) 6 7.88 (d, 1H, J = 8.0 Hz), 7.72 (t, 1H, J = 20.1 Hz), 7.55 (dd, 1H, J = 20.6, 13.1 Hz), 7.42 (dd, 3H, J = 16.5, 7.5 Hz), 7.07 (d, 2H, J = 7.6 Hz), 7.01 -6.85 (m, 1H), 5.04 (q, 2H, J = 14.8 Hz), 4.43 (d, 1H, J - 13.5 Hz), 3.97 (t, 1H, J = 24.0 Hz), 2.96 (t, 1H, J = 12.7 Hz), 2.65 (t, 1H, J = 12.3 Hz), 2.54 (dt, 1H, J = 16.1, 7.8 Hz), 1.97 -1.83 (m, 2H), 1.75 (d, 2H, J = 13.3 Hz); LRMS (ES) m/z 527.3 (IT+1).
Example 46: Synthesis of compound 11215, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-(methylsulfonyl)-N-phenylpiperidine-4-carboxamide HC) =0 0 1C)7L 4111 0, >--CF2N N-N
N-N ,S, 0' sO
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride 15 (0.050 g, 0.107 mmol), synthesized in step 3 of Example 39, and N,N-diisopropylethylamine (0.037 mL, 0.214 mmol) were dissolved in dichloromethane (4 mL) at room temperature, and methanesulfonyl chloride (0.009 mL, 0.118 mmol) was added to the solution. The mixture was stirred at the same temperature 20 for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane - 5% to 70%) and concentrated to give the title compound (0.030 g, 55.1%) as a white solid.
'H NMR (700 MHz, CDC13) 5 7.88 (d, 1H, J = 7.2 Hz), 7.73 (d, 1H, J = 9.2 Hz), 7.56 (t, 1H, J = 6.1 Hz), 7.39 (s, 3H), 7.06 (s, 2H), 6.93 (td, 1H, J = 51.6, 2.2 Hz), 5.03 (d, 2H, J=
14.7 Hz), 3.75 (d, 2H, J = 9.6 Hz), 2.74 (d, 3H, J = 2.3 Hz), 2.55 (t, 2H, J - 11.7 Hz), 2.36 (dd, 1H, J = 10.0, 7.3 Hz), 1.95 (dd, 2H, J = 23.5, 11.5 Hz), 1.75 (d, 2H, J = 13.3 Hz);
LRMS (ES) m/z 509.3 (M++1).
Example 47: Synthesis of compound 11232, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-methyl-N-phenylazetidine-3-carboxamide [Step 1] Synthesis of tert-butyl 3-((2-fluoro-4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate NH N

1:7)() 'N ( 0 Boc Boc' 0 Tert-butyl 3-(phenylcarbamoyl)azetidine-1-carboxylate (2.000 g, 7.237 mmol) synthesized in step 1 of Example 8 was dissolved in tetrahydrofuran (80 mL), and sodium hydride (60.00 %, 0.579 g, 14.475 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The mixture was stirred for 20 minutes, and then methyl 4-(bromomethyl)-3-fluorobenzoate (2.146 g, 8.685 mmol) was added thereto, followed by additional stirring at 50 C for 12 hours.
Then, the reaction mixture was cooled down to room temperature, and water (20 mL) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column W chromatography (Si02, 80 g cartridge; ethyl acetate/hexane =
from 5% to 50%) and concentrated to give the title compound (2.800 g, 87.4%) as colorless oil.
[Step 2] Synthesis of tert-butyl 3-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate N N
NO(L00 1101 N, N H2 Boc oc ' B'NrA0 Tert-butyl 3-((2-fluoro-4-(methoxycarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (2.500 g, 5.650 mmol), synthesized in step 1, and hydrazine monohydrate (5.481 mL, 112.997 mmol) were mixed in ethanol (100 mL) at room temperature, and the mixture was heated at reflux for 12 hours and cooled down to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent, and water was added to the concentrate, followed by extraction with dichloromethane.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (2.400 g, 96.0%) as a white solid.
[Step 3] Synthesis of tert-butyl 3-((2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)(phenyl)carbamoyl)azetidine-l-carboxylate ,NH2 N,NCF3 BoeNr.
0 N Boc,NID7 Tert-butyl 3-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (1.200 g, 2.712 mmol), synthesized in step 2, and triethylamine (0.454 mL, 3.254 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and trifluoroacetic anhydride (0.415 mL, 2.983 mmol) was added to the solution. The mixture was stirred at the same temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.400 g, 95.9%) as colorless oil.
[Step 4] Synthesis of tert-butyl 3-((2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)(phenyl)carbamoyl)azetidine-l-carboxylate 1.1 NC F3 N/-7L0 Boc'N 0 Boc' Tert-butyl 3-((2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate M (1.400 g, 2.600 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.929 g, 3.900 mmol) were mixed in tetrahydrofuran (100 ml) at room temperature. The mixture was heated at reflux for 12 hours, and then cooled down to room temperature. The reaction mixture was 15 concentrated under reduced pressure, and the concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane - from 10% to 30%) and concentrated to give the title compound (0.800 g, 59.1%) as a white solid.
[Step 5] Synthesis of N-(2-fluoro-4-(5-(trifluoromethyl)-20 1,3,4-oxadiazol-2-yl)benzyl)-N-phenylazetidine-3-carboxamide hydrochloride _________________________________________ 40 /-0 = /0 =
Boc,N HN
N-N N-N
HCI
Tert-butyl 3-((2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (0.800 g, 1.537 mmol) synthesized in step 4 was dissolved in 5 dichloromethane (50 mL) at room temperature, and hydrochloric acid (4.00 M solution in dioxane, 1.921 mL, 7.685 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the 10 concentrate was suspended in diethyl ether (50 ml) and filtered.
The obtained solid was washed with diethyl ether and dried to give the title compound (0.600 g, 85.4%) as a white solid.
[Step 6] Synthesis of compound 11232 Oil HCiA /..1kLI

HN
N¨N N¨N
N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.109 hanol), synthesized in step 5, and foLmaldehyde (37.00% solution in water, 0.012 mL, 0.164 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium 20 triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 20%) and concentrated to give the title compound (0.017 g, 35.8%) as a yellow solid.
NMR (0D012, 700 MHz) 5 7.92 - 7.84 (In, 1H), 7.73 (t, 1H, J - 15.4 Hz), 7.60 - 7.51 (ria, 1H), 7.37 (d, 3H, J = 14.7 Hz), 6.93 (dd, 2H, J = 32.2, 3.1 Hz), 5.11 - 5.00 (m, 2H), 3.84 -3.58 (m, 4H), 3.49 - 3.40 (m, 1H), 2.66 - 2.51 (m, 3H); LRMS
(ES) m/z 435.2 (W-F1) .
Example 48: Synthesis of compound 11233, l-ethyl-N-(2-HCI

rD7L0 0 HN
N-N
N-N
N-(2-flnoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride 20 (0.050 g, 0.109 mmol), synthesized in step 5 of Example 47, and acetaldehyde (0.009 m1, 0.164 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0% to 20%) and concentrated to give the title compound (0.015 g, 30.6%) as a brown solid.
1H NMR (CDC13, 700 MHz) 6 7.88 (d, 1H, J = 7.7 Hz), 7.72 (t, 1H, J = 15.3 Hz), 7.58 (t, 1H, J = 6.9 Hz), 7.40 (d, 3H, J
= 39.7 Hz), 6.96 (t, 2H, J = 20.0 Hz), 5.11 - 4.95 (m, 2H), 3.40 (d, 5H, J - 67.9 Hz), 2.62 (d, 2H, J = 4.5 Hz), 0.95 (d, 3H, J = 71.5 Hz); LRMS (ES) m/z 449.3 (M++1).
Example 49: Synthesis of compound 11234, 1-acetyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylazetidine-3-carboxamide HCIT.N.L
0 f.A1 , N 0 HN N-N
N-N õT

N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 47, and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.009 mL, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; dichloromethane/methanol - 0% to 20%) and concentrated to give the title compound (0.027 g, 53.3%) as a yellow solid.
NMR (CDC13, 700 MHz) 5 7.94 - 7.83 (m, 1H), 7.75 (t, 1H, J = 9.4 Hz), 7.62 - 7.54 (m, 1H), 7.39 (s, 3H), 6.99 (d, 2H, J
- 5.4 Hz), 5.08 (s, 2H), 4.47 (t, 1H, J = 7.0 Hz), 4.08 - 4.01 (m, 1H), 3.94 (t, 1H, J = 8.4 Hz), 3.70 (t, 1H, J = 9.5 Hz), 3.38 - 3.27 (m, 1H), 1.84 (s, 3H); LRMS (ES) m/z 463.3 (M++1) .
Example 50: Synthesis of compound 11235, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenyl-1-propionylazetidine-3-carboxamide 1._AN is HCIf.N.

, HN L >-CF3 N-N
N-N

N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 47, and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and propionyl chloride (0.011 mL, 0.120 nvol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.012 g, 23.0%) as a white solid.
NMR (CDC13, 700 MHz) 5 7.87 (dd, 1H, J = 23.0, 10.1 Hz), 7.75 (d, 1H, J= 9.5 Hz), 7.61 (dt, 1H, J= 15.0, 7.6 Hz), 7.44 - 7.34 (m, 3H), 7.00 (d, 2H, J = 5.7 Hz), 5.13 - 5.02 (m, 2H), 4.41 (d, 1H, J = 76.8 Hz), 3.92 (dd, 21-I, J = 97.6, 59.0 Hz), 3.69 (dd, 1H, J = 59.2, 21.2 Hz), 3.40 - 3.28 (Iirt, 1H), 2.11 (d, 2H, J = 51.5 Hz), 1.13 - 1.05 (m, 3H); LRMS (ES) m/z 477.2 (M++1).
Example 51: Synthesis of compound 11236, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-isobutyryl-N-1!,4 phenylazetidine-3-carboxamide N N-N
HN N-N

N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride 5 (0.050 g, 0.109 mmol), synthesized in step 5 of Example 47, and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) were dissolved in dichloromethane (10 m1) at room temperature, and isobutyryl chloride (0.013 mL, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water 10 was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography 15 (Si02, 4 g cartridge; methanol/dichloromethane - from 0% to 20%) and concentrated to give the title compound (0.036 g, 67.1%) as a white solid.
NMR (CDC13, 700 MHz) 6 7.87 (t, 1H, J = 10.4 Hz), 7.74 (d, 1H, J - 9.6 Hz), 7.61 (dt, 1H, J = 29.5, 7.6 Hz), 7.45 -20 7.33 (m, 3H), 6.98 (dd, 2H, J = 28.1, 7.6 Hz), 5.15 - 4.97 (m, 2H), 4.38 (dd, 1H, J = 60.8, 56.4 Hz), 4.14 - 3.57 (m, 3H), 3.39 - 3.28 (m, 1H), 2.45 - 2.32 (m, 1H), 1.07 (s, 6H); LRMS

(ES) m/z 491.3 (M'1-1).
Example 52: Synthesis of compound 11237, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-(methanesulfony1)-N-phenylazetidine-3-carboxamide 01$
ic) HNI
HCI 101 0, 0 ,N Y N-N
N-N Ao N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 47, and 10 N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and methanesulfonyl chloride (0.009 mL, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed 15 by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (5i02, 4 g cartridge; methanol/dichloromethane =
20 from 0% to 20%) and concentrated to give the title compound (0.026 g, 47.7%) as a white solid.
11.1 NMR (CDC13, 700 MHz) 6 7.89 (t, 1H, J = 9.1 Hz), 7.75 (d, 1H, J = 9.4 Hz), 7.57 (t, 1H, J = 7.5 Hz), 7.40 (d, 3H, J =

1.5 Hz), 6.98 (d, 2H, J = 3.7 Hz), 5.08 (s, 2H), 4.13 (t, 2H, J
= 7.5 Hz), 3.70 (t, 2H, J = 8.3 Hz), 3.36 (p, 1H, J = 7.9 Hz), 2.91 (s, 3H); LRMS (ES) m/z 499.2 (M++1) .
Example 53: Synthesis of compound 11238, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-methyl-N-phenylazetidine-3-carboxamide [Step 1] Synthesis of tert-butyl 3-((4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)(phenyl)carbamoyl)azetidine-l-carboxylate N

N , N F2H
B oc' 0 Boo' 0 Tert-butyl 3-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(phenyl)carbamoyl)aztidine-1-carboxylate (1.200 g, 2.712 mmol), synthesized in step 2 of Example 47, and triethylamine (0.454 mL, 3.254 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and difluoroacetic anhydride (0.371 mL, 2.983 mmol) was added to the solution. The mixture was stirred at the same temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.400 g, 99.2%) as colorless oil.
[Step 2] Synthesis of tert-butyl 3-((4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)(phenyl)carbamoyl)azetidine-l-carboxylate N
ti 0 /-'0 NN )LCF2H /DO 0 e Bo N
0 Boc' N-N
Tert-butyl 3-((4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (1.400 g, 2.690 mmol), synthesized in step 1, and 10 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.961 g, 4.035 mmol) were mixed in tetrahydrofuran (100 ml,), and the mixture was heated under reflux for 12 hours and cooled down to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane = from 10% to 30%) to give the title compound (0.700 g, 51.8%) as a white solid.
[Step 3] Synthesis of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenylazetidine-3-carboxamide hydrochloride 'N
-_7A0 110 0, Boc/
, N HN
N-N

Tert-butyl 3-((4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)(phenyl)carbamoyl)azetidine-1-carboxylate (0.700 g, 1.393 mmol) synthesized in step 2 was dissolved in dichloromethane (50 mL) at room temperature, and hydrochloric acid (4.00 M solution in dioxane, 1.741 mL, 6.965 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was suspended in diethyl ether (50 mL) and filtered.
The obtained solid was washed with diethyl ether and dried to give the title compound (0.600 g, 98.1%) as a white solid.
[Step 4] Synthesis of compound 11238 N
N
HCI

H,Er-j 0 , 0 ----CF2H
N-N N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3, and formaldehyde (37.00 % solution in water, 0.013 mL, 0.171 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.036 g, 0.171 nutol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane from 0% to 20%) and concentrated to give the title compound (0.010 g, 21.1%) as a white solid.
NMR (CDC13, 700 MHz) 5 7.88 (d, 1H, J = 7.8 Hz), 7.73 (d, 1H, J = 9.6 Hz), 7.61 - 7.53 (m, 1H), 7.35 (t, 3H, J = 9.7 Hz), 7.15 (d, 1H, J = 6.8 Hz), 6.97 (dd, 2H, J = 29.0, 22.5 Hz), 5.11 - 4.97 (m, 2H), 3.24 (dd, 4H, J = 67.4, 30.6 Hz), 2.32 (s, 3H), 2.00 - 1.68 (m, IH); LRMS (ES) m/z 417.3 (M++1) .
Example 54: Synthesis of compound 11239, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-ethyl-N-phenylazetidine-3-carboxamide ra....to µ1.--CF2H

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and acetaldehyde (0.010 mL, 0.171 mmol) were dissolved in 20 dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.036 g, 0.171 minol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0% to 20%) and concentrated to give the title compound (0.017 g, 34.7%) as a yellow solid.
NMR (CDC13, 700 MHz) 6 7.91 - 7.83 (m, 1H), 7.74 (d, 1H, J = 9.7 Hz), 7.57 - 7.49 (m, 1H), 7.44 - 7.34 (m, 3H), 7.02 -6.83 (m, 3H), 5.10 - 4.99 (m, 2H), 3.71 - 3.59 (m, 2H), 3.52 (dd, 2H, J - 19.3, 11.2 Hz), 3.49 - 3.37 (m, 1H), 2.84 - 2.72 (m, 2H), 1.13 - 1.00 (m, 3H); LRMS (ES) m/z 431.3 (M++1).
Example 55: Synthesis of compound 11240, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-isopropyl-N-phenylazetidine-3-carboxamide 0 =
( HCIr- Os .1 --CF211 HL- 0-.--CF21-1 N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride 20 (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and acetone (0.013 mL, 0.171 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.036 g, 0.171 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane from 0% to 20%) and concentrated to give the title compound (0.025 g, 49.4%) as a yellow solid.
IH NMR (CDC13, 700 MHz) 5 7.92 - 7.82 (m, 1H), 7.73 (t, 1H, J - 8.8 Hz), 7.54 (t, 1H, J = 7.5 Hz), 7.38 (d, 3H, J - 5.3 Hz), 7.04 - 6.82 (m, 3H), 5.03 (d, 2H, J = 21.2 Hz), 3.63 - 3.34 (m, 5H), 2.80 - 2.67 (m, 1H), 1.03 (t, 6H, J = 7.8 Hz); LRMS (ES) m/z 445.3 (M++1).
Example 56: Synthesis of compound 11241, 1-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide 1..LN 0 40 ';)----CF2H
'/.--CF2H

20 N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and N,N-diisopropylethylamine (0.039 mL, 0.228 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.009 mL, 0.125 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 20%) W and concentrated to give the title compound (0.014 g, 27.6%) as a yellow solid.
NMR (CDC13, 700 MHz) 6 7.88 (d, 1H, J = 7.9 Hz), 7.73 (t, 1H, J = 12.4 Hz), 7.58 (t, 1H, J = 7.5 Hz), 7.39 (d, 3H, J
= 5.2 Hz), 7.01 - 6.82 (m, 3H), 5.10 - 5.05 (m, 2H), 4.48 (t, 1H, J - 7.1 Hz), 4.09 - 4.01 (m, 1H), 3.94 (t, 1H, J = 8.3 Hz), 3.70 (t, 1H, J = 9.3 Hz), 3.36 - 3.27 (m, 1H), 1.50 - 1.43 (m, 3H); LRMS (ES) m/z 445.3 (M++1).
Example 57: Synthesis of compound 11242, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenyl-1-propionylazetidine-3-carboxamide N

N-N
N-N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and N,N-diisopropylethylamine (0.039 mL, 0.228 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and propionyl chloride (0.011 mL, 0.125 nwol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.017 g, 32.5%) as a yellow solid.
NMR (CDC13, 700 MHz) 5 7.88 (d, 1H, J = 7.9 Hz), 7.74 (d, 1H, J = 9.7 Hz), 7.57 (dd, 1H, J = 19.2, 11.7 Hz), 7.40 (dd, 3H, J = 16.9, 7.9 Hz), 7.03 - 6.83 (m, 3H), 5.08 (s, 2H), 4.56 - 4.32 (m, 1H), 4.03 (ddd, 4H, J = 153.6, 33.8, 26.6 Hz), 3.36 - 3.28 (m, 1H), 2.89 - 2.80 (m, 1H), 2.07 (d, 2H, J = 8.1 Hz), 1.10 (t, 3H, J= 7.6 Hz); LRMS (ES) m/z 459.3 (M++1) .
Example 58: Synthesis of compound 11243, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-isobutyryl-N-phenylazetidine-3-carboxamide >-CF21-1 ENzr-- N_N
N_N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and 5 N,N-diisopropylethylamine (0.039 nI, 0.228 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and isobutyryl chloride (0.013 mL, 0.125 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with 10 ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane - from 0% to 20%) 15 and concentrated to give the title compound (0.023 g, 42.7%) as a white solid.
NMR (CDC13, 700 MHz) 6 7.88 (dd, 1H, J = 8.0, 1.2 Hz), 7.74 (dd, 1H, J = 9.7, 1.1 Hz), 7.61 - 7.54 (nt, 1H), 7.39 (dt, 3H, J = 11.8, 4.2 Hz), 7.02 - 6.83 (nt, 3H), 5.14 - 4.97 (m, 2H), 20 4.50 (s, 1H), 4.00 (d, 2H, J = 56.0 Hz), 3.74 - 3.61 (m, 1H), 3.38 - 3.24 (m, 1H), 2.43 - 2.34 (m, 1H), 1.07 (d, 6H, J = 25.4 Hz); LRMS (ES) m/z 473.3 (M++1).

Example 59: Synthesis of compound 11244, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-pheny1-1-(2,2,2-trifluoroacetyl)azetidine-3-carboxamide 0 >-CF2H F 3C N 1.1 HN
N-N

5 N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and N,N-diisopropylethylamine (0.039 mL, 0.228 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2,2-10 trifluoroacetic anhydride (0.018 mL, 0.125 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with 15 magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02 plate, 20 x 20 x 1 mm;
methanol/dichloromethane = 10 %) and concentrated to give the title compound (0.005 g, 8.8%) as a white solid.
20 NMR (CDC13, 700 MHz) 6 7.89 (d, 1H, J = 7.9 Hz), 7.76 (d, 1H, J = 9.6 Hz), 7.57 (dd, 1H, J = 15.6, 8.0 Hz), 7.42 (d, 3H, J = 3.2 Hz), 7.02 - 6.83 (m, 3H), 5.13 - 5.07 (in, 2H), 4.74 - 4.67 (m, 1H), 4.30 - 4.24 (m, 1H), 4.19 (t, 1H, J = 9.1 Hz), 3.87 (t, 1H, J = 9.8 Hz), 3.47 (dt, 1H, J = 22.3, 7.9 Hz); LRMS
(ES) m/z 499.1 (1\t+1).
Example 60: Synthesis of compound 11245, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-(methylsulfony1)-N-phenylazetidine-3-carboxamide HCI = N

HN A,N
N-N
N-N
o'\
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylazetidine-3-carboxamide hydrochloride (0.050 g, 0.114 mmol), synthesized in step 3 of Example 53, and N,N-diisopropylethylamine (0.040 mL, 0.228 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and methanesulfonyl chloride (0.010 mL, 0.125 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane =
from 0% to 20 %) and concentrated to give the title compound (0.013 g, 23.7%) as a white solid.

NMR (CDC13, 700 MHz) 5 7.88 (d, 1H, J = 7.9 Hz), 7.75 (d, 1H, J = 9.6 Hz), 7.55 (dd, 1H, J = 18.1, 10.7 Hz), 7.40 (d, 3H, J = 1.6 Hz), 7.02 - 6.84 (m, 3H), 5.07 (d, 2H, J = 14.4 Hz), 4.14 (t, 2H, J= 7.5 Hz), 3.71 (t, 2H, J= 8.3 Hz), 3.39 - 3.32 (m, 1H), 2.91 (s, 3H); LRMS (ES) m/z 481.2 (M++1).
Example 61: Synthesis of compound 11246, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-phenylacetamide [Step 1] Synthesis of methyl 3-fluoro-4-((N-phenylacetamido)methyl)benzoate 010 .
10 0 io OMe OMe Methyl 3-fluoro-4-((phenylamino)methyl)benzoate (0.150 g, 0.579 mmol) and N,N-diisopropylamine (0.199 mL, 1.157 mmol) 15 were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.045 mL, 0.636 mmol) was added to the solution, followed by stirring at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed 20 with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80 %) and concentrated to give the title compound (0.158 g, 90.6%) as colorless oil.
[Step 2] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylacetamide Olt OMe HN,NH2 Methyl 3-fluoro-4-((N-phenylacetamido)methyl)benzoate (0.158 g, 0.524 mmol), synthesized in step 1, and nitrogen oxide (0.495 mL, 10.487 mmol) were mixed in ethanol (10 mL) at room temperature, and the mixture was heated under reflux for 5 hours and cooled down to room temperature. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.150 g, 94.9%) as colorless oil.
[Step 3] Synthesis of N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-phenylacetamide Olt N

N-N).LCF3 HN,NH2 N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylacetamide (0.075 g, 0.249 mmol), synthesized in step 2, and triethylamine (0.069 mL, 0.498 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and trifluoroacetic anhydride (0.042 mL, 0.299 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.090 g, 91.0%) as colorless oil.
[Step 4] Synthesis of compound 11246 F N H 0 _________ F N /10 Nif-j"Lo 41117. 14." N C F2H
Boe Wie N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-phenylacetamide (0.090 g, 0.227 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.081 g, 0.340 mmol) were mixed with dichloromethane (10 mL), and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane - from 0% to 80%) and concentrated to give the title compound (0.004 g, 4.7%) as colorless oil.
'H NMR (CDC13, 400 MHz) 5 7.84 (dd, 1H, J = 8.0, 1.6 Hz), 7.68 (dd, 1H J= 9.7, 1.4 Hz), 7.60 (t, J= 7.6 Hz, 1H), 7.36 -7.28 (m, 3H), 7.05 (dd, 2H, J - 7.9, 1.4 Hz), 5.03 (s, 2H), 1.91 (s, 3H); LRMS (ES) m/z 380.2 (M++1).
Example 62: Synthesis of compound 11247, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-phenylacetamide [Step 1] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-N-phenylacetamide 0 ,,N( H
0 "NACF2H
HN_NH2 N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-phenylacetamide (0.075 g, 0.249 mmol), synthesized in step 2 of Example 61, and triethylamine (0.069 mL, 0.498 litmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.032 mL, 0.299 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.093 g, 98.5%) as colorless oil.
[Step 2] Synthesis of compound 11247 N F2H 0 >---CF2H
N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-phenylacetamide (0.093 g. 0.245 mmol), synthesized in step 1, 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.088 g, 0.368 mmol) were mixed in dichloromethane (10 ml,), and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.005 g, 5.6 %) as colorless oil.

NMR (CDC13, 400 MHz) 5 7.84 (dd, J = 8.0, 1.6 Hz, 1H), 7.69 (dd, J - 9.8, 1.5 Hz, 1H), 7.58 (t, J = 7.6 Hz, 1H), 7.37 - 7.30 (m, 3H),7.06 - 7.03 (m, 2H), 6.90 (t, J = 48.6 Hz, 1H), 5.04 (s, 2H), 1.93 (s, 3H); LRMS (ES) m/z 362.2 (M++1).
Example 63: Synthesis of compound 11325, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluoropheny1)-1-methylazetidine-3-carboxamide [Step 1] Synthesis of tert-butyl 3-((2-fluoro-4-(methoxycarbonyl)benzyl)(3-fluorophenyl)carbamoyl)azetidine-l-carboxylate 410 Olt NH
NN

Boe Boc' Tert-butyl 3-((3-fluorophenyl)carbamoyl)azetidine-1-carboxylate (0.550 g, 1.869 mmol) was dissolved in tetrahydrofuran (80 mL), and sodium hydride (60.00%, 0.149 g, 3.737 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The mixture was stirred for minutes, and then methyl 4-(bramomethyl)-3-fluorobenzoate (0.508 g, 2.056 mmol) was added thereto. The reaction mixture 20 was further stirred at 50 C for 12 hours and cooled to room temperature. Then, water (20 mL) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 80 g cartridge; ethyl acetate/hexane = from 5% to 50%) and concentrated to give the title compound (0.700 g, 81.4%) as a white solid.
[Step 2] Synthesis of tert-butyl 3-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(3-fluorophenyl)carbamoyl)azetidine-1-carboxylate N 40, 'N 0 NIA 0 HN'NH2 Boc Boe Tert-butyl 3-((2-fluoro-4-(methoxycarbonyl)benzyl) (3-fluorophenyl)carbamoyl)azetidine-1-carboxylate (0.700 g, 1.520 mmol), synthesized in step 1, and hydrazine monohydrate (1.475 mL, 30.403 mmol) were mixed in ethanol (50 mi) at room temperature, and the mixture was heated under reflux for 12 hours, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent, and water was added to the concentrate, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.600 g, 85.7 %) as white solid.
[Step 3] Synthesis of tert-butyl 3-((4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)(3-fluorophenyl)carbamoyl)azetidine-1-carboxylate Boc'dal 4111 N,NH2 oe B N,NCF2H

Tert-butyl 3-((2-fluoro-4-(hydrazinecarbonyl)benzyl)(3-fluorophenyl)carbamoyl)azetidine-1-carboxylate (0.600 g, 1.303 mmol), synthesized in step 2, and triethylamine (0.218 mL, 1.564 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and difluoroacetic anhydride (0.178 mL, 1.433 mmol) was added to the solution. The mixture was stirred at the same temperature for 4 hours. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was 0 washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.600 g, 85.5%) as colorless oil.
[Step 4] Synthesis of tert-butyl (difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)(3-fluorophenyl)carbamoyl)azetidine-l-carboxylate Pl'IY N)LCF2H
' N
Boo Boc'N 0 N-N
Tert-butyl 3-((4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)(3-fluorophenyl)carbamoyl)azetidine-1-carboxylate (0.600 g, 1.114 mmol), synthesized in step 3, and 5 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.398 g, 1.671 mmol) were mixed in tetrahydrofuran (15 mL) at room temperature. The mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 40 g cartridge; ethyl acetate/hexane - from 5% to 30%) and concentrated to give the title compound (0.500 g, 86.2%) as a white solid.
[Step 5] Synthesis of N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride f--A0 /-A0 Boc'N HN
N-N N-N
HCI

Tert-butyl 3-((4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)(3-fluorophenyl)carbamoyl)azetidine-1-carboxylate (0.500 g, 0.961 mmol) synthesized in step 4 was dissolved in dichloromethane (50 mL) at room temperature, and hydrochloric acid (4.00 M solution in dioxane, 1.201 mL, 4.803 mmol) was added to the solution. The mixture was stirred at the same temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was suspended in diethyl ether (50 mL) and filtered. The obtained solid was washed with diethyl ether and dried to afford the title compound (0.430 g, 98.0%) as a white solid.
[Step 63 Synthesis of compound 11325 1..t4L1 FHCIrL 1.1 HN ,,141 N-N N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5, and formaldehyde (37.00% solution in water, 0.012 mL, 0.164 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge;
methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.007 g, 14.7%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.87 (dd, 1H, J = 8.0, 1.6 Hz), 7.74 (dd, 1H, J = 9.8, 1.5 Hz), 7.53 (t, 1H, J - 7.6 Hz), 7.34 (td, 1H, J= 8.2, 6.4 Hz), 7.09 (td, 1H, J= 8.3, 2.3 Hz), 6.93 (dd, 11-1, J = 68.9, 34.4 Hz), 6.76 - 6.66 (m, 2H), 4.99 (d, 2H, J = 19.7 Hz), 3.60 (dd, 2H, J = 18.8, 10.8 Hz), 3.46 (t, 2H, J
- 8.0 Hz), 3.35 (dt, 1H, J = 16.2, 8.1 Hz), 2.44 (d, 3H, J =
13.4 Hz); LRMS (ES) m/z 435.2 (M1+1).
Example 64: Synthesis of compound 11326, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-ethyl-N-(3-fluorophenyl)azetidine-3-carboxamide N
HC S

0 0 =
HN N-N
N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and acetaldehyde (0.009 mL, 0.164 mmol) were dissolved in dichloromethane (10 ml) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.007 g, 14.3%) as yellow oil.
NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.0, 1.5 Hz), 7.73 (dd, 1H, J = 9.8, 1.5 Hz), 7.54 (t, 1H, J = 7.6 Hz), 7.33 (td, 1H, J= 8.1, 6.4 Hz), 7.08 (td, 1H, J= 8.3, 1.9 Hz), 6.93 (dd, 1H, J = 69.2, 34.1 Hz), 6.78 - 6.69 (m, 2H), 4.99 (d, 2H, J = 19.8 Hz), 3.50 - 3.18 (m, 5H), 2.59 (q, 2H, J = 7.2 Hz), 0.96 (t, 3H, J= 7.2 Hz); LRMS (ES) m/z 449.3 (W+1).
Example 65: Synthesis of compound 11327, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluoropheny1)-1-propylazetidine-3-carboxamide ioF
F F N

0 i4/
to>¨CF21-1 N-N
H NIY
N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and propionaldehyde (0.010 g, 0.164 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.017 g, 33.6%) as colorless oil.
1H NMR (400 MHz, CDC13) 6 7.86 (dd, 1H, J = 8.0, 1.5 Hz), 7.72 (dd, 1H, J - 9.8, 1.5 Hz), 7.51 (dd, 1H, J = 15.7, 8.0 Hz), 7.32 (tt, 1H, J = 11.9, 5.9 Hz), 7.07 (td, 1H, J = 8.1, 2.1 Hz), 6.90 (dd, 1H, J = 58.6, 44.7 Hz), 6.77 - 6.68 (m, 2H), 4.99 (d, 2H, J = 16.3 Hz), 3.61 - 3.47 (m, 2H), 3.47 - 3.31 (nri, 3H), 2.57 (dd, 2H, J = 18.4, 10.5 Hz), 1.39 (dq, 2H, J = 14.9, 7.4 Hz), 0.90 - 0.81 (m, 3H); LRMS (ES) m/z 463.2 (M++1) .
Example 66: Synthesis of compound 11328, 1-butyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide F N r..=LN
, 0 HN
N-N N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 _____________________________________ synthesized in step 5 of Example 63, and butyraldehyde (0.012 g, 0.164 mmol) were dissolved in dichloromethane (10 ml,) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 0% to 20%) and concentrated to give the title compound (0.020 g, 38.4%) as colorless oil.
NMR (400 MHz, CDC13) 5 7.86 (dd, 1H, J = 8.0, 1.5 Hz), 7.73 (dd, 1H, J = 9.8, 1.5 Hz), 7.51 (t, 1H, J = 7.6 Hz), 7.34 (dt, 1H, J = 14.2, 6.5 Hz), 7.13 - 7.05 (m, 1H), 6.90 (dd, 1H, J = 58.6, 44.7 Hz), 6.77 - 6.64 (m, 2H), 4.99 (d, 2H, J = 13.6 Hz), 3.71 - 3.56 (m, 2H), 3.56 - 3.38 (m, 3H), 2.67 (dd, 2H, J
= 19.4, 11.4 Hz), 1.42 - 1.21 (m, 4H), 0.92 - 0.79 (m, 3H);
LRMS (ES) m/z 477.3 (W+1).

Example 67: Synthesis of compound 11329, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluoropheny1)-1-isopropylazetidine-3-arboxamide /..N 0 F

HNr 0 ./ -CF2H
>-CF21-1 Y N-N
N-N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and acetone (0.012 mi, 0.164 nuol) were dissolved W in dichloromethane (10 mL) at room temperature, and sodium triacetoxyborohydride (0.035 g, 0.164 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed 15 with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si 2, 4 g cartridge; methanol/dichloromethane =
from 0% to 20%) and concentrated to give the title compound 20 (0.010 g, 19.8%) as a white solid.
NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.0, 1.5 Hz), 7.73 (dd, 1H, J = 9.8, 1.5 Hz), 7.54 (t, 1H, J = 7.5 Hz), 7.33 (tt, 1H, J = 12.4, 6.2 Hz), 7.07 (td, 1H, J = 8.2, 2.0 Hz), 7.05 - 6.77 (m, 1H), 6.78 - 6.68 (m, 2H), 4.98 (d, 2H, J - 19.6 Hz), 3.43 (s, 2H), 3.37 - 3.22 (m, 3H), 2.61 - 2.48 (m, 1H), 1.02 - 0.92 (m, 6H); LRMS (ES) m/z 463.2 (M++1).
Example 68: Synthesis of compound 11330, 1-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide F 41: 101 0N"iIIY

N-N
HNra-N-N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mnol), synthesized in step 5 of Example 63, and N,N-diisopropylethylamine (0.038 ml, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.009 mL, 0.120 nunl) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane - from 0% to 90%) and concentrated to give the title compound (0.016 g, 31.6%) as colorless oil.

NMR (400 MHz, CDC13) 6 7.87 (dd, 1H, J = 8.0, 1.6 Hz), 7.74 (dd, 1H, J = 9.8, 1.6 Hz), 7.60 - 7.51 (m, 1H), 7.40 -7.30 (m, 1H), 7.09 (td, 1H, J = 8.2, 2.4 Hz), 7.06 - 6.78 (m, 1H), 6.74 (dt, 2H, J - 7.9, 6.8 Hz), 5.02 (d, 2H, J = 19.1 Hz), 4.45 (s, 1H), 3.99 (d, 2H, J = 33.8 Hz), 3.79 - 3.68 (m, 1H), 3.31 (tt, 1H, J = 8.8, 6.3 Hz), 1.82 (s, 3H); LRMS (ES) m/z 463.2 (M++1).
Example 69: Synthesis of compound 11331, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluorophenyl)-1-propionylazetidine-3-carboxamide FS
N
F N

0 0 I .---CF2H
N-N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and N,N-diisopropylethylamine (0.038 mL, 0.219 mmo1) were dissolved in dichloromethane (10 ml) at room temperature, and propionyl chloride (0.011 NI, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; ethyl acetate/hexane = from 0% to 90%) and concentrated to give the title compound (0.018 g, 34.5%) as a white solid.
111 NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.0, 1.5 Hz), 7.73 (dd, 1H, J = 9.8, 1.4 Hz), 7.54 (dd, 1H, J = 16.0, 8.3 Hz), 7.35 (dd, 1H, J = 14.4, 8.1 Hz), 7.13 - 7.05 (m, 1H), 7.05 -6.77 (m, 1H), 6.74 (dd, 2H, J = 7.5, 5.3 Hz), 5.07 - 4.99 (m, 2H), 4.35 (dd, 1H, J = 24.2, 19.7 Hz), 4.14 - 3.79 (m, 2H), 3.79 - 3.65 (m, 1H), 3.32 (tt, 1H, J = 8.9, 6.4 Hz), 2.11 -1.94 (m, 2H), 1.08 (dd, 3H, J = 10.0, 5.1 Hz); LRMS (ES) m/z 477.3 (M++1) .
Example 70: Synthesis of compound 11332, N-(4-(5-H Nrj/LO )).-C F2 H
N õIirN ---CF2F1 N -N

N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and N,N-diisopropylethylamine (0.038 ml, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and isobutyryl chloride (0.013 mL, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 90%) and concentrated to give the title compound (0.021 g, 39.1%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.87 (dd, 1H, J = 8.0, 1.4 Hz), 7.72 (dt, 1H, J = 15.7, 7.8 Hz), 7.54 (dd, 1H, J = 15.6, 8.0 Hz), 7.36 (dd, 1H, J = 8.3, 6.3 Hz), 7.15 - 7.05 (m, 1H), 7.05 - 6.78 (m, 1H), 6.78 - 6.68 (m, 2H), 5.02 (d, 2H, J = 19.0 Hz), 4.47 (s, 1H), 4.07 - 3.62 (m, 3H), 3.38 - 3.25 (m, 1H), 2.48 -2.30 (m, 1H), 1.11 - 0.95 (m, 6H); LRMS (ES) m/z 491.2 (M++1) .
Example 71: Synthesis of compound 11333, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluoropheny1)-1-(methylsulfonyl)azetidine-3-carboxamide 41$
F N
4ci ----CF2F1 2µs,N N-N
N-N
o-\
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and N,N-diisopropylethylamine (0.038 mi, 0.219 mmol) were dissolved in dichloromethane (10 ml) at room temperature, and methanesulfonyl chloride (0.009 mi, 0.120 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 90%) and concentrated to give the title compound (0.012 g, 22.0%) as a white solid.
NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.0, 1.5 Hz), 7.74 (dd, 1H, J = 9.8, 1.4 Hz), 7.52 (dd, 1H, J = 15.1, 7.5 Hz), 7.36 (dd, 1H, J = 11.1, 5.0 Hz), 7.14 - 7.07 (m, 1H), 7.05 -6.78 (m, 1H), 6.78 - 6.69 (in, 2H), 5.08 - 4.98 (m, 2H), 4.16 -4.07 (m, 2H), 3.77 - 3.68 (ra, 2H), 3.41 - 3.28 (m, 1H), 2.89 (d, 31-I, J = 5.3 Hz); LRMS (ES) m/z 499.2 (M++1).
Example 72: Synthesis of compound 11334, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-(ethylsulfony1)-N-(3-fluorophenyl)azetidine-3-carboxamide F N
F N

).--0 0, CF2H
N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)azetidine-3-carboxamide hydrochloride (0.050 g, 0.109 mmol), synthesized in step 5 of Example 63, and N,N-diisopropylethylamine (0.038 mL, 0.219 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and ethanesulfonyl chloride (0.015 mL, 0.120 mmol) was added to the solution. The mixture was stirred at the sane temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 90%) and concentrated to give the title compound (0.020 g, 35.7%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.87 (dd, 1H, J = 8.0, 1.6 Hz), 7.79 - 7.70 (m, 1H), 7.56 (dd, 1H, J= 15.7, 8.1 Hz), 7.35 (td, 1H, J = 8.1, 6.4 Hz), 7.10 (td, 1H, J = 8.1, 2.1 Hz), 7.07 -6.78 (m, 1H), 6.78 - 6.70 (m, 2H), 5.10 - 4.98 (m, 2H), 4.22 -4.10 (m, 2H), 3.74 - 3.61 (nt, 2H), 3.41 - 3.30 (m, 1H), 3.00 -2.90 (m, 2H), 1.34 (q, 3H, J - 7.4 Hz); LRMS (ES) m/z 513.2 (M++1).
Example 73: Synthesis of compound 11339, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluorophenyl)acetamide [Step 1] Synthesis of methyl 4-(bromomethyl)-3-fluorobenzoate (10 Br OMe OMe Methyl 3-fluoro-4-methylbenzoate (8.500 g, 50.544 mmol), 1-bromopyrolidin-2,5-one (NBS, 9.446 g, 53.071 mmol) and azobisisobutyronitrile (AIBN, 0.415 g, 2.527 mmol) were mixed in dichloromethane (150 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. Water was added to the reaction mixture, 0 followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 40 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (7.600 g, 60.9%) as a white solid.
[Step 2] Synthesis of methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate FN

OMe 3-Fluoroaniline (1.000 g, 8.999 mmol), methyl 4-(bromomethyl)-3-fluorobenzoate (2.446 g, 9.899 mol)synthesized in step 1, and N,N-diisopropylethylamine (3.102 mL, 17.999 5 mmol) were dissolved in acetonitrile (50 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride 10 solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 24 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (2.170 g, 87.0%) as colorless oil.
[Step 3] Synthesis of methyl 3-fluoro-4-((N-(3-fluorophenyl)acetamido)methyl)benzoate OMe OMe Methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate (0.200 g, 0.721 mmol), synthesized in step 2, and N,N-diisopropylethylamine (0.251 mL, 1.443 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and acetyl chloride (0.061 mL, 0.866 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.210 g, 91.2%) as yellow oil.
[Step 4] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)acetamide FS
= IN N
7NLo OMe N,NH2 Methyl 3-fluoro-4-((N-(3-fluorophenyl)acetamido)methyl)benzoate (0.210 g, 0.658 mmol), synthesized in step 3, and hydrazine hydrate (0.658 g, 13.153 mmol) were mixed in ethanol (10 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.187 g, 89.0%) as white foam solid.
[Step 5] Synthesis of compound 11339 0, N H2 /1.-CF2H

N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)acetamide (0.090 g, 0.282 mmol), synthesized in step 4, and triethylamine (0.079 mL, 0.564 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.037 mL, 0.338 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.071 g, 66.4%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.85 (dt, 1H, J = 13.6, 6.8 Hz), 7.75 - 7.66 (m, 1H), 7.63 - 7.52 (m, 1H), 7.32 (tt, 1H, J =
12.0, 6.0 Hz), 7.10 - 7.01 (m, 1H), 6.94 - 6.75 (m, 3H), 5.02 (s, 2H), 1.95 (s, 3H); LRMS (ES) m/z 380.2 (M+1).

Example 74: Synthesis of compound 11340, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-N-(3-fluorophenyl)acetamide [Step 1] N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-(3-fluorophenyl)acetamide N_NH2 'N)LCF3 N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)acetamide (0.090 g, 0.282 mmol), synthesized in step 4 of Example 73, and triethylamine (0.079 mL, 0.564 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and trifluoroacetic anhydride (0.048 mL, 0.338 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.112 g, 95.7%) as yellow oil.
[Step 2] Synthesis of compound 11340 ="" 'N'ILCF3 N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzy1)-N-(3-fluorophenyl)acetamide (0.120 g, 0.289 mmol), synthesized in step 1, and 1-methoxy-N-5 triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.103 g, 0.433 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at room temperature for 1 hour, and then cooled to room temperature to teLminate the reaction. Water was added to the reaction mixture, followed W by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =-15 from 0% to 80%) and concentrated to give the title compound (0.029 g, 25.3%) as colorless oil.
NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.0, 1.4 Hz), 7.73 (d, 1H, J = 9.7 Hz), 7.61 (t, 1H, J = 7.6 Hz), 7.34 (td, 1H, J = 8.1, 6.5 Hz), 7.05 (td, 1H, J = 8.3, 2.1 Hz), 6.84 (dd, 20 2H, J - 22.0, 8.5 Hz), 5.03 (s, 2H), 1.95 (s, 3H); LRMS (ES) m/z 398.1 (M++1).
Example 75: Synthesis of compound 11341, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-N-phenylisonicotinamide [Step 1] Synthesis of methyl 6-((N-phenylisonicotinanddo)nethyl)nicotinate el N
'1:,,Thr õ el N
____...
I ; OMe N( I ,:r. ,,, IN:o rOMe I

Methyl 6-((phenylamino)methyl)nicotinate (0.050 g, 0.206 mmol) and triethylamine (0.058 m.L, 0.413 'alto') were dissolved in dichloromethane (10 mL) at room temperature, and isonicotinoyl chloride hydrochloride (0.044 g, 0.248 mmol) was added to the solution, followed by stirring at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then 0 concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.071 g, 99.0%) as colorless oil.
[Step 2] Synthesis of N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylisonicotinamide 41$ 1 NN=I'l r-N 1N ___.a. I H A0 1 / OMe I r ri.1µ1%/H2 I

Methyl 6-((N-phenylisonicotinamido)methyl)nicotinate (0.071 g, 0.204 mmol), synthesized in step 1, and hydrazine hydrate (0.199 mL, 4.088 mmol) were dissolved in ethanol (10 mL) at 90 C, and the solution was stirred at the same temperature for 1 hour, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.070 g, 98.6%) as colorless oil.
[Step 3] Synthesis of compound 11341 ))-1 N--r'N'==-"14-'N H2 (L 0 N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylisonicotinamide (0.070 g, 0.202 mmol), synthesized in step 2, and triethylamine (0.056 mL, 0.403 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.028 mL, 0.262 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 100%) and concentrated to give the title compound (0.045 g, 54.8%) as colorless oil.
NM (400 MHz, CDC13) 6 9.29 (d, 1H, J = 1.7 Hz), 8.47 (d, 2H, J - 5.3 Hz), 8.38 (dd, 1H, J = 8.2, 2.2 Hz), 7.63 (d, 1H, J = 8.2 Hz), 7.25 - 7.16 (m, 5H), 7.16 - 7.09 (m, 2H), 7.09 - 6.79 (m, 1H), 5.28 (d, 2H, J = 21.7 Hz); LRMS (ES) m/z 408.3 (M++1).
Example 76: Synthesis of compound 11356, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluorophenyl)propionamide [Sep 1] Synthesis of methyl 3-fluoro-4-((N-(3-fluorophenyl)propionamido)nethyl)benzoate [1 OMe F 7 Nev OMe Methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate (0.100 g, 0.361 mmol), synthesized in step 2 of Example 73, and N,N-diisopropylethylamine (0.126 mL, 0.721 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and propionyl chloride (0.041 mL, 0.469 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.100 g, 83.2%) as colorless oil.
[Step 2] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)propionamide __________________________________ F
)L,:, N
OMe N,NH2 Methyl 3-fluoro-4-((N-(3-fluorophenyl)propionamido)methyl)benzoate (0.100 g, 0.300 mmol), synthesized in step 1, and hydrazine monohydrate (0.292 mi, 6.000 mmol) were mixed in ethanol (6 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.098 g, 98.0%) as colorless oil.
[Step 3] Synthesis of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)propionamide N,N H2 Ai 0 is N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)propionamide (0.098 g, 0.294 mmol), synthesized in step 2, and triethylamine (0.082 mL, 0.588 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.038 mL, 0.353 mmol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.120 g, 99.2%) as colorless oil.
[Step 4] Synthesis of compound 11356 (L
F N irt N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)propionamide (0.120 g, 0.292 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.104 g, 0.438 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.018 g, 15.7%) as colorless oil.
11i NMR (400 MHz, CDC13) 5 9.29 (d, 1H, J = 1.7 Hz), 8.47 (d, 2H, J - 5.3 Hz), 8.38 (dd, 1H, J = 8.2, 2.2 Hz), 7.63 (d, 1H, J = 8.2 Hz), 7.25 - 7.16 (m, 5H), 7.16 - 7.09 (Iirt, 2H), 7.09 - 6.79 (m, 1H), 5.28 (d, 2H, J = 21.7 Hz); LRMS (ES) m/z 408.3 (M++1).
Example 77: Synthesis of compound 11357, N-(4-(5-(diflucromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-(3-fluorophenyl)butyramide [Step 1] Synthesis of methyl 3-fluarc-4-((N-(3-fluorophenyl)butyramido)methyl)benzoate OMe ILI
OMe Methyl 3-fluoro-4-(((3-flucrophenyl)amino)methyl)benzoate (0.100 g, 0.361 mmol), synthesized in step 2 of Example 73, and N,N-diisopropylethylamine (0.126 mL, 0.721 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and butyryl chloride (0.049 mL, 0.469 limol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.103 g, 82.2%) as colorless oil.
[Step 2] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)butyramide F Ni1 (101 OMe N,NH2 Methyl 3-fluoro-4-((N-(3-fluorophenyl)butyramido)methyl)benzoate (0.103 g, 0.297 mmol), synthesized in step 1, and hydrazine monohydrate (0.288 mL, 5.930 mmol) were mixed in ethanol (6 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.100 g, 97.1%) as colorless oil.
[Step 3] Synthesis of N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)butyramide N (101 F N H
N ,N H 2 N ,141}=cCF2H
'AC) N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)butyramide (0.100 g, 0.288 mmol), synthesized in step 2, and triethylamine (0.080 niL, 0.576 mml) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.038 mL, 0.345 amol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.120 g, 98.0%) as colorless oil.
[Step 4] Synthesis of compound 11357 git f,t F N

>-CF2H

20 N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)butyramide (0.120 g, 0.282 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.101 g, 0.423 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.012 g, 10.4%) as colorless oil.
NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J = 8.1, 1.7 Hz), 7.72 (dd, 1H, J = 9.8, 1.7 Hz), 7.59 (t, 1H, J - 7.6 Hz), 7.33 (td, 1H, J= 8.1, 6.3 Hz), 7.11 - 7.01 (m, 1H), 6.93 - 6.75 (m, 3H), 5.02 (s, 2H), 2.10 (t, 2H, J - 7.4 Hz), 1.64 (h, 2H, J =
7.4 Hz), 0.86 (t, 3H, J = 7.4 Hz); LRMS (ES) m/z 408.2(M+1) Example 78: Synthesis of compound 11358, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-N-(3-fluoropheny1)-3-methylbutanamide [Step 1] Synthesis of methyl 3-fluoro-4-((N-(3-fluoropheny1)-3-methylbutananddo)methyl)benzoate N
H F N om OMe Methyl 3-fluoro-4-(((3-fluorophenyl)amino)methyl)benzoate (0.100 g, 0.361 mmol), synthesized in step 2 of Example 73, and N,N-diisopropylethylamine (0.126 mL, 0.721 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 3-methylbutanoyl chloride (0.057 mL, 0.469 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.115 g, 88.2%) as colorless oil.
[Step 2] Synthesis of N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluorophenyl)-3-methylbutanamide .L.1 VLI
OMe N,NH2 Methyl 3-fluoro-4-((N-(3-fluoropheny1)-3-methylbutanamido)methyl)benzoate (0.115 g, 0.318 mmol), synthesized in step 1, and hydrazine monohydrate (0.309 mL, 6.364 mmol) were mixed in ethanol (6 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.105 g, 91.3%) as colorless oil.
[Step 3] N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-N-(3-fluorophenyl)-3-methylbutanamide =

H
N , NH2 N F2H

N-(2-fluoro-4-(hydrazinecarbonyl)benzy1)-N-(3-fluoropheny1)-3-methylbutanamide (0.105 g, 0.291 mmol), synthesized in step 2, and triethylamine (0.081 mL, 0.581 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.038 mL, 0.349 mmol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.122 g, 95.6%) as colorless oil.

[Step 4] Synthesis of compound 11358 011 40), NH,N)LCF2H

1.--CF2H

N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzy1)-N-(3-fluoropheny1)-3-methylbutanamide (0.140 g, 0.319 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.114 g, 0.478 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (0.011 g, 8.2%) as colorless oil.
'H NMR (400 MHz, CDC13) 5 7.87 (dd, 1H, J - 8.0, 1.7 Hz), 7.72 (dd, 1H, J = 9.8, 1.7 Hz), 7.60 (t, 1H, J = 7.6 Hz), 7.33 (td, 1H, J = 8.1, 6.3 Hz), 7.10 - 7.02 (m, 1H), 6.93 - 6.74 (m, 3H), 5.03 (s, 2H), 2.18 (dq, 1H, J = 13.5, 6.7 Hz), 2.01 (d, 2H, J - 7.0 Hz), 0.87 (d, 6H, J = 6.6 Hz); LRMS (ES) m/z 422.3 (W+1).

Example 79: Synthesis of compound 11359, N-(3-fluoropheny1)-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)isonicotinamide [Step 1] Synthesis of methyl 6-((N-(3-fluorophenyl)isonicotinamido)methyl)nicotinate 01$
N F
H I
!õ,yome Methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate (0.200 g, 0.768 mmol) and N,N-diisopropylethylamine (0.268 mL, 1.537 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and isonicotinoyl chloride hydrochloride (0.178 g, 0.999 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, -filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 100%) and concentrated to give the title compound (0.277 g, 98.7%) as colorless oil.
[Step 2] Synthesis of N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)isonicotinamide F N
I
r-Ao 0 M e Methyl 6-((N-(3-fluorophenyl)isonicotinamido)methyl)nicotinate (0.277 g, 0.758 mmol), synthesized in step 1, and hydrazine monohydrate (0.737 mL, 15.163 mmol) were mixed in ethanol (10 mL), and the mixture was heated by microwave irradiation at 120 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.220 g, 79.4%) as white foam solid.
[Step 3] Synthesis of N-(3-fluoropheny1)-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)isonicotinamide I I H
0 - N'Fr `C F3 N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)isonicotinamide (0.100 g, 0.274 mmol), synthesized in step 2, and triethylamine (0.076 mL, 0.547 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and trifluoroacetic anhydride (0.050 mL, 0.356 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.121 g, 95.8%) as colorless oil.
[Step 4] Synthesis of compound 11359 010 N Olt N

1 JL, N-(3-fluoropheny1)-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-l-carbonyl)pyridin-2-yl)methyl)isonicotinamide (0.130 g, 0.282 mmol), synthesized in step 3, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.101 g, 0.423 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to telminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; ethyl acetate/hexane = from 0% to 100%) and concentrated to give the title compound (0.024 g, 19.2%) as yellow oil.

NMR (400 MHz, CDC13) 5 9.37 - 9.26 (m, 1H), 8.61 - 8.48 (m, 2H), 8.40 (dd, 1H, J - 8.2, 2.2 Hz), 7.63 (d, 1H, J = 8.2 Hz), 7.32 - 7.27 (m, 2H), 7.18 (td, 1H, J = 8.2, 6.2 Hz), 7.02 (dt, 1H, J = 9.4, 2.3 Hz), 6.96 - 6.87 (m, 2H), 5.28 (s, 2H);
LRMS (ES) m/z 444.3 (M++1).
Example 80: Synthesis of compound 11360, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-N-(3-fluorophenyl)isonicotinamide [Sep 1] Synthesis of N-((5-(2-(2,2-difluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)isonicotinamide 010 F H F r41 0 I
o N'NH2I0 N. N F2 H

N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)isonicotinamide (0.120 g, 0.328 mmol), synthesized in step 2 of Example 79, and triethylamine (0.092 mL, 0.657 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.046 mL, 0.427 mmol) was added to the solution. The mixture was stirred at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.140 g, 96.1%) as colorless oil.

[Step 2] Synthesis of Compound 11360 0N 0F,H

N-((5-(2-(2,2-difluoroacetyl)hydrazine-l-carbonyl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)isonicotinamide (0.140 g, 0.316 mmol), synthesized in step 1, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.113 g, 0.474 mmol) were mixed in tetrahydrofuran (10 mL), and the mixture was heated by microwave irradiation at 150 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 100%) and concentrated to give the title compound (0.021 g, 15.6%) as brown oil.
111 NMR (400 MHz, CDC13) 6 9.35 - 9.24 (m, 1H), 8.57 - 8.48 (rrl, 2H), 8.40 (dd, 1H, J = 8.2, 2.2 Hz), 7.62 (d, 1H, J = 8.2 Hz), 7.24 (d, 2H, J = 1.5 Hz), 7.18 (td, 1H, J - 8.2, 6.3 Hz), 7.08 - 6.98 (m, 1H), 6.95 - 6.80 (m, 3H), 5.27 (s, 2H); LRMS
(ES) m/z 426.3 (M++1) .

Example 81: Synthesis of compound 11376, N-((5-(5-(difluoramethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-N-(3-fluorophenyl)nicotinamide [Step 1] Synthesis of methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate N N
F 14111 NH2 t,17,1(0Me H c7.,5,0Me 3-Fluoroaniline (1.500 g, 13.499 mmol) and methyl 6-formylnicotinate (2.452 g, 14.849 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and sodium W triacetoxyborohydride (4.291 g, 20.248 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (2.830 g, 80.5%) as a yellow solid.
[Step 2] Synthesis of methyl fluorophenyl)nicotinamido)methyl)nicotinate H I
ThrOMe HCI
I OMe Methyl 6-(((3-fluorophenyl)amino)methyl)nicotinate (0.100 g, 0.384 mmol), synthesized in step 1, and triethylamine (0.107 mL, 0.768 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and nicotinoyl chloride hydrochloride (0.103 g, 0.576 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.111 g, 79.1%) as yellow oil.
[Step 3] Synthesis of N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)nicotinamide I OMe N, Methyl 6-((N-(3-fluorophenyl)nicotinamido)methyl)nicotinate (0.111 g, 0.304 mmol), synthesized in step 2, and hydrazine monohydrate (0.295 mL, 6.076 mmol) were mixed in ethanol (10 mL) at room temperature, and the mixture was heated under reflux for 18 hours, and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.108 g, 97.3%) as yellow oil.
[Step 4] Synthesis of N-((5-(2-(2,2-difluoroacetyl)hydrazine-l-carbonyl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)nicotinamide Olt _________________________________________ F H 0 I I N )1.C F2H

N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)nicotinamide (0.111 g, 0.304 mmol), synthesized in step 3, and triethylamine (0.085 mL, 0.608 mmol) were dissolved in tetrahydrofuran (10 ml,) at room temperature, and 2,2-anhydride (0.050 mL, 0.456 mmol) was added to the solution. The mixture was stirred at 80 C for 18 hours, and then cooled to room temperature to telminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.133 g, 98.7%) as colorless oil.

[Step 5] Synthesis of compound 11376 F
N
H ll V.L0 .11%1 '4CF2H

N-((5-(2-(2,2-difluoroacetyl)hydrazine-l-carbonyl)pyridin-2-yl)methyl)-N-(3-fluorophenyl)nicotinamide (0.140 g, 0.316 mmol), synthesized in step 4, and 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.226 g, 0.947 mmol) were mixed in tetrahydrofuran (10 mi), and the mixture was heated by microwave irradiation at 150 C for 1 hour, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.018 g, 13.4%) as brown oil.
NMR (400 MHz, CDC13) 5 9.35 - 9.24 (m, 2H), 8.81 (d, 1H, J = 5.1 Hz), 8.64 - 8.51 (m, 2H), 8.41 (ddd, 1H, J = 8.3, 3.6, 2.3 Hz), 7.81 - 7.62 (m, 2H), 7.26 - 7.15 (m, 2H), 6.88 - 6.42 (m, 2H), 5.32 (d, 2H, J = 2.8 Hz); LRMS (ES) m/z 426.4 (M++1) .
Example 82: Synthesis of compound 11414, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-1-methyl-N-phenylpipetidine-4-carboxamide [Step 1] Synthesis of methyl 6-((1-(tert-butoxycarbony1)-N-phenylpiperidine-4-carboxamido)methyl)nicotinate Oil NH
Br12 Si N
r-0 ____________________________________ , N
Boc'N Bocg 0 Tert-butyl 4-(phenylcarbamoyl)piperidine-1-carboxylate (0.400 g, 1.314 mmol) was dissolved in tetrahydrofuran (30 mL), and sodium hydride (60.00 %, 0.079 g, 1.971 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The mixture was stirred for 20 minutes. Methyl 6-(bromomethyl)nicotinate (0.333 g, 1.446 mmol) was added to the reaction solution, followed by additional stirring at room temperature for 12 hours. Then, water (2 mL) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes.
After completion of the reaction, water was added to the reaction mixture, followed by extraction with dichloromethane.
The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 5% to 40%) and concentrated to give the title compound (0.390 g, 65.4%) as a foam solid.

[Step 2] Synthesis of methyl 6-((N-phenylpiperidine-4-carboxamido)methyl)nicotinate hydrochloride N

I

Boc'N
Methyl 6-((1-(tert-butoxycarbony1)-N-phenylpiperidine-4-carboxamido)methyl)nicotinate (0.390 g, 0.860 mmol), synthesized in step 1, was dissolved in dichloromethane (30 mL), and hydrochloric acid (4.00 M solution in dioxane, 2.150 mL, 8.599 mmol) was added to the solution at 0 C. The mixture was stirred at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.330 g, 98.4%) as white solid.
[Step 3] Synthesis of methyl 6-((l-methyl-N-phenylpiperidine-4-carboxamido)methyl)nicotinate I + )1, _________ Methyl 6-((N-phenylpiperidine-4-carboxamido)methyl)nicotinate hydrochloride (0.150 g, 0.385 mmol) synthesized in step 2, formaldehyde (37.00 % solution in water, 0.143 mL, 1.924 mmol) and sodium triacetoxyborohydride (0.204 g, 0.962 mmol) were dissolved in dichloromethane (20 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane.
The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane - from 0% to 10%) and concentrated to give the title compound (0.120 g, 84.9%) as a foam solid.
[Step 4] Synthesis of N-((5--(hydrazinecarbonyl)pyridin-141N 141, , r(),2 Methyl 6-((l-methyl-N-phenylpiperidine-4-carboxamido)methyl)nicotinate (0.120 g, 0.327 mmol), synthesized in step 3, and hydrazine monohydrate (0.079 mL, 1.633 mmol) were dissolved in ethanol (10 mL) at room temperature, and the solution was heated under reflux for 12 hours, and then cooled to room temperature to terminate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 5% to 30%) and concentrated to give the title compound (0.115 g, 95.8%) as a foam solid.
[Step 5] Synthesis of compound 11414 Nrsi'=== 1:10101 N_ 0 0 N¨N
N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methyl-N-phenylpiperidine-4-carboxamide (0.200 g, 0.544 mmol) synthesized in step 4, 2,2-difluoroacetic anhydride (0.178 mL, 1.633 mmol) and triethylamine (0.152 mL, 1.089 mmol) were dissolved in tetrahydrofuran (10 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated W aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02 plate, 20 x 20 x 1 mm; methanol/dichloromethane = 20 %) and concentrated to give the title compound (0.002 g, 0.9%) as a white solid.
NMR (400 MHz, CDC13) 6 9.30 - 9.24 (m, 1H), 8.36 (dd, 11-I, J = 8.2, 2.2 Hz), 7.58 - 7.33 (m, 5H), 7.25 - 7.22 (m, 1H), 7.10 - 6.80 (m, 1H), 5.05 (s, 2H), 3.46 (d, 2H, J = 11.1 Hz), 3.26 (d, 2H, J - 11.8 Hz), 2.91 (s, 2H), 2.74 (d, 3H, J = 4.1 Hz), 2.36 (s, 1H), 1.96 (d, 2H, J = 14.7 Hz); LRMS (ES) m/z 428.5 (M++1).
Example 83: Synthesis of compound 11418, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-N-(3-fluoropheny1)-1-methylpiperidine-4-carboxamide [Step 1] Synthesis of methyl 6-((1-(tert-butoxycarbony1)-N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate NH N F NYN

r.L0 (21 _______ Boc,N
Tert-butyl 4-((3-fluorophenyl)carbamoyl)piperidine-1-carboxylate (0.400 g, 1.241 mmol) was dissolved in tetrahydrofuran (30 and sodium hydride (60.00 %, 0.074 g, 1.861 mmol) was added slowly to the solution while the temperature was maintained at 0 C. The reaction mixture was stirred for 20 minutes. Then, methyl 6-(bromomethyl)nicotinate (0.314 g, 1.365 mmol) was added to the reaction solution, followed by additional stirring at room temperature for 12 hours. Then, water (2 ml) was added to the reaction mixture at 0 C, followed by stirring for 5 minutes. After completion of the reaction, water was added to the reaction mixture, followed by extraction with dichloromethane. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 5% to 40%) and concentrated to give the title compound (0.400 g, 68.4%) as a foam solid.
[Step 2] Synthesis of methyl 6-((N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate hydrochloride =
rA0 friCI õ

Methyl 6-((1-(tert-butoxycarbony1)-N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate (0.400 g, 0.848 mmol) synthesized in step 1 was dissolved in dichloromethane (30 mL), and hydrochloric acid (4.00 M
solution in dioxane, 2.121 mL, 8.483 mmol) was added to the solution at 0 C. The mixture was stirred at room temperature for 12 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (0.340 g, 98.3%) as white solid.
[Step 3] Synthesis of methyl 6-((N-(3-fluoropheny1)-1-methylpiperidine-4-carboxamido)methyl)nicotinate .F
HNra 0r t-11111j", 0 HM
/ 0 + I /

Methyl 6-((N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate hydrochloride (0.150 g, 0.368 mmol) synthesized in step 2, foLmaldehyde (37.00 % solution in water, 0.137 mL, 1.839 mmol) and sodium triacetoxyborohydride (0.156 g, 0.736 mmol) were dissolved in dichloromethane (20 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane W = from 0% to 10%) and concentrated to give the title compound (0.130 g, 91.7%) as a foam solid.
[Step 4] Synthesis of N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methylpiperidine-4-carboxamide F F = ___________________________________________ Nk--=
I , (-õ-L0 Jõ.õ--1(0, ThiN-NH2 N, Methyl 6-((N-(3-fluoropheny1)-1-methylpiperidine-4-carboxamido)methyl)nicotinate (0.130 g, 0.337 mmol), synthesized in step 3, and hydrazine monohydrate (0.082 mL, 1.686 mmol) were dissolved in ethanol (10 mL) at room temperature, and the solution was heated under reflux for 12 hours, and then cooled to room temperature to telminate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 5% to 30%) and concentrated to give the title compound (0.120 g, 92.3%) as a foam solid.
[Step 5] Synthesis of compound 11418 I
0 N., N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-1-methylpiperidine-4-carboxamide (0.200 g, 0.519 mmol), synthesized in step 4, and triethylamine (0.145 mL, 1.038 mmol) were dissolved in tetrahydrofuran (13 mL), and 2,2-difluoroacetic anhydride (0.085 mL, 0.778 mmol) was added to the solution at room temperature. The reaction solution was heated under reflux for 12 hours, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with dichloromethane.
The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated, and then the obtained material was further purified by chromatography (Si02 plate, 20 x 20 x 1 mm; methanol/dichloromethane = 10 %) and concentrated to give the title compound (0.015 g, 6.5%) as a white solid.

NMR (400 MHz, CDC13) 5 9.25 (m, 1H), 8.38 (nt, 1H), 7.54 (m, 1H), 7.35 (m, 1H), 7.10 - 6.82 (m, 4H), 5.05 (s, 2H), 2.95 (m, 2H), 2.42 - 2.32 (m, 5H), 1.99 - 1.78 (m, 5H); LRMS
(ES) m/z 446.4 (M++1).
Example 84: Synthesis of compound 11419, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-y1)methyl)-1-ethyl-N-(3-fluorophenyl)piperidine-4-carboxamide [Step 1] Synthesis of methyl 6-((1-ethyl-N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate N
010 Olt HCI +
rA'0 -11 Methyl 6-((N-(3-fluorophenyl)piperidine-4-carboxamido)methyl)nicotinate hydrochloride (0.150 g, 0.368 mmol) synthesized in step 2 of Example 83, acetaldehyde (0.104 mL, 1.839 mmol) and sodium triacetoxyborohydride (0.156 g, 0.736 mmol) were dissolved in dichloromethane (20 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with dichloromethane. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane =
from 0% to 10%) and concentrated to give the title compound (0.130 g, 88.5%) as a foam solid.
[Step 2] Synthesis of 1-ethyl-N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-carboxamide Oit lit 0;:tly 0 N 'NH2 rN
Methyl 6- ((1-ethyl-N- (3-fluorophenyl)piperidine-4-carboxamido)methyi)nicotinate (0.130 gf 0.325 mmol), synthesized in step 1, and hydrazine monohydrate (0.079 mL, 1.627 mmol) were dissolved in ethanol (10 mL) at room temperature, and the solution was heated under reflux for 12 hours, and then cooled to room temperature to telminate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 5% to 30%) and concentrated to give the title compound (0.120 g, 92.3%) as a foam solid.
[Step 3] Synthesis of compound 11419 010 1%1 F N H
N - NH2 r() rN 0 rN N-- N
1-ethyl-N-(3-fluoropheny1)-N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)piperidine-4-carboxamide (0.200 g, 0.501 mmol), synthesized in step 2, and triethylamine (0.140 mL, 1.001 mmol) were dissolved in tetrahydrofuran (13 mL), and 2,2-difluoroacetic anhydride (0.082 mL, 0.751 mmol) was added to the solution at room temperature. The reaction solution was heated under reflux for 12 hours, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with dichloromethane. The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure.
The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated, and then the obtained material was further purified by chromatography (Si02 plate, 20 x 20 x 1 mm;
methanol/dichloromethane = 10%) and concentrated to give the title compound (0.015 g, 6.5%) as a white solid.
IH NMR (400 MHz, CDC13) 6 9.25 (m, 1H), 8.37 (m, 1H), 7.52 (m, 1H), 7.36 (m, 1H), 7.12 - 6.82 (m, 4H), 5.04 (s, 2H), 3.11 (m, 2H), 2.63 - 2.16 (m, 4H), 2.01 - 1.90 (m, 5H), 1.18 (m, 3H); LENS (ES) m/z 460.5 (M++1).
Example 85: Synthesis of compound 11534, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(pyrolidin-1-yl)acetamide [Step 1] Synthesis of 2-(benzyloxy)-N-(4-chloro-3-fluorophenyl)acetamide CI

NH
Bn0,,,JLOH

OBn 4-chloro-3-fluoroaniline (1.000 g, 6.870 mmol), 2-(benzyloxy)acetic acid (1.179 mL, 8.244 mmol), 1-ethy1-3-(3-dimethylaminopropyl)carbodiimide (EDC, 2.133 g, 13.740 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (HOBt, 1.857 g, 13.740 mmol) and N,N-diisopropylethylamine (2.393 mL, 13.740 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (1.880 g, 93.2%) as a yellow solid.
[Step 2] Synthesis of methyl 4-((2-(benzyloxy)-N-(3-chloro-4-fluorophenyl)acetamido)methyl)-3-fluorobenzoate NH _ Br 401 , CI
r0 OMe 1101 OMe OBn 0 OBn 0 2-(Benzyloxy)-N-(4-chloro-3-fluorophenyl)acetamide (1.880 g, 6.401 mmol), synthesized in step 1, and calcium carbonate (1.327 g, 9.601 minol) were dissolved in tetrahydrofuran (50 mL) at 0 C, and methyl 4-(bromomethyl)-3-fluorobenzoate (1.898 g, 7.681 mmol) was added to the solution. The mixture was stirred at room temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate.
The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane = from 0% to 50%) and concentrated to give the title compound (1.780 g, 60.5%) as yellow oil.
[Step 3] Synthesis of 2-(benzyloxy)-N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)acetamide Cl (10 , CI 1101 OMe N,NH2 OBn 0 OBn 0 Methyl 4-((2-(benzyloxy)-N-(3-chloro-4-fluorophenyl)acetamido)methyl)-3-fluorobenzoate (1.780 g, 3.871 mmol), synthesized in step 2, and hydrazine monohydrate (5.644 20 mL, 116.120 mmol) were dissolved in ethanol (8 mL)/water (2 mL) at room temperature, and the solution was stirred at 80 C for 12 hours, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (1.580 g, 88.8%, yellow solid).
[Step 4] Synthesis of 2-(benzyloxy)-N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)acetamide N,2 , CI4 410 H ?
NH
'1-1 OBn 0 OBn 0 NCF2 2-(Benzyloxy)-N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)acetamide (1.580 g, 3.436 mmol), synthesized in step 3, and triethylamine (0.958 mL, 6.871 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.513 mL, 4.123 mmol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (1.120 g, 60.6%) as colorless oil.

[Step 5] Synthesis of N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzyl)-2-hydroxyacetamide CI 0 __________ CIN.L 0 =
0 N1. (oCF2H N'N)LCF2H
OBn 0 OH 0 2-(Benzyloxy)-N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzyl)acetamide (0.880 g, 1.636 mmol) synthesized in step 4 was dissolved in methanol (50 mL) at room temperature, and 10%-Pd/C (600 mg) was added slowly to the solution. The mixture was stirred at the same temperature for 5 hours under a hydrogen balloon. The reaction mixture was filtered through a celite pad to remove solids, and water was added to the filtrate, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.658 g, 89.8%) as yellow oil.
[Step 6] Synthesis of 2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate CI N
r..o CI
'NACF2H 0 r0 */ .¨CF21-1 OH 0 0Ms N-N
N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzy1)-2-hydroxyacetamide (0.658 g, 1.470 mmol), synthesized in step 5, and N,N-diisopropylethylamine (0.768 mL, 4.409 mmol) were dissolved in dichloromethane (50 mL) at room temperature, and methanesulfonyl chloride (0.284 mL, 3.674 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 50%) and concentrated to give the title compound (0.254 g, 34.0%) as yellow oil.
[Step 7] Synthesis of compound 11534 CI
(HL
0, Ho --CF2H N¨N
0Ms N--N
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6, pyrrolidine (0.011 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge;
methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.013 g, 27.3%) as colorless oil.
11.1 NMR (400 MHz, CDC13) 6 7.91 (dd, 1H, J = 8.0, 1.7 Hz), 7.76 (dd, 1H, J = 9.9, 1.7 Hz), 7.65 (t, 1H, J = 7.6 Hz), 7.29 (dd, 1H, J - 6.2, 2.6 Hz), 7.22 - 7.07 (m, 2H), 7.06 - 6.75 (Iirt, 1H), 5.01 (s, 2H), 3.88 - 3.73 (m, 4H), 3.20 (t, 2H, J = 8.7 Hz), 2.17 (d, 4H, J = 6.2 Hz); LRMS (ES) m/z 483.4 (M++1).
Example 86: Synthesis of compound 11535, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-morpholinoacetamide F
F
CI
c, (NL io EIN,) 0 ()Ms 0 N¨N
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 Ruaol) synthesized in step 6 of Example 85, morpholine (0.013 mL, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 al) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.042 g, 85.5%) as yellow oil.
NMR (400 MHz, CDC13) 6 7.88 (ddd, 1H, J = 8.0, 4.9, 1.7 Hz), 7.73 (ddd, 1H, J - 9.8, 8.0, 1.7 Hz), 7.62 (td, 1H, J =
7.6, 2.3 Hz), 7.27 - 7.23 (m, 1H), 7.18 - 7.05 (m, 2H), 7.05 -6.76 (m, 1H), 5.03 - 4.90 (m, 2H), 3.82 (dt, 4H, J = 23.4, 4.8 Hz), 3.27 - 3.04 (m, 2H), 2.77 (d, 4H, J = 55.3 Hz); IRKS (ES) m/z 499.5 (M++1).
Example 87: Synthesis of compound 11536, (S)-N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(3-hydroxypyrrolidin-1-y1)acetamide F
F ta OH CI
CI
rN.L
Hcr r"Lo 10 0, N-N
0Ms N--N
OH
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, (S)-pyrrolidin-3-ol (0.013 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl M acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/dichloromethane = from 0% to 30%) and concentrated to give the title compound (0.044 g, 89.6%) as yellow oil.
IH NMR (400 MHz, CDC13) 6 7.88 (t, 1H, J = 7.0 Hz), 7.79 -7.51 (m, 2H), 7.24 - 7.05 (m, 3H), 6.92 (t, 1H, J = 51.8 Hz), 5.02 (s, 2H), 4.21 - 3.43 (m, 4H), 3.27 (d, 1H, J = 47.5 Hz), 2.49 (s, 5H); LRMS (ES) m/z 499.5 (M++1).
Example 88: Synthesis of compound 11537, (R)-N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)acetamide F

CI *
)---CF2H
(cLO 0 Hb Ms N-N
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, (R)-pyrrolidin-2-ylmethanol (0.015 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 4 g cartridge; methanol/hexane = from 0% to 15%) and concentrated to give the title compound (0.019 g, 37.6%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.89 (ddd, 1H, J = 8.2, 6.9, 1.7 Hz), 7.75 (ddd, 1H, J = 9.9, 6.1, 1.7 Hz), 7.60 (dt, 1H, J =
14.8, 7.6 Hz), 7.25 - 7.05 (m, 3H), 7.03 - 6.77 (m, 1H), 5.08 -4.92 (m, 2H), 3.92 - 2.66 (m, 7H), 2.29 - 1.47 (m, 4H); LRMS
(ES) m/z 513.5 (M++1) .

Example 89: Synthesis of compound 11538, (S)-1-(2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl)pyrrolidine-2-carboxamide F
F
...-CF21-1 o_iNH2 CI
c, os 0 'w '/---CF21-1HN 0 N-N

2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, (S)-pyrrolidin-2-carboxamide (0.017 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 4 g cartridge; methanol/dichloromethane = from 0% to 15%) and concentrated to give the title compound (0.041 g, 79.2%) as colorless oil.
NMR (400 MHz, CDC13) 6 7.89 (td, 1H, J = 7.4, 1.6 Hz), 7.75 (ddd, 1H, J = 9.8, 6.0, 1.6 Hz), 7.60 (dt, 1H, J = 14.8, 7.5 Hz), 7.25 - 7.05 (m, 2H), 7.06 - 6.76 (m, 2H), 5.09 - 4.91 (m, 2H), 3.85 - 2.98 (m, 6H), 3.18 - 3.02 (m, 1H), 2.22 - 1.68 (m, 4H); LRMS (ES) m/z 526.5 (M++1) .
Example 90: Synthesis of compound 11584, N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)pyridin-2-yl)methyl)isonicotinamide [Step 1] Synthesis of N-phenyl-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)isonicotinamide OAI0 rNCF3 N 0 N-((5-(hydrazinecarbonyl)pyridin-2-yl)methyl)-N-phenylisonicotinamide (1.000 g, 2.879 mmol), synthesized in step 2 of Example 75, and triethylamine (0.802 mL, 5.757 mmol) were dissolved in tetrahydrofuran (30 mL), and trifluoroacetic anhydride (0.813 mL, 5.757 nuaol) was added to the solution at room temperature. The mixture was heated under reflux for 12 hours, and then cooled to room temperature to terminate the reaction. Saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The title compound was used without further purification (0.750 g, 61.2%) as colorless oil.
[Step 2] Synthesis of compound 11584 re-e--N'-=
I H
cF, 0 0 " N-N
N-phenyl-N-((5-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)pyridin-2-yl)methyl)isonicotinamide (0.900 g, 2.030 mmol), synthesized in step 1, 1-methoxy-N-triethylammoniosulfonyl-methanimidate (Burgess reagent, 0.484 g, 2.030 Imo') were mixed in tetrahydrofuran (15 ml,) at room temperature, and the mixture was heated by microwave irradiation at 150 C for 30 minutes, and then cooled to room temperature to terminate the reaction. Water was added to the reaction mixture, followed by extraction with dichloromethane.
The extract was filtered through a plastic filter to remove the solid residue and the aqueous layer, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 80 g cartridge; ethyl acetate/hexane =
from 10% to 60%) and concentrated, and then the obtained product was further purified by chromatography (Si02, 40 g cartridge; ethyl acetate/hexane = from 10% to 60%) and concentrated to give the title compound (0.470 g, 54.4%) as a white solid.
311 NMR (400 MHz, CDC13) 6 9.32 (m, 1H), 8.54 (m, 2H), 8.40 (m, 1H), 7.65 (m, 1H), 7.40 (m, 2H), 7.25 (m, 3H), 7.17 (m, 2H), 5.32 (s, 2H); LRMS (ES) m/z 426.4 (M++1).
Example 91: Synthesis of compound 11602, N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [Step 1] Synthesis of N-(3-chloro-4-fluorophenyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide OH ____________________________________________ CI NH
CI NH2 0=,0)( 0' 3-Chloro-4-fluoroaniline (0.700 g, 4.809 mmol), tetrahydro-2H-thiopyran-4-carboxylic acid 1,1-dioxide (0.943 g, 5.290 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HC1, 1.844 g, 9.618 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (HOBt, 1.300 g, 9.618 mmol) and N,N-diisopropylethylamine (1.675 mL, 9.618 mmol) were dissolved in dichloromethane (100 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 40 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.988 g, 67.2%) as a white solid.
[Step 2] Synthesis of methyl 4-((N-(3-chloro-4-fluoropheny1)-1,1-dioxidotetrahydro-2H-thiopyran-4-carboxamido)methyl)-3-fluorobenzoate CIS NH Br cl40 N ao OMe OMe Or 0 0=/S 0 N-(3-chloro-4-fluorophenyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (1.000 g, 3.271 mmol), synthesized in step 1, and sodium hydride (60.00 %, 0.262 g, 6.541 mmol) were dissolved in N,N-dimethylformamide (50 mL) at room temperature, and methyl 4-(bromomethyl)-3-fluorobenzoate (1.212 g, 4.906 mmol) was added to the solution. The mixture was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (5i02, 12 g cartridge; ethyl acetate/hexane = from 0% to 100%) and concentrated to give the title compound (1.240 g, 80.3%) as a white solid.
[Step 3] Synthesis of N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide CI N 10/ C I aLl OMe 0=sõ, 0 0=s 0 Methyl 4-((N-(3-chloro-4-fluoropheny1)-1,1-dioxidotetrahydro-2H-thiopyran-4-carboxamido)methyl)-3-fluorobenzoate (1.240 g, 2.628 mmol), synthesized in step 2, and hydrazine monohydrate (2.554 rnL, 52.554 mittol) were dissolved in ethanol (20 mL)/water (5 mL) at room temperature, and the solution was stirred at 80 C for 5 hours, and then cooled to room temperature to terminate the reaction. The reaction mixture was concentrated under reduced pressure to remove the solvent. The title compound was used without further purification (1.180 g, 95.2%) as yellow solid.
[Step 4] Synthesis of N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide F

H
N N H2 N )1, N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (0.200 g, 0.424 nmol), synthesized in step 3, 1,1-dioxide (0.200 g, 0.424 mmol) and triethylamine (0.118 mL, 0.848 mmol) were dissolved in tetrahydrofuran (10 mL) at room temperature, and trifluoroacetic anhydride (0.180 mL, 1.271 mmol) was added to the solution. The mixture was stirred at 8000 for 1 hour, and then cooled to room temperature to terminate the reaction. The reaction mixture was filtered to remove solids, and the filtrate was concentrated under reduced W pressure to remove the solvent. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane - from 0% to 80%) and concentrated to give the title compound (0.160 g, 66.5%) as colorless oil.
[Step 5] Synthesis of compound 11602 CI = N 0 CI = N
40, H 0 N'N).(CF3 (0 1161 0 0=S N-N

N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(2-(2,2,2-trifluoroacetyl)hydrazine-1-carbonyl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (0.160 g, 0.282 mmol), synthesized in step 4, and triethylamine (0.079 mL, 0.563 mmol) were dissolved in dichloromethane (15 71) at room temperature, and methanesulfonyl chloride (0.033 mL, 0.423 mmol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.030 g, 19.4%) as a white solid.
NMR (400 MHz, CDC13) 6 7.89 (dd, 1H, J = 8.0, 1.7 Hz), 7.76 (dd, 1H, J = 9.8, 1.7 Hz), 7.54 (t, 1H, J = 7.6 Hz), 7.21 - 7.12 (m, 2H), 6.91 (ddd, 1H, J = 8.7, 4.1, 2.7 Hz), 4.98 (s, 2H), 3.38 - 3.25 (m, 1H), 2.79 (ddd, 2H, J = 13.9, 9.9, 3.7 Hz), 2.50 (tt, 1H, J = 7.8, 3.6 Hz), 2.43 - 2.29 (m, 2H), 2.18 -2.06 (m, 3H); LRMS (ES) 550.4 m/z (M++1).
Example 92: Synthesis of compound 11603, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [Step 1] Synthesis of N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-1-carbony1)-2-fluorobenzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide F F
Cl rAll" N 0 CI 0 H
N, )( 0 =,S,, 0 0 N-(3-chloro-4-fluoropheny1)-N-(2-fluoro-4-(hydrazinecarbonyl)benzyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (0.200 g, 0.424 mmol), synthesized in step 3 of Example 91, and triethylamine (0.118 mL, 0.848 mmol) were dissolved in tetrahydrofuran (10 mL) at room temperature, and 2,2-difluoroacetic anhydride (0.158 mL, 1.271 mmol) was added to the solution. The mixture was stirred at 80 C for 2 hours, and then cooled to room temperature to terminate the reaction.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane =
from 0% to 80%) and concentrated to give the title compound (0.170 g, 72.9%) as colorless oil.
[Step 2] Synthesis of compound 11603 CI N c I
N, 0 Od N-(3-chloro-4-fluoropheny1)-N-(4-(2-(2,2-difluoroacetyl)hydrazine-l-carbony1)-2-fluorobenzyl)tetrahydro-20 2H-thiopyran-4-carboxamide 1,1-dioxide (0.170 g, 0.309 mmol), synthesized in step 1, and triethylamine (0.086 mL, 0.618 mmol) were dissolved in dichloromethane (15 mL) at room temperature, and methanesulfonyl chloride (0.036 mL, 0.464 mmol) was added to the solution. The mixture was stirred at the same temperature for 2 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; ethyl acetate/hexane = from 0% to 80%) and concentrated to give the title compound (0.015 g, 9.1%) as a white solid.
111 NI R (400 MHz, CDC13) 5 7.88 (dd, 1H, J=8.0, 1.7 Hz), 7.75 (dd, 1H, J = 9.9, 1.7 Hz), 7.52 (t, 1H, J = 7.6 Hz), 7.21 - 7.10 (m, 2H), 7.06 - 6.76 (m, 2H), 4.97 (s, 2H), 3.37 - 3.26 (m, 2H), 2.79 (ddd, 2H, J - 13.9, 9.8, 3.6 Hz), 2.50 (tt, 1H, J
= 7.9, 3.6 Hz), 2.42 - 2.28 (m, 2H), 2.19 - 2.05 (m, 2H) ; LRMS
(ES) m/z 532.3 (D1P+1).
Example 93: Synthesis of compound 11610, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-2-(1,1-dioxidothiomorpholino)acetamide F

N (NH CI

r__.1 =0 1.(Lo 0Ms N--N
AL
o'b 2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, thiomorpholine 1,1-dioxide (0.020 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours.
Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane =
from 0% to 5%) and concentrated to give the title compound (0.030 g, 55.7%) as a white solid.
NMR (400 MHz, CDC13) 5 7.87 (td, 1H, J = 7.7, 1.7 Hz), 7.74 (td, 1H, J = 9.8, 1.7 Hz), 7.56 (t, 1H, J = 7.5 Hz), 7.19 (dd, 1H, J = 6.4, 2.6 Hz), 7.15 (t, 1H, J = 8.5 Hz), 7.09 -6.99 (m, 1H), 6.97 - 6.77 (m, 1H), 4.99 (d, 2H, J = 5.7 Hz), 3.15 - 3.06 (m, 10H); LRMS (ES) m/z 547.4 (M++1) .
Example 94: Synthesis of compound 11611, 2-(4-acetylpiperazin-1-y1)-N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)acetamide F
IWP
CI riLl is C I 1.1rNL 0 #¨CF2H 0 0 ./ ¨CF2F1 , N-N
( OMs N -N
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, 1-(piperazin-1-yl)ethane (0.019 g, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to give the title compound (0.046 g, 86.5%) as brown oil.
111 NMR (400 MHz, CDC13) 5 7.85 (ddd, 1H, J = 8.0, 6.3, 1.7 Hz), 7.72 (td, 1H, J = 9.7, 1.7 Hz), 7.63 - 7.54 (m, 1H), 7.22 (dd, 1H, J = 6.4, 2.6 Hz), 7.12 (t, 1H, J = 8.5 Hz), 7.07 -7.00 (m, 1H), 6.99 - 6.75 (m, 1H), 4.98 (d, 2H, J = 4.5 Hz), 3.62 (dt, 2H, J - 10.1, 4.9 Hz), 3.48 (dt, 2H, J = 9.9, 4.9 Hz), 3.00 (d, 2H, J = 8.3 Hz), 2.64 - 2.38 (m, 4H), 2.04 (d, 3H, J =
1.1 Hz); LRMS (ES) m/z 540.4 (M++1).
Example 95: Synthesis of compound 11612, N-(3-chloro-4-fluoropheny1)-2-(4-(cyclopropanecarbonyl)piperazin-1-y1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)acetamide F
F
( CI
, rNH rto 11101 CI
L
0, Art4,) 0 ( ) 0Ms N --N
vA0 2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.050 g, 0.098 mmol) synthesized in step 6 of Example 85, cyclopropyl(piperazin-l-yl)methanone (0.021 mL, 0.148 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.197 mmol) were dissolved in acetonitrile (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane =

from 0% to 15%) and concentrated to give the title compound (0.045 g, 80.8%) as yellow oil.
NMR (400 MHz, CDC13) 6 7.86 (td, 1H, J - 7.1, 6.2, 1.7 Hz), 7.73 (t, 1H, J = 9.6 Hz), 7.60 (t, 1H, J = 7.6 Hz), 7.25 -7.20 (m, 1H), 7.12 (t, 1H, J - 8.5 Hz), 7.04 (d, 1H, J = 6.4 Hz), 7.01 - 6.74 (m, 1H), 4.99 (d, 2H, J = 4.6 Hz), 3.68 (s, 4H), 3.03 (d, 2H, J = 12.1 Hz), 2.54 (d, 4H, J = 35.4 Hz), 1.68 (tt, 1H, J= 8.1, 4.6 Hz), 0.95 (dt, 2H, J= 6.5, 3.4 Hz), 0.74 (dq, 2H, J = 7.2, 3.8 Hz); LRMS (ES) m/z 566.4 (M++1).
Example 96: Synthesis of compound 11613, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(4-(methylsulfonyl)piperazin-1-yl)acetamide [Step 1] Synthesis of N-(3-chloro-4-fluorophenyl)-N-(4-(5-F

rNH

+ 0 >¨CF21-1 r10 N¨N
OMs N¨N C
2-((3-chloro-4-fluorophenyl)(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)amino)-2-oxoethyl methanesulfonate (0.200 g, 0.394 mmol) synthesized in step 6 of Example 85, piperazine (0.051 g, 0.591 mmol) and N,N-diisopropylethylamine (0.137 mL, 0.788 mmol) were dissolved in acetonitrile (10 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (S102, 12 g cartridge; ethyl acetate/hexane =
from 0% to 15%) and concentrated to give the title compound W (0.158 g, 80.6%) as a white solid.
[Step 2] Synthesis of compound 11613 CI
'N

CI 1:1.L0 o, 9 /}--cF,H + r N--N

C )) Ii 0 0=S=
N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(piperazin-1-yl)acetamide (0.050 g, 0.100 mmol) synthesized in step 1, methanesulfonyl chloride (0.012 mL, 0.151 mmol) and N,N-diisopropylethylandne (0.035 mL, 0.201 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. 1.0N-hydrochloric acid aqueous solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge;
methanol/dichloromethane - from 0% to 5%) and concentrated to give the title compound (0.054 g, 93.4%) as a white solid.
IR NKR (400 MHz, CDC13) a 7.85 (ddd, 1H, J = 8.2, 6.4, 1.7 Hz), 7.71 (td, 1H, J= 9.8, 1.7 Hz), 7.57 (td, 1H, J= 7.7, 7.2, 1.7 Hz), 7.20 (dd, 1H, J = 6.4, 2.6 Hz), 7.12 (t, 1H, J = 8.5 Hz), 7.03 (td, 1H, J = 5.3, 4.7, 1.7 Hz), 6.84 (dd, 1H, J =
51.7, 1.4 Hz), 4.98 (d, 2H, J = 4.6 Hz), 3.28 - 3.19 (m, 4H), 2.98 (s, 2H), 2.75 (d, 3H, J = 1.4 Hz), 2.59 (q, 4H, J = 5.7, 4.9 Hz); LRMS (ES) m/z 576.4 (M++1) .
Example 97: Synthesis of compound 11614, N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(4-(oxetan-3-yl)piperazin-1-y1)acetamide F
F
C I
CI
41#

r N -N rt F2H
C

N-(3-chloro-4-fluoropheny1)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-2-(piperazin-1-y1)acetamide (0.050 g, 0.100 mmol) synthesized in step 1 of Example 96, sodium triacetoxyborohydride (0.043 g, 0.201 mmol) and oxetan-3-one (0.011 g, 0.151 mmol) were dissolved in dichloromethane (5 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. 1.0N-hydrochloric acid aqueous solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge;
methanol/dichloromethane = from 0% to 5%) and concentrated to give the title compound (0.046 g, 82.7%) as yellow oil.
NMR (400 MHz, CDC13) 5 7.85 (ddd, 1H, J = 7.9, 6.2, 1.7 Hz), 7.71 (td, 1H, J= 9.9, 1.7 Hz), 7.59 (td, 1H, J = 7.6, 5.4 Hz), 7.22 (dd, 1H, J = 6.5, 2.6 Hz), 7.10 (t, 1H, J = 8.5 Hz), 7.03 (s, 1H), 7.03 - 6.75 (m, 1H), 4.98 (d, 2H, J = 4.3 Hz), 4.67 - 4.52 (m, 4H), 3.57 - 3.44 (m, 1H), 2.94 (s, 2H), 2.44 (d, 8H, J = 60.9 Hz); LRMS (ES) m/z 554.5 (M++1).
Example 98: Synthesis of compound 11621, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-y1)benzyl)-1-(oxetan-3-y1)-N-phenylpiperidine-4-carboxamide N
ro ,,_0F, N-N
N-N

N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.150 g, 0.309 mmol) synthesized in step 5 of Example 31, sodium triacetoxyborohydride (0.131 g, 0.619 mmol) and cyclobutanone (0.026 g, 0.371 mmol) were dissolved in dichloromethane (10 mI) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column chromatography (Si02, 12 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to afford N-(4-(5-(difluoromety1)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-(oxetan-3-y1)-N-phenylpiperidine-4-carboxamide (0.130 g, 83.3%) as a white solid.
NMR (400 MHz, CDC13) 6 = 7.85 (dd, 1H, J - 8.0, 1.7 Hz), 7.71 (dd, 1H, J = 9.7, 1.7 Hz), 7.56 (t, 1H, J = 7.6 Hz), 7.41 - 7.31 (m, 3H), 7.06 - 6.99 (m, 2H), 5.02 (s, 2H), 4.66 (s, 2H), 4.59 (t, 2H, J = 6.6 Hz), 3.46 (s, 1H), 2.79 (s, 2H), 2.28 (s, 1H), 1.91 (s, 1H), 1.73 (s, 5H) ; LRMS (ES) m/z 505.2 (M++1).
Example 99: Synthesis of compound 11622, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-oxet an- 3-y1 ) -N-phenylpiperidine-4-carboxamide HCI + Er 0 = 0 .----CF2H
HN N-N
N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzy1)-N-phenylpiperidine-4-carboxamide hydrochloride (0.150 g, 0.321 mmol) synthesized in step 3 of Example 39, sodium triacetoxyborohydride (0.136 g, 0.643 mmol) and cyclobutanone (0.027 g, 0.386 mmol) were dissolved in dichloromethane (10 mL) at room temperature, and the solution was stirred at the same temperature for 18 hours. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated aqueous sodium chloride solution, dried with magnesium sulfate anhydrous, filtered, and then concentrated under reduced pressure. The concentrate was purified by column 0 chromatography (Si02, 12 g cartridge; methanol/dichloromethane =
from 0% to 15%) and concentrated to afford N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-y1)-2-fluorobenzyl)-1-(oxetan-3-y1)-N-phenylpiperidine-4-carboxamide (0.130 g, 83.2%) as a white solid.
1HNMR (400 MHz, CDC13) 5 7.85 (dd, 1H, J = 8.0, 1.7 Hz), 7.70 (dd, 1H, J = 9.8, 1.7 Hz), 7.54 (t, 1H, J = 7.6 Hz), 7.35 (dd, 3H, J = 4.9, 2.0 Hz), 7.06 - 6.99 (m, 2H), 6.84 (d, 1H, J
= 51.7 Hz), 5.02 (s, 2H), 4.65 (s, 2H), 4.59 (t, 2H, J = 6.5 Hz), 3.45 (s, 1H), 2.78 (s, 2H), 2.28 (s, 1H), 2.03 - 1.85 (rci, 2H), 1.73 (s, 4H); LRMS (ES) m/z 487.2 (M++1) .
Measurement of Activity of the Compounds of the Present Invention and Analysis Protocol Experimental Example 1: HDAC enzyme activity inhibition assays (in vitro) In order to examine the HDAC6 selectivity of the compounds of formula I of the present invention by HDAC1 and HDAC6 enzymatic activity inhibition assays, an experiment was performed using a conventional substance as a control.
HDAC enzyme activity was measured using a HDAC
Fluorimetric Drug Discovery Kit (BML-AK511, 516) from Enzo Life Science. For the HDAC1 enzyme activity test, human recombinant HDAC1 (BML-SE456) was used as an enzyme source, and Fluor de LysSIRT1 (BNL-K1177) was used as a substrate. A 5-fold dilution of the compound was seeded into a 96-well plate, and then 0.3 pg of the enzyme and 10 pM of the substrate were added to each well of the plate and allowed to react at 30 C for 60 minutes. Then, Fluor de LysCLDeveloper II (BML-K1176) was added thereto and allowed to react for 30 minutes, after which the fluorescence value (Ex 360, Em 460) was measured using a multi-plate reader (Flexstation 3, Molecular Device). The HDAC6 enzyme was tested using human recombinant HDAC6 (382180) from Calbiochem, according to the same protocol as the HDAC1 enzyme activity test method. Based on the resulting values, each IC50 value was calculated using GraphPad Prism4.0 program.

[Table 2] Results of HDAC enzyme activity inhibition assays HDAC6 selectivity Ex. Comp. HDAC1 (nM) HDAC6 (nM) (fold)
13 11139 ND 129 775
14 11140 ND 209 478 As can be seen in Table 2 above, the 1,3,4-oxadiazole amide derivative compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention showed about 36 to about 3846 times higher selective HDAC6 inhibitory activities in the HDAC1 and HDAC6 activity inhibition assays.
Experimental Example 2: Analysis of the Effect of HDAC6-Specific Inhibitors on Mitochondrial Axonal Transport (in vitro) The effect of HDAC6-specific inhibitors on mitochondrial axonal transport was analyzed. Specifically, in order to examine whether the compounds represented by formula I

according to the present invention selectively inhibit HDAC6 activity to increase the acetylation of tubulin, which is a major substrate of HDAC6, thereby improving the mitochondrial axonal transport velocity reduced by amyloid-beta treatment in neuronal axons, a comparison experiment was performed using a compound that have already been developed as a control.
Hippocampal neurons from Sprague-Dawley (SD) rat embryos at embryonic day 17-18 (E17-18) were cultured in an extracellular matrix-coated dish for imaging for 7 days, and then treated with 1 pM of an amyloid-beta peptides. After 24 hours, the neurons were treated with compounds on the 8th days in vitro and 3 hours later, treated with MitoTracker Red CMXRos (Life Technologies, NY, USA) for the last 5 minutes to stain the mitochondria. Axonal transport of the stained mitochondria was imaged using a confocal microscope (Leica 5P8; Leica Microsystems, UK) at 1-second intervals for 1 minute, and the transport velocity per second of each mitochondrion was determined using the IMARIS analysis software (BITPLANE, Zurich, Switzerland).
As a result, it was found that the 1,3,4-oxadiazole amide derivative compounds, stereoisomers thereof or pharmaceutically acceptable salts according to the present invention improved the velocity of mitochondrial axonal transport.

Claims (11)

    [CLAIMS]
  1. [Claim 1]
    An 1,3,4-oxadiazole amide derivative compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
    <MG>
    wherein L1, L2 or L3 are each independently -(C0-C2alkyl)-;
    Z1 to Z4 are each independently N or CR Z, wherein three or more of Z1 to Z4 may not be simultaneously N, and R Z is -H or -X;
    R1 is -CX2H or -CX3;
    R2 is -(C1-C4 alkyl), -(C1-C4 alkyl)-O(C1-C4 alkyl), -(C1-C4 alkyl)-C(=O)-O(C1-C4 alkyl), -(C3-C6 cycloalkyl), -aryl, -heteroaryl, wherein at least one H of the -(C3-C6 cycloalkyl), -aryl or -heteroaryl may be substituted with -X, -OH, -(C1-C4 alkyl), -O(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-O(C1-C4 alkyl) or -CF3, Y is -N-, -O- or -S (=O) 2-, when Y is -N-, R4 and R8 are each independently -H, - (C1-C4 alkyl) , -C (=O) - (C1-C4 alkyl) , -C (=O) - (C3-C6 cycloalkyl) , -C (=O) -0 (C1-C4 alkyl) , -C (=O) -CF3, -S (=O) 2- (C1-C4 alkyl) , -(C2-C6 heterocycloalkyl) , benzyl or amine protecting group, wherein the - (C2-C6 heterocycloalkyl) may contain an N, O or S atom in the ring, and when Y is -O- or -S (=O) 2-, R4 and R8 are null, R5 to R8 are each independently -H, - (C1-C4 alkyl) , -OH, -CH2OH or -C (=O) -NH2, and a to c are each independently an integer of 1, 2 or 3;
    R3 is -H, - (C1-C4 alkyl) , - (C1-C4 alkyl) -O (C1-C4 alkyl) , - (C1-C4 alkyl) -C (=O) -O (C1-C4 alkyl) , - (C3-C6 cycloalkyl) , -aryl, -heteroaryl, or wherein at least one H of the - (C3-C6 cycloalkyl) , -aryl or -heteroaryl may be each independently substituted with -X, -OH, - (C1-C4 alkyl) , -O (C1-C4 alkyl) , -C (=O) - (C1-C4 alkyl) , -C (=O) -0 (C1-C4 alkyl) or -CF3 , and R4, R5, R6, Y, a, b, R1, L1, Z1, Z2, Z3 and Z4 are as defined above; and X is F, Cl, Br or I.
  2. [Claim 2]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein L1 and L3 are -(C0 alkyl)-;
    L2 is -(C1-C2 alkyl)-;
    Z1 to Z4 are each independently N or CRz, wherein two or more of Z1 to Z4 may not be simultaneously N, and Rz is -H or -X;
    R1 is -CX2H or -CX3;
    R2 is -(C1-C4 alkyl), -(C3-C6 cycloalkyl), -aryl, -heteroaryl, wherein at least one H of the -(C3-C6 cycloalkyl), -aryl or -heteroaryl may be substituted with -X, -OH, -O(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-0(C1-C4 alkyl) or -CF3, Y is -N-, -O- or -S(=O)2-, when Y is -N-, R4 and R8; are each independently -H, -(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-CF3, -S(=O)2-(C1-C4 alkyl), -(C2-C6 heterocycloalkyl), -C(=O)-(C3-C6 cycloalkyl), benzyl or amine protecting group, wherein the -(C2-C6 heterocycloalkyl) may contain an O atom in the ring, and when Y is -O- or -S(=O)2-, R4 and R8 are null, R5 tO R8 are each independently -H, -(C1-C4 alkyl), -OH, -CH2OH or -C(=O)-NH2, and a to c are each independently an integer of 1, 2 or 3;
    R3 is -aryl or -heteroaryl, wherein at least one H of the -aryl or -heteroaryl may be independently substituted with -X, -OH, -(C1-C4 alkyl), -O(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-0(C1-C4 alkyl) or -CF3; and X is F, Cl, Br or I.
  3. [Claim 3]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 2, Wherein L1 and L3 are - (C0 alkyl)-;
    L2 is -(C1 alkyl)-;
    Z1 to Z4 are each independently N or CRZ, wherein two or more of Z1 to Z4 may not be simultaneously N, and Rz is -H or -X;
    R1 is -CF2H or -CF3;
    R2 is -(C1-C4 alkyl), -pyridinyl or wherein at least one H of the pyridinyl may be substituted with -X, -OH, -(C1-C4 alkyl), -O(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-0(C1-C4alkyl) or -CF3, Y is -N-, R4 is -(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl) or -S(=O)2-(C1-C4 alkyl), R5 or R6 are each independently -H or -(C1-C4alkyl), and a and b are each independently an integer of 1 or 2;
    R3 is -aryl, wherein at least one H of the aryl may be substituted with -X; and X is F, Cl, Br or I.
  4. [Claim 4]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 3, wherein L1 and L3 are -(C0 alkyl)-;
    L2 is -(C1 alkyl)-;
    Z1 to Z4 are each independently N or CRz, wherein two or more of Z1 to Z4 may not be simultaneously N, and Rz is -H or -X;
    R1 is -CF2H or -CF3;
    R2 is -pyridinyl or wherein at least one H
    of the pyridinyl may be substituted with -X, -OH, -(C1-C4 alkyl), -O(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -C(=O)-0(C1-C4 alkyl) or -CF3, Y is -N-, R4 is -(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl) or -S(=O)2-(C1-C4 alkyl), R5 or R6 are each independently -H, and a and b are each independently an integer of 1 or 2;
    R3 is -aryl, wherein at least one H of the aryl may be substituted with -X; and X is F, Cl, Br or I.
  5. [Claim 5]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  6. [Claim 6]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 5, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  7. [Claim 7]
    The 1,3,4-oxadiazole amide derivative compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to claim 6, wherein the compound represented by formula I is selected from the group consisting of compounds described in the following table:
  8. [Claim 8]
    A pharmaceutical composition for preventing or treating histone deacetylase-mediated disease, comprising, as an active ingredient, the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7.
  9. [Claim 9]
    The pharmaceutical composition of claim 8, wherein the histone deacetylase-mediated disease is selected from among infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders;
    neurological diseases; diseases of the eye and adnexa;

    cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue;
    diseases of the musculoskeletal system and connective tissue;
    or congenital malformations, deformations and chromosomal abnormalities.
  10. [Claim 10]
    A method for treating histone deacetylase-mediated disease, comprising administering a therapeutically effective amount of the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7.
  11. [Claim 11]
    Use of the compound represented by formula I, stereoisomer thereof or pharmaceutically acceptable salt thereof according to any one of claims 1 to 7 in preparation of a medicament for treating histone deacetylase-mediated disease.
CA2993918A 2015-07-27 2016-07-27 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same Active CA2993918C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0106007 2015-07-27
KR20150106007 2015-07-27
PCT/KR2016/008216 WO2017018804A1 (en) 2015-07-27 2016-07-27 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

Publications (2)

Publication Number Publication Date
CA2993918A1 true CA2993918A1 (en) 2017-02-02
CA2993918C CA2993918C (en) 2020-09-29

Family

ID=57886896

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2993918A Active CA2993918C (en) 2015-07-27 2016-07-27 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same

Country Status (20)

Country Link
US (1) US10584117B2 (en)
EP (1) EP3330259B1 (en)
JP (1) JP6559325B2 (en)
KR (1) KR101799009B1 (en)
CN (1) CN108026056B (en)
AU (1) AU2016299485B2 (en)
CA (1) CA2993918C (en)
DK (1) DK3330259T3 (en)
ES (1) ES2814229T3 (en)
HK (1) HK1251939A1 (en)
HR (1) HRP20201304T1 (en)
HU (1) HUE051537T2 (en)
MX (1) MX2018001196A (en)
MY (1) MY190301A (en)
NZ (1) NZ739211A (en)
PH (1) PH12018500162B1 (en)
PL (1) PL3330259T3 (en)
PT (1) PT3330259T (en)
RU (1) RU2700696C2 (en)
WO (1) WO2017018804A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11325286B2 (en) * 2009-09-24 2022-05-10 Sealed Air Corporation (Us) Mixing machine for producing foam within a bag
MY194018A (en) * 2015-07-27 2022-11-08 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3328843B1 (en) 2015-07-27 2022-10-26 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2700696C2 (en) 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-oxadisolamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof
BR112018002304B1 (en) 2015-08-04 2023-12-19 Chong Kun Dang Pharmaceutical Corp COMPOUNDS OF 1,3,4-OXADIAZOLE DERIVATIVE AS A HISTONE DEACETYLASE 6 INHIBITOR AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
PT3362445T (en) 2015-10-12 2023-03-20 Chong Kun Dang Pharmaceutical Corp Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN111032651A (en) 2017-07-31 2020-04-17 武田药品工业株式会社 Heterocyclic compounds
WO2019040105A2 (en) * 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
KR102316234B1 (en) 2018-07-26 2021-10-22 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
JP7470058B2 (en) 2019-01-30 2024-04-17 武田薬品工業株式会社 Heterocyclic compounds
AU2020259100A1 (en) * 2019-04-17 2021-11-11 Fundación Kertor 1,3,4-oxadiazole derivatives as histone deacetylase inhibitors
AU2020284606B2 (en) * 2019-05-31 2023-01-19 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3976604A4 (en) * 2019-05-31 2022-12-07 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
WO2021060567A1 (en) 2019-09-27 2021-04-01 Takeda Pharmaceutical Company Limited 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors
KR102576148B1 (en) * 2020-04-13 2023-09-07 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
KR20220139752A (en) * 2021-04-08 2022-10-17 주식회사 종근당 1,3,4-Oxadiazole Thiocarbonyl Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
JP2024514356A (en) 2021-04-23 2024-04-01 テナヤ セラピューティクス， インコーポレイテッド HDAC6 inhibitors for use in the treatment of dilated cardiomyopathy
AU2022270657A1 (en) 2021-05-04 2023-11-16 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
KR20230144686A (en) * 2022-04-07 2023-10-17 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and Uses thereof
KR20240035172A (en) * 2022-09-08 2024-03-15 주식회사 종근당 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and Uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871753A (en) 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
KR100265385B1 (en) 1998-02-27 2000-11-01 윤여표 Extract of rhodiola sp. for prevending and treating circulating diseases
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003028729A2 (en) 2001-10-03 2003-04-10 Pharmacia Corporation Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade
ATE430727T1 (en) 2001-12-20 2009-05-15 Bristol Myers Squibb Co ALPHA-(N-SULFONAMIDE)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS
WO2005040152A1 (en) * 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Heteroyclylphenyl-and heterocyclylpyridyl-substituted azolecarboxamides as herbicides
BRPI0613429A2 (en) 2005-07-14 2009-02-10 Takeda San Diego Inc histone deacetylase inhibitors
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
WO2007032445A1 (en) 2005-09-16 2007-03-22 Kyowa Hakko Kogyo Co., Ltd. Protein kinase inhibitors
WO2007055941A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
AU2007228539B2 (en) 2006-03-23 2013-01-10 Biota Scientific Management Pty Ltd Antibacterial agents
TW200808707A (en) 2006-06-14 2008-02-16 Methylgene Inc Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
EP1878730A1 (en) 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same
BRPI0717688A2 (en) 2006-12-11 2013-01-22 Genentch Inc Empresa Americana Methods for Treating Neoplasms and Methods for Treating Plasma Neoplasms
WO2009010479A2 (en) 2007-07-13 2009-01-22 Euroscreen S.A. Heterocyclic methylene piperidine derivatives and their use
KR100903743B1 (en) 2007-08-28 2009-06-19 전병태 Food composition for improving and preventing digestive system diseases
BRPI0817897A2 (en) 2007-11-02 2019-09-24 Methylgene Inc compound, composition, and methods for inhibiting hdac activity, and treating a disease responsive to an hdac activity inhibitor
CN101842392B (en) 2007-11-02 2014-08-27 动量制药公司 Non-anticoagulant polysaccharide compositions
RU2515611C2 (en) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Deacetylase inhibitors and their application
CN102802623A (en) 2009-04-20 2012-11-28 人类健康研究所 Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
WO2010126002A1 (en) 2009-04-28 2010-11-04 塩野義製薬株式会社 Pharmaceutical product containing heterocyclic sulfonamide compound
JP2011008205A (en) 2009-05-27 2011-01-13 Fujifilm Corp Composition for producing biaxial optical anisotropic film
EP2456757B1 (en) 2009-07-22 2019-05-01 The Board of Trustees of the University of Illionis Hdac inhibitors and therapeutic methods using the same
KR101781663B1 (en) * 2010-01-13 2017-09-25 템페로 파마슈티칼즈, 인크. Compounds for inhibiting histone deacetylase enzymes and methods of making the same
EP2523664A4 (en) 2010-01-13 2013-06-26 Tempero Pharmaceuticals Inc Compounds and methods
DK2526093T3 (en) 2010-01-22 2016-11-14 Acetylon Pharmaceuticals Inc Reverse amide compounds as proteindeacetylasehæmmere and methods of use thereof
CA2791162A1 (en) 2010-02-25 2011-09-01 Piramal Enterprises Limited Oxadiazole compounds, their preparation and use
AR081331A1 (en) 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP5851516B2 (en) * 2010-12-09 2016-02-03 ウォックハート リミテッド Ketolide compounds
KR101262870B1 (en) 2011-01-28 2013-05-09 환인제약 주식회사 A composition comprising extract of Polygoni cuspidati Radix for treating or preventing respiratory disease
US9056843B2 (en) 2011-07-08 2015-06-16 Novartis Ag Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EP2734500A4 (en) 2011-07-20 2015-04-08 Gen Hospital Corp Histone deacetylase 6 selective inhibitors for the treatment of bone disease
WO2013041407A1 (en) 2011-09-19 2013-03-28 Cellzome Ag Hydroxamic acids as hdac6 inhibitors
AU2012319188B2 (en) 2011-10-03 2016-11-24 Sloan-Kettering Institute For Cancer Research Novel molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066835A2 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
CA2856334A1 (en) * 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
JP6272773B2 (en) 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Heterocyclic amide compounds for HDAC6 inhibitors and antitumor agents
JP6233812B2 (en) 2012-03-07 2017-11-22 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Selective histone deacetylase 6 inhibitor
KR20160081898A (en) 2013-09-06 2016-07-08 오리진 디스커버리 테크놀로지스 리미티드 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
PT3080125T (en) 2013-12-12 2018-12-14 Chong Kun Dang Pharmaceutical Corp Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
CN104744446B (en) 2013-12-30 2019-06-25 广东东阳光药业有限公司 Heteroaryl compound and its application in drug
BR112017010402B1 (en) 2014-11-24 2023-12-12 Medifron Dbt Inc SUBSTITUTED CARBOXAMIDE BASED ON THIAZOLE AND OXAZOLE AND UREA DERIVATIVES AS VANILLOID II RECEPTOR LIGANDS
CN106349451B (en) 2015-07-14 2020-11-13 罗门哈斯公司 Process for preparing hydrophobically modified alkylene oxide urethane polymers
MY194018A (en) 2015-07-27 2022-11-08 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2700696C2 (en) 2015-07-27 2019-09-19 Чонг Кун Данг Фармасьютикал Корп. 1,3,4-oxadisolamide derivative compound as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof
EP3328843B1 (en) 2015-07-27 2022-10-26 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
BR112018002304B1 (en) 2015-08-04 2023-12-19 Chong Kun Dang Pharmaceutical Corp COMPOUNDS OF 1,3,4-OXADIAZOLE DERIVATIVE AS A HISTONE DEACETYLASE 6 INHIBITOR AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
PT3362445T (en) 2015-10-12 2023-03-20 Chong Kun Dang Pharmaceutical Corp Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
PH12018500162A1 (en) 2018-07-30
PH12018500162B1 (en) 2018-07-30
AU2016299485B2 (en) 2019-02-07
KR20170013187A (en) 2017-02-06
US10584117B2 (en) 2020-03-10
HRP20201304T1 (en) 2020-11-27
MY190301A (en) 2022-04-13
ES2814229T3 (en) 2021-03-26
CA2993918C (en) 2020-09-29
RU2018106914A (en) 2019-08-27
US20180215743A1 (en) 2018-08-02
MX2018001196A (en) 2018-05-22
RU2018106914A3 (en) 2019-08-27
JP6559325B2 (en) 2019-08-14
RU2700696C2 (en) 2019-09-19
PL3330259T3 (en) 2021-02-08
CN108026056A (en) 2018-05-11
AU2016299485A1 (en) 2018-02-08
HK1251939A1 (en) 2019-05-03
EP3330259B1 (en) 2020-06-10
HUE051537T2 (en) 2021-03-01
EP3330259A1 (en) 2018-06-06
KR101799009B1 (en) 2017-11-17
WO2017018804A1 (en) 2017-02-02
EP3330259A4 (en) 2019-01-16
BR112018001716A2 (en) 2018-11-06
DK3330259T3 (en) 2020-08-10
CN108026056B (en) 2021-08-03
PT3330259T (en) 2020-09-03
NZ739211A (en) 2019-05-31
JP2018521110A (en) 2018-08-02

Similar Documents

Publication Publication Date Title
CA2993918A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
KR101799005B1 (en) 1,3,4-Oxadiazole Sulfamide Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same
US10538498B2 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
CA2994688C (en) 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
RU2351596C2 (en) N-[heteroaryl(piperidine-2-yl)methyl]benzamide derivatives and application in therapy
JP7428833B2 (en) 1,3,4-oxadiazole derivative compound as a histone deacetylase 6 inhibitor and a pharmaceutical composition containing the same
JP2024516122A (en) 1,3,4-OXADIAZOLETHIOCARBONYL COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
JP7525662B2 (en) 1,3,4-OXADIAZOLE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
JP7492033B2 (en) 1,3,4-OXADIAZOLE DERIVATIVE COMPOUND AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
RU2810081C1 (en) 1,3,4-oxadiazole derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition containing them
RU2822624C1 (en) 1,3,4-oxadiazole derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition containing thereof
BR112018001716B1 (en) COMPOUND OF 1,3,4-OXADIAZOLE AMIDE DERIVATIVE AS A HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180126